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A B S T R A C T
Background
Modern immunosuppressive regimens aBer kidney transplantation usually use a combination of two or three agents of diLerent classes
to prevent rejection and maintain graB function. Most frequently, calcineurin-inhibitors (CNI) are combined with corticosteroids and a
proliferation-inhibitor, either azathioprine (AZA) or mycophenolic acid (MPA). MPA has largely replaced AZA as a first line agent in primary
immunosuppression, as MPA is believed to be of stronger immunosuppressive potency than AZA. However, treatment with MPA is more
costly, which calls for a comprehensive assessment of the comparative eLects of the two drugs.
Objectives
This review of randomised controlled trials (RCTs) aimed to look at the benefits and harms of MPA versus AZA in primary
immunosuppressive regimens aBer kidney transplantation. Both agents were compared regarding their eLicacy for maintaining graB
and patient survival, prevention of acute rejection, maintaining graB function, and their safety, including infections, malignancies
and other adverse events. Furthermore, we investigated potential eLect modifiers, such as transplantation era and the concomitant
immunosuppressive regimen in detail.
Search methods
We searched Cochrane Kidney and Transplant's Specialised Register (to 21 September 2015) through contact with the Trials' Search Co-
ordinator using search terms relevant to this review.
Selection criteria
All RCTs about MPA versus AZA in primary immunosuppression aBer kidney transplantation were included, without restriction on language
or publication type.
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Data collection and analysis
Two authors independently determined study eligibility, assessed risk of bias and extracted data from each study. Statistical analyses
were performed using the random-eLects model and the results were expressed as risk ratio (RR) for dichotomous outcomes and mean
diLerence (MD) for continuous outcomes with 95% confidence intervals (CI).
Main results
We included 23 studies (94 reports) that involved 3301 participants. All studies tested mycophenolate mofetil (MMF), an MPA, and 22 studies
reported at least one outcome relevant for this review. Assessment of methodological quality indicated that important information on
factors used to judge susceptibility for bias was infrequently and inconsistently reported.
MMF treatment reduced the risk for graB loss including death (RR 0.82, 95% CI 0.67 to 1.0) and for death-censored graB loss (RR 0.78, 95%
CI 0.62 to 0.99, P < 0.05). No statistically significant diLerence for MMF versus AZA treatment was found for all-cause mortality (16 studies,
2987 participants: RR 0.95, 95% CI 0.70 to 1.29). The risk for any acute rejection (22 studies, 3301 participants: RR 0.65, 95% CI 0.57 to 0.73, P
< 0.01), biopsy-proven acute rejection (12 studies, 2696 participants: RR 0.59, 95% CI 0.52 to 0.68) and antibody-treated acute rejection (15
studies, 2914 participants: RR 0.48, 95% CI 0.36 to 0.65, P < 0.01) were reduced in MMF treated patients. Meta-regression analyses suggested
that the magnitude of risk reduction of acute rejection may be dependent on the control rate (relative risk reduction (RRR) 0.34, 95% CI 0.10
to 1.09, P = 0.08), AZA dose (RRR 1.01, 95% CI 1.00 to 1.01, P = 0.10) and the use of cyclosporin A micro-emulsion (RRR 1.27, 95% CI 0.98 to
1.65, P = 0.07). Pooled analyses failed to show a significant and meaningful diLerence between MMF and AZA in kidney function measures.
Data on malignancies and infections were sparse, except for cytomegalovirus (CMV) infections. The risk for CMV viraemia/syndrome (13
studies, 2880 participants: RR 1.06, 95% CI 0.85 to 1.32) was not statistically significantly diLerent between MMF and AZA treated patients,
whereas the likelihood of tissue-invasive CMV disease was greater with MMF therapy (7 studies, 1510 participants: RR 1.70, 95% CI 1.10
to 2.61). Adverse event profiles varied: gastrointestinal symptoms were more likely in MMF treated patients and thrombocytopenia and
elevated liver enzymes were more common in AZA treatment.
Authors' conclusions
MMF was superior to AZA for improvement of graB survival and prevention of acute rejection aBer kidney transplantation. These benefits
must be weighed against potential harms such as tissue-invasive CMV disease. However, assessment of the evidence on safety outcomes
was limited due to rare events in the observation periods of the studies (e.g. malignancies) and inconsistent reporting and definitions (e.g.
infections, adverse events). Thus, balancing benefits and harms of the two drugs remains a major task of the transplant physician to decide
which agent the individual patient should be started on.
P L A I N   L A N G U A G E   S U M M A R Y
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients
ABer kidney transplantation, patients receive a combination of immunosuppressive medications to prevent rejection of the transplanted
kidney. These regimens usually contain a calcineurin-inhibitor (tacrolimus or cyclosporin A), corticosteroids and an antiproliferative
agent (mycophenolic acid (MPA), e.g. mycophenolate mofetil (MMF), or azathioprine (AZA)). MPA is considered to be of stronger
immunosuppressive potency than AZA, but the benefits on survival of the graB and its safe use over a long period of time are insuLiciently
understood.
In this systematic review, we compared the eLicacy and safety of MPA versus AZA in randomised controlled trials (RCTs) when given as part
of the immunosuppressive regimen immediately aBer kidney transplantation.
Searches to 21 September 2015 identified 23 studies in which 3301 patients were treated with MPA (all studies used MMF) or AZA.
Methodological quality of the studies was limited, e.g. only in two RCTs was the study medication administered in a blinded fashion.
MMF was more eLective than AZA for reducing the risk of graB loss (by approximately 20%) and acute rejection (by approximately 30%).
No diLerence in mortality was observed. Moreover, graB function appeared to be similar in both treatments.
When drugs are given to suppress the immune system, this can result in serious side eLects such as infections and malignancies. The data
on adverse events was limited by relatively short follow up in the studies as some of these side eLects occur aBer several years of treatment.
Furthermore, the studies did not focus on these harms and did not use harmonised diagnostic criteria. The incidence of cytomegalovirus
infections did not diLer between MMF and AZA, but there was a 1.7-fold increased risk for the more severe, tissue-invasive cytomegalovirus
disease in MMF-treated patients. Information on malignancies was reported only in five studies; therefore no robust conclusions can be
drawn. Gastrointestinal side eLects (e.g. nausea, diarrhoea) were more common with MMF-treatment, whereas bone marrow suppression
(e.g. thrombocytopenia) and elevated liver enzymes were observed more frequently in AZA treated patients.
In general, evidence for eLicacy outcomes is of high quality and can be seen as considerably robust, but there is less certainty on aspects
of safety. Therefore, caregivers should balance potential benefits and harms of MMF and AZA according to individual patient's risks and
preferences. Physicians need to individualise the decision between these agents as components of the immunosuppressive regimen.
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Summary of findings for the main comparison.   Mycophenolate mofetil (MMF) versus azathioprine (AZA) for primary immunosuppression in kidney
transplant recipients
MMF compared to AZA for primary immunosuppression in kidney transplant recipients
Patient or population: patients with kidney transplant recipients
Settings: primary immunosuppressive regimens (RCTs)
Intervention: MMF
Comparison: AZA
Illustrative comparative
risks* (95% CI)
Assumed risk Correspond-
ing risk
Outcomes
AZA MMF
Relative ef-
fect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Death, all cause
Follow-up: 0.5 to 5 years
49 per 1000 47 per 1000
(34 to 63)
RR 0.95 
(0.7 to 1.29)
2987 (16) ⊕⊕⊕⊝
moderate1
No evidence for difference due to
low precision
GraB loss, censored for death
Follow-up: 0.5 to 6 years
11 per 100 9 per 100
(7 to 11)
RR 0.78 
(0.61 to 0.98)
2540 (17) ⊕⊕⊕⊕
high2
Statistically significant risk re-
duction of meaningful magnitude
(˜20%) with MMF treatment
Malignancy, any
Follow-up: 1 to 6 years
10 per 100 8 per 100
(6 to 11)
RR 0.81 
(0.6 to 1.09)
1735 (5) ⊕⊝⊝⊝
very low3,4,5
Statistically not significant
favourable point estimate (˜20%)
with MMF treatment, but very
low quality evidence
Acute rejection, steroid resistant/antibody
treated
As reported in the articles
Follow-up: 0.5 to 3 years
11 per 100 5 per 100
(4 to 7)
RR 0.48 
(0.36 to 0.65)
2914 (15) ⊕⊕⊕⊕
high
Statistically significant risk re-
duction of meaningful magnitude
(˜50%) with MMF treatment
Infection, CMV tissue invasive
As reported in the articles
Follow-up: 0.5 to 3 years
4 per 100 7 per 100
(5 to 11)
RR 1.7 
(1.1 to 2.61)
1510 (7) ⊕⊕⊕⊕
high3,6
Statistically significantly in-
creased risk of meaningful mag-
nitude (1.7 fold) with MMF treat-
ment
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Acute rejection, total
Any treated acute rejection, including biop-
sy-proven
Follow-up: 0.5 to 5 years
35 per 100 23 per 100
(20 to 26)
RR 0.65 
(0.57 to 0.73)
3301 (22) ⊕⊕⊕⊕
high
Statistically significant risk re-
duction of meaningful magnitude
(˜35%) with MMF treatment
Chronic allograft nephropathy
Biopsy required in 2 RCTs, one study with op-
tional biopsy
Follow-up: 1 to 6 years
36 per 100 25 per 100
(17 to 36)
RR 0.69 
(0.48 to 0.99)
203 (3) ⊕⊕⊝⊝
low3,4
Statistically significant risk re-
duction of meaningful magni-
tude (30%) with MMF treatment,
but low quality evidence due to
sparse data
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
AZA - azathioprine; CMV - cytomegalovirus; MMF - mycophenolate mofetil; RCT - randomised controlled trial
1 InsuLicient statistical power to detect a small eLect of either treatment on the outcome
2 Large beneficial eLect of MMF treatment
3 Considerable risk of reporting bias as data were provided by a limited number of studies only
4 Study populations in which the outcome were reported are a subset not representative for patients enrolled in all trials identified for the review
5 InsuLicient statistical power due to sparse data on a potential beneficial eLect on the incidence of malignancies with MMF treatment
6 Substantial harm caused by MMF
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B A C K G R O U N D
Description of the condition
While there are several immunosuppressive drugs available,
usually a combination of two or three agents of diLerent classes
is used to prevent rejection and maintain graB function aBer
kidney transplantation. In most regimens, calcineurin inhibitors
(CNI) (cyclosporin A (CsA) or tacrolimus (Tac)), form the cornerstone
of treatment and are combined with corticosteroids and a
proliferation-inhibitor with its representatives azathioprine (AZA)
and mycophenolic acid (MPA). There are currently two formulations
available for MPA, mycophenolate mofetil (MMF) and the more
recently approved enteric-coated mycophenolate sodium (ec-MPS)
(Hardinger 2013; Marcen 2009)
Description of the intervention
MMF was approved by the US Food and Drug Administration (FDA)
in 1995 for the prevention of acute rejection in kidney transplant
recipients. This was based on the results of three randomised
controlled trials (RCT), the pivotal trials, where a total of 1493
patients in North America, Europe and Australia were enrolled.
MMF was compared to AZA (MMF TRI Study 1996; MMF US Study
1995) or placebo (European MMF Study Group 1995) in a regimen
with concomitant use of CsA (original formulation) and steroids.
In all three studies, MMF showed superior ability to prevent acute
rejection within the first six months aBer transplantation.
In the past decade, MPA was tested against AZA in various
immunosuppressive regimens in kidney transplantation as a
variety of new drugs have been developed, including mammalian
target of rapamycin (mTOR) inhibitors (Webster 2006), Tac and a
micro-emulsion formulation of CsA (CsA-ME) (Webster 2005).
How the intervention might work
Both proliferation inhibitors, MPA and AZA, reduce purine synthesis
either through direct inhibition of the cell cycle (AZA) or on the level
of nucleotide synthesis (MPA) (Staatz 2007). AZA was one of the first
drugs used for immunosuppression in kidney transplantation in the
1960s (Mowbray 1965). Following the results of the pivotal trials,
AZA was widely replaced by MPA, particularly MMF, as a component
of primary immunosuppressive regimens in most of the developed
countries (Halloran 2004; Hardinger 2013), since acute rejection has
been shown to be a strong predictor for diminished graB function
and reduced graB survival (Pascual 2002).
Why it is important to do this review
Despite MMF being considered to be more eLective than AZA
in the prevention of acute rejection, its superior eLect on long-
term graB function and graB survival has not been shown in RCTs
(Srinivas 2005). Instead, similar kidney function and graB survival
was found in long-term follow-up data of two of the pivotal trials
(MMF TRI Study 1996; MMF US Study 1995). The lack of statistical
power within the single studies is a crucial aspect that needs to
be considered for this phenomenon. Calculations have shown that
a sample size of 8 to 10 times the number actually enrolled in
the pivotal trials would have been needed to prove a benefit on
graB survival (Ekberg 2003). Meta-analyses are the tool of choice to
address the limitation of under-powered studies.
Observational evidence also highlighted that the use of
considerably strong immunosuppressive regimens in recent years
has led to acute rejection rates as low as 10% to 15%, sometimes
even lower; but that this reduced acute rejection rate has not
translated into similar prolongation of long-term graB survival
(Tantravahi 2007). This may be due to side eLects directly
related to the level of immunosuppression, such as (opportunistic)
infections (e.g. Polyoma BK/JC virus or cytomegalovirus (CMV)
(Marcen 2009; Staatz 2007) and malignancies (Domhan 2009;
Johnston 2010). These complications not only impact patient
survival. For example, MMF was reported to be associated with the
incidence of the very rare but life threatening progressive multifocal
leukoencephalopathy which is caused by JC-virus activation (FDA
2008). In addition, these complications have been shown to directly
impair graB function, e.g. polyomavirus-associated nephropathy
(PVAN). Finally, one of the major causes for death in patients with a
functioning graB is cardiovascular disease (CVD) (Israni 2010). Side
eLects of immunosuppressive agents, particularly CNI and mTOR-
inhibitors, further aggravate classical CVD risk factors, such as
hypertension, diabetes and dyslipidaemia (Webster 2005; Webster
2006).
Aside from safety issues due to the general level of
immunosuppression, specific adverse events vary for both
proliferation-inhibitors. AZA oBen provokes leucopenia and may
increase the risk of cancer through accumulation of mutagenic
metabolites (Domhan 2009). MPA causes more gastrointestinal
problems like nausea and diarrhoea and is also contraindicated
in pregnancy because of negative eLects on foetal development
(Sifontis 2006).
The relative eLicacy of MMF versus AZA in the prevention of
rejection and their impact on long-term graB survival might also be
modulated by the concomitant immunosuppressive therapy and
by the overall level of modern transplant therapy. The MYSS Study
2004 compared both drugs in a CsA-ME based regimen and showed
similar acute rejection rates, graB function and survival in both
groups up to seven years of follow-up.
O B J E C T I V E S
This review of RCTs aimed to look at the benefits and harms of
MPA versus AZA in primary immunosuppressive regimens aBer
kidney transplantation. Both agents were compared regarding
their eLicacy for maintaining graB and patient survival, prevention
of acute rejection, maintaining graB function, and their safety,
including infections, malignancies and other adverse events.
Furthermore, we investigated potential eLect modifiers, such
as transplantation era and the concomitant immunosuppressive
regimen in detail.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs and quasi-RCTs (RCTs in which allocation
to treatment was performed by somewhat predictable methods)
looking at the direct comparison of MPA versus AZA in primary
immunosuppressive regimens in kidney transplantation, without
restriction on language or publication type.
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Types of participants
Inclusion criteria
We included studies investigating children (< 18 years) and adult
kidney transplant recipients with any duration of follow-up in the
review, regardless of donor type (living or deceased) or previous
transplantation status.
Exclusion criteria
We excluded studies that involved multi-organ transplantation
(e.g. kidney-pancreas, kidney-liver) as well as studies in which
the intervention was performed in secondary regimens (when the
immunosuppressive therapy was changed due to acute rejection,
chronic allograB nephropathy (CAN), CNI toxicity or in stable graB
function status).
Types of interventions
We included studies in the review in which MPA, namely MMF or
ec-MPS, was tested against AZA in primary immunosuppressive
regimens along with any concomitant immunosuppressive therapy
(e.g. use of induction antibody treatment, any formulation
of CNI (CsA original formulation, CsA-ME, Tac), various CNI
target levels, treatment with or without steroids or mTOR
inhibitors). Concomitant immunosuppression regimens needed to
be identical in both the intervention and control groups (e.g.
studies investigating MMF/CsA versus AZA/Tac were excluded).
Types of outcome measures
Primary outcomes
GraB loss and all-cause mortality were considered primary
outcomes of interest in terms of eLicacy and safety, respectively.
Secondary outcomes
Secondary outcomes were acute rejection, CAN, graB function
measures (e.g. serum creatinine (SCr), creatinine clearance
(CrCl), proteinuria), immunosuppression related (malignancies,
infections) and drug specific (e.g. new onset diabetes aBer
transplantation (NODAT), haematological disorders, such as
leucopenia, anaemia, elevated liver enzymes) side eLects.
Following the suggestions of the GRADE working group (Atkins
2004) we classified outcomes of interest according to clinical
importance (critical – high – moderate).
Critical importance• Death and death with a functioning graB• GraB loss, and graB loss censored for death• Malignancies (except non-melanoma skin cancer).
High importance• Acute rejection, biopsy-confirmed acute rejection, and steroid
resistant/antibody-treated acute rejection• CAN• Infections of any type, including CMV infection, tissue invasive
CMV disease, PVAN• Non-melanoma skin cancer.
Moderate importance• Kidney function measures: absolute values of measured
glomerular filtration rate (GFR), estimated GFR, CrCl, SCr, and
proteinuria (in any measurement and metric)• Adverse events, including hypertension, hyperlipidaemia,
NODAT, leucopenia, anaemia, nausea, diarrhoea, elevation of
liver enzymes or bilirubin.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised
Register (to 21 September 2015) through contact with the Trials'
Search Co-ordinator using search terms relevant to this review
(Appendix 1). The Specialised Register contains studies identified
from the following sources.
1. Quarterly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the proceedings
of major kidney and transplant conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based on
the scope of Cochrane Kidney and Transplant. Details of these
strategies as well as a list of handsearched journals, conference
proceedings and current awareness alerts are available in the
Specialised Register section of information about the Cochrane
Kidney and Transplant.
Searching other resources
We also checked the reference lists of nephrology textbooks, review
articles, and identified studies for this review. In particular, we
reconciled the studies included in previous systematic reviews
addressing MMF versus AZA (Knight 2009; Wang 2004a; Wang 2004b;
Wang 2005; Zhang 2004).
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and
abstracts potentially relevant to the review. All titles and abstracts
were screened by at least two authors. Studies not applicable to
the review were discarded. Those references that might include
relevant data or information on studies were retrieved in full text
and the described authors determined if the studies satisfied the
inclusion criteria.
Data extraction and management
All articles of eligible studies were retrieved in full text and data
relevant for the review were extracted into standardized forms in
duplicate independently by two authors.
• Data about study design, inclusion and exclusion criteria,
items of quality assessment, definitions of primary and
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secondary study endpoints, etc. were extracted into an Excel file.
Information from multiple publications of the same study were
reconciled and condensed accordingly• Data on outcomes of interest were extracted in a separate Excel
file. Results for dichotomous outcomes were extracted as actual
numbers of patients achieving the respective outcome. If only
proportions were reported in the studies, we calculated the
numbers based on intention-to-treat (ITT) population or on-
treatment population as specified in the article.• Studies reported in non-English language were translatedand
data were assessed respectively
Disagreements were resolved via discussion among authors. All
data were entered into Review Manager 5 and checked twice.
Assessment of risk of bias in included studies
The following items were assessed using the risk of bias assessment
tool (Higgins 2011) (see Appendix 2).
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study?* Participants and personnel (performance bias)* Outcome assessors (detection bias)• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e<ect
Dichotomous outcome results (e.g. death, graB loss, acute
rejection) are expressed as risk ratio (RR) with 95% confidence
intervals (CI). For treatment eLects on continuous scales of
measurement (e.g. SCr, CrCl, GFR), the mean diLerence (MD)
was used. The proportion of events per treatment arm at the
desired time-points were extracted from Kaplan Meier curve
graphs using planimetric (digitising) soBware, such as the Engauge
Digitizer program (http://digitizer.sourceforge.net/), assuming no
censoring. The mean and the standard error (SE)/standard
deviation (SD) of continuous outcomes were assessed at the
respective time-points along with the number of patients at risk for
the given outcome. If the SD was missing for continuous outcomes,
it was imputed based on the median SD of studies in which the
relevant outcome was reported.
Dealing with missing data
Any further information required from the original author was
requested by written correspondence (e.g. emailing corresponding
author) and any relevant information obtained was included in the
review. Evaluation of important numerical data such as screened,
randomised patients as well as ITT, as-treated and per-protocol
population was carefully performed. Attrition rates, for example
drop-outs, losses to follow-up and withdrawals were investigated.
Issues of missing data and imputation methods (for example, last-
observation-carried-forward) were critically appraised (Higgins
2011).
If information about covariates that were further investigated in
meta-regression analyses (see below) was missing, we imputed the
year of transplantation from the year of first publication minus
duration of follow-up minus two years, to account for lag between
study completion and publication. If the AZA dose was reported to
be body-weight-adjusted (mg/kg/d) it was transformed into mg/d
using the mean body weight as reported in the study, and by using
70 kg (60 kg in exclusively Asian populations) if information on body
weight was missing. Looking at the year of transplantation, it was
likely that the original oil-based formulation of CsA was used in
many studies not providing detailed information on which kind of
CsA drug was tested, and thus CsA original formulation and studies
without this information were grouped and compared to studies
reporting the use of CsA-ME. Studies in which more than one MMF
dose was tested, i.e. 3 g versus 2 g (MMF TRI Study 1996; MMF US
Study 1995), 2 g versus 1.5 g (Ling 1998) and 2 g versus 1 g (Mendez
1998), were split into two independent studies and each compared
to half of the group and events of the patients treated with AZA. In
the case of uneven numbers, the nearest integer was used.
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance
and with the I2 test (Higgins 2003). I2 values of 25%, 50% and
75% correspond to low, medium and high levels of heterogeneity.
Considerable clinical heterogeneity was assumed due to a
multitude of concomitant immunosuppressive regimens in studies
of a long era of kidney transplantation, and over a variety of
diLerent study populations and clinical settings.
Assessment of reporting biases
We planned to construct funnel plots to assess for the potential
existence of small study bias (Higgins 2011).
Data synthesis
Review Manager 5 was used for all meta-analyses, using Der
Simonian and Laird random-eLects models by default because of
clinical heterogeneity rather than fixed-eLects models although
we frequently found no evidence for statistical heterogeneity.
Summary results, i.e. RR and MD, are presented in forest-plots
according to subgroups of clinically relevant time intervals (≤ 6
months, 6 to 12 months or ≤ 1 year, 1 to 4 years, ≥ 4 years). Moreover,
a subgroup longest duration of follow-up was defined that included
data on the longest time interval of each study for the primary study
population, i.e. we used six months data provided for the entire
study population, rather than 24 months data of only a subgroup
of the original study. These study data were further used for meta-
regression analyses (adjusted for duration of follow-up, see below).
Subgroup analysis and investigation of heterogeneity
Meta-regression
We performed random eLects meta-regression analyses (Meta-
Analyst for Windows 7, version December 2013, Brown University,
Providence, RI, USA; Wallace 2009) to explore possible sources
of heterogeneity on the following outcomes: mortality, death-
censored graB loss, malignancy (any), acute rejection (any), CMV
viraemia/syndrome, tissue-invasive CMV disease, SCr, diarrhoea
and leucopenia. The logarithmic form of the RR was analysed and
back-transformed regression coeLicients are presented as relative
risk ratio (RRR) with 95% CI. For continuous outcomes, the MD was
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modelled and the coeLicient with 95% CI is displayed in the table.
Furthermore, bubble plots with the size of the bubble reflecting
weight of the study in the meta-regression, visualise the direction
of the association between the covariate and the logarithmic RR
of MMF versus AZA. Tested covariates included study level factors
(year of transplantation, donor type, previous transplantation,
dose of the study drugs, antibody induction therapy, maintenance
CNI (Tac versus CsA), CsA formulation) and items of study quality
and risk of bias (blinding, publication type, industry funding).
The fact that we tested a multitude of factors on a variety of
outcomes on a dataset with limited sample size (22 studies)
provided a high chance that associations were found or even
missed only by chance. Our primary interest was the direction of
any eLect modification rather than the magnitude of the relative
eLect. Therefore, and also with our concern about type II error, we
have used a threshold of P ≤ 0.10 and presented these results in
the respective sections (and highlighted these results accordingly
in the table).
Subgroup analyses
To further investigate heterogeneity, subgroup analyses were
performed (using Review Manager 5) on the following strata: RCT
versus quasi-RCT, inclusion of children, ITT analysis, publication
type and source of funding.
Sensitivity analysis
Sensitivity analyses (performed in Meta-Analyst) were used to test
the robustness of findings. Results from studies were sequentially
included or excluded from the analysis with a particular focus on
the largest or most dominant studies.
R E S U L T S
Description of studies
Results of the search
The literature search yielded a total of 2852 citations (Figure 1),
including handsearching of the reference lists of included studies
and previously published systematic reviews on MMF versus AZA in
kidney transplantation. Notably, the reference lists of two Chinese
systematic reviews about MMF versus AZA (Wang 2004a; Wang
2004b; Wang 2005; Zhang 2004) were reconciled with the search
results of the current review which led to the addition of two eligible
studies not identified by the electronic searches.
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Figure 1.   Literature search and identification of studies
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In total, 94 reports of 23 studies (Army Hospital 2002; Baltar 2002;
Busque 2001; COSTAMP Study 2002; Egfjord 1999; Folkmane 2001;
Isbel 1997; Ji 2001; Joh 2005; Johnson 2000; Keven 2003; Ling 1998;
Merville 2004; Miladipour 2002; Mendez 1998; MMF TRI Study 1996;
MMF US Study 1995; MYSS Study 2004; Sadek 2002; Suhail 2000;
Sun 2002b; Tuncer 2002; Weimer 2002) enrolling 3301 patients were
included (see Characteristics of included studies). In addition, one
ongoing Italian study that aims to investigate MMF versus AZA
as sole immunosuppressive treatment aBer antibody (IL-2, ATG)
induction and CsA-ME based regimen for one year, was identified
(ATHENA Study 2012, see Characteristics of ongoing studies). While
15 studies were reported at least once as full article in a peer
reviewed journal (Baltar 2002; COSTAMP Study 2002; Ji 2001; Joh
2005; Johnson 2000; Keven 2003; Merville 2004; Mendez 1998; MMF
TRI Study 1996; MMF US Study 1995; MYSS Study 2004; Sadek 2002;
Sun 2002b; Tuncer 2002; Weimer 2002), five studies (Busque 2001;
Folkmane 2001; Miladipour 2002; Suhail 2000; Tuncer 2002) were
published in Transplantation Proceedings only, and three studies
(Army Hospital 2002; Egfjord 1999; Isbel 1997) were presented
solely as conference abstracts. Nineteen studies published at least
one article in English, three studies were published exclusively
in Chinese (Ji 2001; Ling 1998; Sun 2002b) and one study was in
Spanish language (Baltar 2002). Of the identified 23 studies, one
(Isbel 1997) did not provide any information on outcomes relevant
for the review.
Prior to publication an additional report was identified (Do 2001a).
This appears to be a report of Joh 2005. Details will be assessed in
a future update of this review
Included studies
All studies investigated MMF versus AZA, whereas no study used
ec-MPS. Doses of study drugs were reported in 19 studies (Busque
2001; COSTAMP Study 2002; Egfjord 1999; Folkmane 2001; Ji 2001;
Joh 2005; Johnson 2000; Keven 2003; Ling 1998; Merville 2004;
Miladipour 2002; Mendez 1998; MMF TRI Study 1996; MMF US
Study 1995; MYSS Study 2004; Sadek 2002; Suhail 2000; Sun 2002b;
Tuncer 2002) and ranged from 1 to 3 g/d for MMF, and 50 to
175 mg/d for AZA. Patients were enrolled in the studies between
1992 and 2002 and 78% (2575 participants) were studied in nine
multicentre studies (Busque 2001; COSTAMP Study 2002; Johnson
2000; Merville 2004; Mendez 1998; MMF TRI Study 1996; MMF US
Study 1995; MYSS Study 2004; Sadek 2002).
Participants
In 14 studies (Baltar 2002; Busque 2001; Egfjord 1999; Folkmane
2001; Ji 2001; Joh 2005; Johnson 2000; Ling 1998; Merville 2004;
Mendez 1998; MMF TRI Study 1996; MMF US Study 1995; MYSS
Study 2004; Suhail 2000), only deceased donor transplantation
was performed; one study exclusively investigated living donor
transplantation (Army Hospital 2002); five studies included both
deceased and living (COSTAMP Study 2002; Keven 2003; Sadek
2002; Tuncer 2002; Weimer 2002); and three studies did not report
the type of graB donation (Isbel 1997; Miladipour 2002; Sun 2002b).
Two studies included children (Johnson 2000; Mendez 1998), eight
exclusively enrolled adult recipients (Busque 2001; COSTAMP Study
2002; Keven 2003; Merville 2004; MMF TRI Study 1996; MMF US
Study 1995; MYSS Study 2004; Sadek 2002) and no information
was provided in the remaining 13 studies (Army Hospital 2002;
Baltar 2002; Egfjord 1999; Folkmane 2001; Isbel 1997; Ji 2001; Joh
2005; Ling 1998; Miladipour 2002; Suhail 2000; Sun 2002b; Tuncer
2002; Weimer 2002). The inclusion of patients that previously lost
a kidney graB and the values of panel reactive antibodies (PRA)
are widely considered measures of baseline immunological risk of
the study population; however, this information was limited in the
studies.
Patients with previous kidney transplants were included in seven
studies (COSTAMP Study 2002; Egfjord 1999; Folkmane 2001;
Miladipour 2002; Mendez 1998; MMF TRI Study 1996; Weimer 2002)
(ranging from 5.3% to 14.3% of participants), excluded in 10 studies
(Army Hospital 2002; Baltar 2002; Busque 2001; Johnson 2000;
Merville 2004; MMF US Study 1995; MYSS Study 2004; Sadek 2002;
Suhail 2000; Tuncer 2002), and not reported in six studies (Isbel
1997; Ji 2001; Joh 2005; Keven 2003; Ling 1998; Sun 2002b). In
only eight studies (Ji 2001; Joh 2005; Johnson 2000; Merville
2004; Mendez 1998; MMF TRI Study 1996; MMF US Study 1995;
Weimer 2002), information about PRA was provided, however this
information was not described consistently (e.g. as proportion
above a certain cut-oL (> 10% or > 20%), or maximum PRA level).
Overall, most studies enrolled patients with considerably low to
moderate immunological risk.
Concomitant Immunosuppression
A depleting antibody induction therapy (ATG, ALG or OKT3) was
used in five studies (Egfjord 1999; Ji 2001; Merville 2004; Mendez
1998; MMF US Study 1995) as initiating immunosuppressive agent
in all patients. This therapy was only used in a subset of patients
in five studies (e.g. those with higher immunological baseline
risk, or patients experiencing delayed graB function) (Busque
2001; Johnson 2000; Keven 2003; Tuncer 2002; Weimer 2002). The
remaining 13 studies (Army Hospital 2002; Baltar 2002; COSTAMP
Study 2002; Folkmane 2001; Isbel 1997; Joh 2005; Ling 1998;
Miladipour 2002; MMF TRI Study 1996; MYSS Study 2004; Sadek
2002; Suhail 2000; Sun 2002b) did not use any antibody induction
therapy. All maintenance immunosuppressive regimens were CNI
based, while 18 studies used CsA (Army Hospital 2002; Baltar 2002;
Egfjord 1999; Folkmane 2001; Isbel 1997; Ji 2001; Joh 2005; Ling
1998; Merville 2004; Miladipour 2002; MMF TRI Study 1996; MMF
US Study 1995; MYSS Study 2004; Sadek 2002; Suhail 2000; Sun
2002b; Tuncer 2002; Weimer 2002), four studies used Tac (Busque
2001; COSTAMP Study 2002; Johnson 2000; Mendez 1998) and one
study (Keven 2003) reported the use of either CsA or Tac. Of those
using CsA, six studies (Egfjord 1999; Merville 2004; MYSS Study 2004;
Sadek 2002; Suhail 2000; Weimer 2002) reported treatment with
CsA-ME, two studies (MMF TRI Study 1996; MMF US Study 1995)
clearly stated the use of the original CsA solution, one study used
both CsA and CsA-ME (Tuncer 2002), and 10 studies (Army Hospital
2002; Baltar 2002; Folkmane 2001; Isbel 1997; Ji 2001; Joh 2005;
Keven 2003; Ling 1998; Miladipour 2002; Sun 2002b) did not clearly
specify the CsA formulation.
Target CNI trough levels were reported for all four studies using
Tac (C0 levels at month 3: 5 to 15 ng/mL), but in only six studies
using CsA (C0levels at month 3: 100 to 500 ng/mL) (Folkmane
2001; Ji 2001; Ling 1998; Merville 2004; MYSS Study 2004; Sadek
2002). Two CsA studies reported the dosage of CsA as being
delivered “according to local practice” (MMF TRI Study 1996; MMF
US Study 1995) and no information was provided in 11 studies
(Army Hospital 2002; Baltar 2002; Egfjord 1999; Isbel 1997; Joh
2005; Keven 2003; Miladipour 2002; Suhail 2000; Sun 2002b; Tuncer
2002; Weimer 2002). Corticosteroids completed the concomitant
immunosuppressive regimen in all studies, while in one study
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(MYSS Study 2004) steroid therapy was withdrawn according to
protocol. Notably, IL-2 receptor antibody induction or mTOR-
inhibitor therapy was not used in the studies identified for the
review.
Excluded studies
A total of 87 records (38 studies) were excluded as they did not fulfil
the inclusion criteria (see Characteristics of excluded studies). The
reasons for exclusion were as follows.
• Study design not RCT or quasi-RCT (nine studies)• Not solely kidney transplantation (two studies); studies
enrolling patients undergoing multiorgan transplantation, e.g.
simultaneous kidney-pancreas transplantation were excluded.• Not primary immunosuppressive regimen (18 studies), i.e. the
randomisation to MPA versus AZA was not performed at the time
of transplantation, but subsequently during the maintenance
phase (e.g. due to previous acute rejection, CAN, CNI-toxicity or
in stable graB function status)• Randomised intervention not of interest for the review (eight
studies), i.e. not MPA versus AZA• Unequal concomitant regimen (four studies), i.e. diLerent
immunosuppressive regimens were administered to patients
randomised to treatment and control group (e.g. MMF/CsA
versus AZA/Tac.
Risk of bias in included studies
Details of the risk of bias assessment tool (Appendix 2) can be
found for each study in Characteristics of included studies and are
displayed in Figure 2, Figure 3.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
 
Allocation
Details about the methodology of studies were generally limited.
Of the included 23 studies, 21 were considered RCTs, while two
studies reported allocation methods that classified them as quasi-
RCT (studies in which the method of allocation to the respective
treatments was somewhat predictable) (Ji 2001; Joh 2005). In
most studies, no detailed information was provided on allocation
concealment (19 studies) or the procedure for randomisation (21
studies).
Blinding
Only two studies blinded the intervention of the study drug to
patients and study personnel using placebo (MMF TRI Study 1996;
MMF US Study 1995).
Incomplete outcome data
Broad descriptions of the course of patients in the study and drop-
out rates were reported in 14 studies (COSTAMP Study 2002; Ji
2001; Joh 2005; Johnson 2000; Keven 2003; Ling 1998; Merville
2004; Mendez 1998; MMF TRI Study 1996; MMF US Study 1995; MYSS
Study 2004; Sadek 2002; Suhail 2000; Weimer 2002), while very
detailed information about patients (e.g. information about cross-
over treatments, MMF to AZA and vice versa) was available in four
studies (Johnson 2000; Mendez 1998; Suhail 2000; Weimer 2002).
Selective reporting
Outcome reporting and outcome details varied substantially
among studies (see Figure 1). One study did not report any
outcome information relevant for the review (Isbel 1997). GraB-
related outcomes were available for the majority of studies. All
22 studies provided information on acute rejection, 17 reported
graB loss (Busque 2001; Egfjord 1999; Folkmane 2001; Ji 2001; Joh
2005; Johnson 2000; Ling 1998; Merville 2004; Miladipour 2002;
Mendez 1998; MMF TRI Study 1996; MMF US Study 1995; MYSS
Study 2004; Sadek 2002; Suhail 2000; Tuncer 2002; Weimer 2002)
and 15 reported a measure of graB function (Army Hospital 2002;
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Busque 2001; COSTAMP Study 2002; Egfjord 1999; Johnson 2000;
Ling 1998; Merville 2004; Miladipour 2002; MMF TRI Study 1996;
MMF US Study 1995; MYSS Study 2004; Sadek 2002; Suhail 2000;
Sun 2002b; Weimer 2002). Mortality rates were also reported in 16
studies (Busque 2001;COSTAMP Study 2002; Egfjord 1999; Ji 2001;
Joh 2005; Johnson 2000; Ling 1998; Mendez 1998; Merville 2004;
MMF US Study 1995; MMF TRI Study 1996; MYSS Study 2004; Sadek
2002; Suhail 2000; Tuncer 2002; Weimer 2002). Data on CAN were
sparse (three studies, Merville 2004; Tuncer 2002; Weimer 2002).
Complications of immunosuppressive therapy were reported much
less frequently than eLicacy outcomes: any malignancy was
reported in five studies (Mendez 1998; MMF TRI Study 1996; MMF US
Study 1995; MYSS Study 2004; Sadek 2002) and infections such as
Herpes was reported in four studies (COSTAMP Study 2002; Johnson
2000; MMF TRI Study 1996; MMF US Study 1995), and pneumocystis
in five studies (Johnson 2000; Mendez 1998; MMF TRI Study 1996;
MMF US Study 1995; MYSS Study 2004). Events and details of CMV
viraemia/syndrome were reported in 13 studies (COSTAMP Study
2002; Ji 2001; Joh 2005; Johnson 2000; Keven 2003; Merville 2004;
Mendez 1998; Miladipour 2002; MMF TRI Study 1996; MMF US Study
1995; MYSS Study 2004; Sadek 2002; Weimer 2002), and CMV tissue-
invasive disease in seven studies (Folkmane 2001; Ji 2001; Johnson
2000; Mendez 1998; MMF TRI Study 1996; MMF US Study 1995; Suhail
2000). Only one study provided information on PVAN (Weimer
2002). Aside from diarrhoea (11 studies) (COSTAMP Study 2002; Ji
2001; Ling 1998; Mendez 1998; Miladipour 2002; MMF TRI Study
1996; MMF US Study 1995; MYSS Study 2004; Sadek 2002; Suhail
2000; Sun 2002b), and leucopenia (12 studies) (Army Hospital 2002;
COSTAMP Study 2002; Ji 2001; Ling 1998; Mendez 1998; Miladipour
2002; MMF TRI Study 1996; MMF US Study 1995; MYSS Study 2004;
Sadek 2002; Suhail 2000; Sun 2002b), the occurrence of adverse
events was inconsistently and rarely reported, and most oBen not
defined in detail.
Other potential sources of bias
Analysis of outcomes by ITT was stated by the authors and
supported by details of the presented results in 12 studies
(COSTAMP Study 2002; Egfjord 1999; Ji 2001; Johnson 2000; Ling
1998; Mendez 1998; Merville 2004; MMF TRI Study 1996; MMF US
Study 1995; MYSS Study 2004; Sadek 2002; Weimer 2002). The type
of analysis was unclear in an additional nine studies (Baltar 2002;
Busque 2001; Folkmane 2001; Isbel 1997; Joh 2005; Miladipour
2002; Suhail 2000; Sun 2002b; Tuncer 2002) and not performed
by ITT in two studies (Army Hospital 2002; Keven 2003). Only two
studies (Merville 2004; MYSS Study 2004) clearly stated funding
independent from pharmaceutical companies (407 patients, 12%),
while nine studies (2252 patients, 68%) reported industry support
(Baltar 2002; Busque 2001; COSTAMP Study 2002; Johnson 2000;
Mendez 1998; MMF TRI Study 1996; MMF US Study 1995; Sadek 2002;
Weimer 2002). For the remaining 11 studies the funding source was
unclear (Army Hospital 2002; Egfjord 1999; Folkmane 2001; Isbel
1997; Ji 2001; Joh 2005; Keven 2003; Ling 1998; Miladipour 2002;
Suhail 2000; Sun 2002b; Tuncer 2002).
E<ects of interventions
See: Summary of findings for the main comparison
Mycophenolate mofetil (MMF) versus azathioprine (AZA) for
primary immunosuppression in kidney transplant recipients
Summary analyses of the comparative eLicacy and safety of MMF
versus AZA can be found in the section Analyses 1. Outcomes of
interest for the review were frequently reported at multiple time
points, thus subgroups of clinically meaningful time intervals are
displayed. Summary results reported in the text represent longest
duration of follow-up unless stated otherwise.
Primary outcomes
Death
No statistically significant diLerence for MMF versus AZA treatment
was found for all-cause mortality at any time interval (Analysis
1.1.4 (16 studies, 2987 participants): RR 0.95, 95% CI 0.70 to 1.29;
I2 = 0%). Disease-specific mortality was reported less frequently;
therefore no robust conclusions can be drawn. While being clearly
not statistically significant, the point estimate for death due to
cardio-, cerebrovascular disease favoured MMF (11 studies: RR 0.66,
95% CI 0.37 to 1.18, P = 0.16), and the point estimate for death
due to infectious causes suggested reduced risk in AZA patients (11
studies: RR 1.28, 95% CI 0.57 to 2.91, P = 0.55) (detailed data not
shown).
Gra loss
Consistently across all time-intervals, MMF treatment significantly
reduced the risk for graB loss including death (Analysis 1.2.4 (15
studies, 2653 participants): RR 0.82, 95% CI 0.67 to 1.00; I2 = 0%) as
well as for death-censored graB loss (Analysis 1.3.4 (17 studies, 2540
participants): RR 0.78, 95% CI 0.62 to 0.99; I2 = 0%). In particular,
the risk of graB loss due to rejection was markedly reduced in MMF
treated patients (13 studies, RR 0.59, 95% CI 0.41 to 0.86, P < 0.01),
while data on graB loss because of any other specific cause was
rarely reported (detailed data not shown).
Non-functioning gra
Information regarding primary non-function of the graB was
provided by 11 studies, however, only 18 events were observed
by four studies investigating a total of 1601 patients indicating no
significant diLerence between the treatments (Analysis 1.4: RR 0.47,
95% CI 0.19 to 1.18; I2 = 0%).
Statistical heterogeneity was not observed for these primary
outcomes. Meta-regression analyses (See Table 1: Meta-regression
analyses) suggested a more pronounced risk for death-censored
graB loss in AZA patients, if higher doses of MMF were used (RRR
0.26, 95%CI 0.06 to 1.24, P = 0.09; Figure 4, panel A). Neither
of the remaining study level factors indicated any modification
of the treatment eLect. In particular, varying baseline risk for
death censored graB loss as indicated by the control rate (i.e. the
incidence of death censored graB loss in AZA treated patients) was
not related to the magnitude of the treatment eLect of MMF versus
AZA (RRR 0.13, 95% CI 0.01 to 10.70, P = 0.37, Figure 4, panel B).
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Figure 4.   Meta-regression of logarithmic relative risk of death censored graB loss by MMF dose (panel A) and by
control rate (panel B)
 
Secondary outcomes
Malignancy
The summary eLect for any malignancy indicated a reduced risk in
MMF-treated patients (Analysis 1.5.1 (5 studies, 1734 participants):
RR 0.81, 95% CI 0.60 to 1.09; I2 = 0%), but this finding was not
statistically significant. Similarly, the risk for non-melanoma skin
cancer tended to be reduced by approximately 20% in MMF treated
patients, but the association did not reach statistical significance
due to the limited number of studies and events (Analysis 1.5.3 (4
studies, 1416 participants): RR 0.78, 95% CI 0.46 to 1.34; I2 = 19%).
Acute rejection
A consistent risk reduction for any acute rejection (about 35%) was
observed with MMF-treatment across all time intervals (Analysis
1.6.4 (22 studies, 3301 participants): RR 0.65, 95% CI 0.57 to 0.73;
I2 = 9%). The eLect was approximately 40% for biopsy-proven
acute rejection (Analysis 1.7.4 (12 studies, 2696 participants): RR
0.59, 95% CI 0.52 to 0.68; I2 = 0%) and approximately 50% in
steroid-resistant/antibody-treated acute rejection (Analysis 1.8.4
(15 studies, 2914 participants): RR 0.48, 95% CI 0.36 to 0.65; I2 = 14%)
both with low statistical heterogeneity. In meta-regression analyses
(see Table 1), a higher AZA dose (RRR 1.01, 95% CI 1.00 to 1.01, P
= 0.10, Figure 5, panel B) and the use of CsA-ME rather than the
original CsA solution (RRR 1.27, 95% CI 0.98 to 1.65, P = 0.07) tended
to attenuate the benefit of MMF versus AZA for acute rejection (i.e.
a RR closer to 1, but still favouring MMF treatment). No clear signal
was observed for transplantation in the most recent era (RRR 1.03,
95% CI 0.99 to 1.06, P = 0.12, Figure 5, panel A) and a higher MMF
dose (RRR 0.90, 95% CI 0.74 to 1.08, P = 0.24, Figure 5, panel C).
Moreover, the benefit of MMF over AZA treatment on the reduction
of acute rejection was more pronounced with an increased control
rate, indicating elevated immunological baseline risk of the study
population (RRR 0.34, 95% CI 0.10 to 1.09, P = 0.08, Figure 5, panel
D).
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Figure 5.   Meta-regression of logarithmic relative risk of any acute rejection by year of transplantation (panel A),
AZA-dose (panel B), MMF-dose (panel C) and by control rate (panel D)
 
Chronic allogra nephropathy
Meta-analysis showed a significant reduction of the risk for CAN
with MMF treatment (Analysis 1.9.4 (3 studies, 203 participants): RR
0.69, 95% CI 0.48 to 0.99; I2 = 0%). Two studies required diagnosis
by biopsy (Merville 2004; Weimer 2002) and in one study biopsy was
optional (Tuncer 2002).
Infection
Evidence on infections such as urinary tract infection/cystitis,
Herpes zoster, Candida and Aspergillus infections, is limited due
to inconsistent and sparse reporting (Analysis 1.10). Only CMV
viraemia/syndrome was reported by a substantial number of
studies and no clear signal of a benefit for any treatment was
found (Analysis 1.11.3 (13 studies, 2880 participants): RR 1.06, 95%
CI 0.85 to 1.32; I2 = 24%). However, in seven studies the risk of
tissue-invasive CMV disease was significantly elevated with MMF
treatment (Analysis 1.12.3 (7 studies, 1510 participants): (RR 1.70,
95% CI 1.10 to 2.61; I2 = 0%). None of the tested study level
factors indicated treatment eLect modification in meta-regression
analyses on either CMV viraemia/syndrome or tissue-invasive CMV
disease (See Table 1). Only one study reported no observed events
of PVAN (Weimer 2002). Although Pneumocystis carinii/jiroveci
pneumonia (PCP) were generally rare diseases in the studies (5
studies, 9 events in 1650 patients), eight of these events occurred
in AZA-treated patients, thus resulting in a statistically significant
result favouring MMF treatment (Analysis 1.10: RR 0.19, 95% CI 0.05
to 0.69; I2 = 0%).
Gra function
While 15 studies reported a measure of graB function, the vast
majority did not provide detailed information on either the number
of patients in whom these measurements were performed (those
with a functioning graB at the various time points) or the standard
error/deviation of the reported mean. In general, graB function did
not diLer substantially at the various time intervals as indicated by
point estimates between 0.01 and 0.05 mg/dL. Still, numerically,
slightly lower mean values of SCr were observed in AZA treated
patients (Analysis 1.13.3 (15 studies, 2233 participants): MD 0.05
mg/dL, 95% CI -0.05 to 0.15; I2 = 60%). Substantial heterogeneity
was observed. Meta-regression on study level factors (See Table
1) suggested even greater benefit for AZA treatment if exclusively
patients receiving their first graB were studied (MD coeLicient -0.13,
95% CI -0.25 to -0.02; P = 0.03). While higher doses of AZA tended
to further enhance the benefit for AZA treatment on graB function
(MD coeLicient 0.004, 95% CI -0.001 to 0.009, P = 0.08, Figure 6,
panel A), yet no such trend was found for higher doses of MMF
although the point estimate of the coeLicient suggested possible
eLect modification (MD coeLicient 0.08, 95% CI -0.04 to 0.19, P =
0.20, Figure 6, panel B). Further measures of graB function (CrCl
or GFR) were less frequently reported but demonstrated similar
results (Analysis 1.14). Data on proteinuria were provided by only
three studies (Merville 2004; MMF TRI Study 1996; MYSS Study 2004)
and no reliable conclusions could be drawn (Analysis 1.15).
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Figure 6.   Meta-regression of mean di<erence in serum creatinine (mg/dL) by AZA dose (panel A), and by MMF dose
(panel B)
 
Adverse events
Adverse events and side eLects were very inconsistently reported.
Gastrointestinal disorders were more common under MMF therapy
with a statistically significant diLerence for diarrhoea (Analysis
1.17.1 (11 studies, 2638 participants): RR 1.55, 95% CI 1.32 to 1.83;
I2 = 0%) and trends for both abdominal pain (Analysis 1.17.2 (3
studies, 1311 participants): RR 1.18, 95% CI 0.97 to 1.44; I2 = 0%)
and vomiting (Analysis 1.17.3 (4 studies, 1587 participants): RR 1.27,
95% CI 0.83 to 1.94; I2 = 67%). The only two studies reporting
gastrointestinal bleeding suggest a significantly elevated risk in
MMF treated patients (Analysis 1.17.4 (575 participants): RR 3.99,
95% CI 1.07 to 14.86; I2 = 0%).
Insulin-treated NODAT was reported in four studies where the
maintenance regimen was based on Tac, which itself is a known
risk factor for the occurrence of NODAT (Webster 2005). The risk for
NODAT was further significantly enhanced by AZA treatment, vice
versa reduced by MMF (Analysis 1.18.1 (4 studies, 445 participants):
RR 0.57, 95% CI 0.34 to 0.95; I2 = 0%). No clear eLect of either
treatment on anaemia, leucopenia, or dyslipidaemia was observed.
The risk of thrombocytopenia tended to be reduced by MMF
treatment (Analysis 1.19.5 (5 studies, 1492 participants): RR 0.73,
95% CI 0.52 to 1.03; I2 = 0%), as well as the risk of elevated liver
enzymes (Analysis 1.18.4 (3 studies, 272 participants): RR 0.50, 95%
CI 0.21 to 1.23; I2 = 50%).
Investigation of confounding, small study bias and sensitivity
analyses
We performed meta-regression analysis (Table 1) and subgroup-
analyses (Analyses 2 to 6) to investigate potential confounding by
various factors (e.g. study quality factors, data-analysis, publication
type) regarding their association with the eLect size of MMF versus
AZA.
Confounding by study design and data analysis
Blinding of the intervention, which was only performed by the two
pivotal trials (MMF TRI Study 1996; MMF US Study 1995), indicated
a possible eLect modification towards a greater diLerence in acute
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rejection favouring MMF treatment (RRR 0.87, 95% CI 0.70 to 1.07,
P = 0.19) and a reduced risk for tissue-invasive CMV disease (RRR
0.42, 95% CI 0.12 to 1.50, P = 0.18), but both results were not
statistically significant. The two studies classified as quasi-RCTs (Ji
2001; Joh 2005) reported a lower risk for CMV viraemia/syndrome
as compared to true RCTs (Analysis 2.3). No eLects on graB loss,
acute rejection, or SCr were found. Stronger eLects favouring MMF
treatment were reported in studies where ITT analysis was unclear
or certainly not performed for graB loss (Analysis 3.1) and acute
rejection (Analysis 3.2). In these studies, superior graB function in
MMF-treated patients was reported (Analysis 3.4). No substantial
heterogeneity of the results was observed if studies enrolling adults
only were compared to studies that also enrolled children (Analysis
4).
Confounding by funding source and publication type
Studies clearly reporting industry funding demonstrated a
potentially higher risk for CMV viraemia/syndrome in AZA treated
patients (Analysis 5.3; meta-regression RRR 1.53, 95% CI 0.96 to
2.41, P = 0.07). Studies that were explicitly not supported by
industry (Merville 2004; MYSS Study 2004) reported a smaller non-
significant benefit in the reduction of acute rejection in MMF treated
patients (Analysis 5.2; RRR 0.84, 95% CI 0.66 to 1.07, P = 0.17) and a
significant greater mean diLerence in SCr favouring AZA treatment
(Analysis 5.4; meta-regression MD coeLicient -0.14, 95% CI -0.25 to
-0.02, P = 0.02). Studies published at least once as a full manuscript
in a peer reviewed journal reported a somewhat attenuated risk
for death-censored graB loss (Analysis 6.1; RRR 1.82, 95% CI 0.84 to
3.95, P = 0.13). No other diLerences were found for the other tested
outcomes.
Small study bias and sensitivity analyses
Investigation of funnel plots did not indicate strong signals for
asymmetry (Figure 7). However, there are many explanations for
why an inverted funnel plot may be asymmetric, including chance,
heterogeneity, publication and reporting bias (Sterne 2011). Visual
judgment of funnel plots has been shown to be misleading in
empirical research (Lau 2006; Terrin 2005).
 
Figure 7.   Funnel plots of outcomes. GraB loss: censored for death (panel A, Analysis 1.3); acute rejection: total
(panel B, Analysis 1.6); Infection: cytomegalovirus viraemia/syndrome (panel C, Analysis 1.11)
 
Finally, in sensitivity analyses, the robustness of eLect estimates
and potential influence of single studies was tested by sequential
inclusion and exclusion of each study. In general, the point
estimates of all tested outcomes (mortality, death-censored graB
loss, any acute rejection, CMV viraemia/syndrome, tissue-invasive
CMV disease, SCr, diarrhoea and leucopenia) remained fairly stable
in each exclusion/inclusion step. Only two studies resulted in an
attenuation of significance for death-censored graB loss (MMF TRI
Study 1996: RR 0.79, 95% CI 0.60 to 1.03, P = 0.08; Egfjord 1999: RR
0.79, 95% CI 0.62 to 1.003, P = 0.053, respectively), but did not aLect
the magnitude of the summary eLect. Similarly, by leaving out MMF
US Study 1995 in tissue-invasive CMV disease, the eLect estimate
did not change markedly, but the association lost significance (RR
1.76, 95% CI 0.89 to 3.48, P = 0.11). No significant changes in the
mean diLerence for SCr were observed which would not make the
diLerence in SCr clinically meaningful (all MD < 0.09 mg/dL).
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D I S C U S S I O N
Summary of main results
Summarising the evidence from 23 RCTs identified for this review,
MMF was superior over AZA in eLicacy outcomes aBer kidney
transplantation. In particular, MMF demonstrated a statistically
significant risk reduction of about 20% for any graB loss as well as
death-censored graB loss compared to AZA. A stronger beneficial
eLect, although not statistically significant, was suggested in
studies using higher doses of MMF. The risk of acute rejection was
significantly reduced by about 35%, 40% if the rejection was proven
by biopsy and 50% for more severe rejection episodes that required
antibody treatment. This finding was more pronounced in studies
of enhanced overall baseline risk (as indicated by a higher control
rate). On the other hand, higher AZA dose and the concomitant
use of CsA-ME rather than CsA suggested an attenuated benefit
from MMF over AZA treatment. Although based on sparse data, MMF
treatment was related to lower rates of CAN. GraB function did
not diLer between the two drugs and the observed trend towards
slightly lower creatinine levels of 0.05 mg/dL in AZA treated patients
may not yield a clinically relevant benefit.
Evidence regarding safety outcomes was more limited since a
smaller number of studies reported these. Also definitions of
adverse events were rarely provided and likely varied across
studies. The non-significant summary eLect for towards lower rates
of malignancies in MMF-treated patients was supported by five
studies only. One study reported no events of PVAN and nine events
reported in five studies showed the significantly reduced risk for
PCP in MMF-treated patients. Data on CMV viraemia/syndrome
were provided by a substantial number of studies (n = 13) showing
no diLerence between the two drugs, however tissue-invasive
CMV disease was significantly less likely in AZA-treated patients
based on seven studies only. The incidence of insulin-dependent
NODAT was reported exclusively in studies investigating Tac-based
regimens and was significantly higher in AZA-treated patients.
Gastrointestinal side eLects were more common in MMF-treated
patients, while no significant diLerences were found for elevated
liver enzymes and hematologic disturbances such as leucopenia,
anaemia or thrombocytopenia.
Applying current standards to assess methodological quality of
the studies (Higgins 2011) indicated that important information on
factors used to judge susceptibility for bias were infrequently and
inconsistently reported.
Overall completeness and applicability of evidence
Based on an exhaustive search process, we tried to
comprehensively collect any published evidence for our research
objectives. A large number of published abstracts were screened
and many abstracts from conferences in the early and mid-1990s
were retrieved and assessed for eligibility. In total, we included 23
studies enrolling 3301 patients in our review. Study populations
varied across continents and patients were treated in a multitude of
diLerent health care systems including not only the USA, Canada,
various western European countries and Australia, but also China,
Singapore, Korea, India, Latvia, Hungary, Turkey, Brazil and Iran.
When this information was available, it appeared that studies
included patients who were at low to moderate immunological
baseline risk as frequently patients received their first kidney
graB of a deceased donor. Further details on known markers
of immunological risk, such as PRA level, HLA mismatch, or
the proportion of patients of African American ancestry were
inconsistently and rarely reported.
Quality of the evidence
Items of study quality such as blinding, ITT analysis, allocation
concealment can help assess the risk of bias and thus judge
the validity of the results. Based on the criteria defined for
Cochrane reviews (Higgins 2011), most of the studies of this
review lacked suLicient information on methodological items.
Many of the studies were sponsored by industry, in particular
by the company that held the patent on MMF. Most studies
were published at least once as a full manuscript in a peer
reviewed journal but a substantial number (eight studies) were
conference abstracts or Transplantation Proceedings articles only
and thus underwent an abbreviated peer review process. These
factors (low methodological quality, industry sponsorship, and
publication in non-peer-reviewed journals) have the potential to
being associated with modification of treatment eLects of over- or
underestimation (Moher 1998; Pittler 2000; Ridker 2006). Overall,
although we found evidence suggestive for the eLect estimates
being associated with study quality/risk of bias factors, we would
not claim clinically relevant impact on the summary eLects.
Studies of lower quality and with unclear ITT analysis tended
to overestimate eLicacy results as did publications in non-peer
reviewed journals and those sponsored by industry. These studies
were also more likely to report attenuated risks for tissue invasive
CMV disease and MMF-specific side eLects such as diarrhoea. The
most important limitation of our data is the lack of evidence and a
considerably large reporting bias in particular for safety outcomes
and conditional outcomes, such as graB function which naturally
can be measured only in those with a functioning graB. However,
numbers of patients at risk or those with a functioning graB were
rarely provided.
Potential biases in the review process
We followed high standards to reduce risk of bias in the
methodology of this review, such as a comprehensive literature
search that was not restricted to publications in English language,
article selection and data extraction performed independently by
two or more authors and the collection of all potentially relevant
outcomes from the included studies. However, the main limitations
of the current review are two-fold: First, while the body of evidence
is fairly robust for eLicacy outcomes, any conclusion on safety lacks
certainty. Only few studies reported data on malignancies, and
only CMV-related diseases/infections were commonly presented.
Second, most of the studies did not report outcome data with
enough follow-up to be able to detect development of specific
diseases, in particular malignancies, with long induction and latent
periods. Finally, most of the studies that investigated MMF versus
AZA were performed in the late 1990s and early 2000, a certainly
diLerent era of kidney transplantation as we are in nowadays.
During the time of these studies, outcomes of interest diLered from
what we judge important today: CAN or more specifically IF/TA
(interstitial fibrosis/tubular atrophy in graB biopsies) and Polyoma
BK/JC virus reactivation and PVAN are considered as of higher
long-term importance than acute rejection episodes, which are
frequently mild and if diagnosed early can be treated and cured.
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Agreements and disagreements with other studies or
reviews
Our results are consistent with a systematic review by Knight 2009
who also investigated the comparative eLicacy and safety of MMF
versus AZA. This review used fixed-eLects models if no statistical
heterogeneity was detected while we chose the more conservative
random-eLects model by default given the clinical heterogeneity.
Moreover, we tried to investigate potential eLect modification in
detail by a number of a priori defined study level and study quality
factors. Another existing systematic review by Wang et al. included
studies of secondary regimens (Wang 2004a; Wang 2004b; Wang
2005; Zhang 2004) and is thus not directly comparable.
Observational data can help to understand the findings of the
review, in particular how benefits of MMF regarding lower rates
of rejection and improved graB survival are balanced against the
potential for harm such as infections and malignancies associated
with stronger immunosuppressive regimens. Temporal trends in
cohort studies have reported diminishing acute rejection rates but
higher incidence of Polyoma BK/JC virus infections/reactivations
and PVAN during the last decade (Ramos 2009), likely to be caused
by the use of stronger immunosuppressive regimens, rather than by
a specific agent (Brennan 2005; Snyder 2009). Polyoma BK/JC virus
infections/reactivations and PVAN are characterised by impaired
graB function and an aggravated risk of graB loss and the rare but
life-threatening progressive multifocal leukoencephalopathy (FDA
2008). The total burden of PVAN especially in the setting of RCTs so
far has probably been underestimated since these outcomes were
only rarely reported in RCTs in the past.
An about 3- to 4-fold increased risk for cancer in kidney transplant
recipients was described when compared to the general population
(Domhan 2009). As with infections, the risk is associated with
the overall level of immunosuppression rather than a specific
drug (Wimmer 2007). We found a non-significant point estimate
suggesting higher risk for PTLD/lymphomas, but also trends
towards fewer malignancies in general with MMF treatment,
although being of stronger immunosuppressive potency. These
findings could be explained by AZA directly causing accumulation
of mutagenic metabolites (Domhan 2009), but data are conflicting
(KauLman 2006; Meier-Kriesche 2003; Morath 2004; Schold 2009).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found that while the risks for graB loss and acute rejection
were reduced by MMF treatment, graB function did not diLer
in a clinically relevant magnitude and evidence regarding safety
outcomes was limited. Thus, it is still a major task of the transplant
physician to balance benefits and harms of the two drugs and
to decide which agent the individual patient should be started
on. Patient’s risks and preferences should be considered to
individualise this decision.
In this context it should be mentioned, that although none of
the included studies tested ec-MPS against AZA, it is unlikely
that ec-MPS treatment would have considerably changed the
evidence derived from MMF-studies. MPA is the active agent of
both, MMF and ec-MPS, but the latter was developed to limit
gastrointestinal disorders since it is absorbed in the gut rather than
in the stomach. Studies that have directly compared MMF versus ec-
MPS showed similar eLicacy and adverse event profiles including
gastrointestinal adverse events (Budde 2004; Salvadori 2004).
Another important aspect is the fact that MPA is contraindicated
in pregnancy (Sifontis 2006) and frequently MMF gets replaced
by AZA in transplant patients before pregnancy is attempted.
The current review did not address the comparison of MPA
versus AZA in secondary regimens, including the change of the
immunosuppressive regimen in patients with stable graB function.
However, Sadek 2002 found that replacement of MMF by AZA three
months post-transplant overall was safe and eLective up to 12
months follow-up in this study.
Finally, a general limitation of how results from meta-analyses can
be applied to the individual patient should briefly be mentioned.
Patients enrolled in RCTs (which subsequently get summarised in
meta-analyses) typically diLer from each other in their baseline
risk for achieving the outcome of interest. Although being equally
distributed between treatment and control group, frequently a
higher risk group of patients may experience most of the events
that drive the main results of the intervention (Kent 2007). The
phenomenon of varying treatment eLects dependent on baseline
risk is likely to be relevant in the setting of kidney transplantation
(Wagner 2009). Meta-analyses and meta-regression analyses are
not helpful to identify the benefits and harms of a particular
treatment to the individual patient (Schmid 2004).
Implications for research
Our review highlights the need for consistent ascertainment and
reporting of adverse events in kidney transplant intervention
studies (Ioannidis 2004), including infections (e.g. Polyoma BK
virus) and malignancies. Further, the deficiencies in the reporting
of study quality items point to the need for editors to hold kidney
transplant trialists to universal reporting guidelines, such as the
CONSORT statement (Moher 2001).
As most of the evidence about MMF versus AZA is based on the
late 1990s and early 2000s, it will be interesting how the two drugs
compare in the current era. The ongoing ATHENA Study 2012 will
provide insights about the two proliferation-inhibitors in a low-
dose CNI regimen with scheduled CNI withdrawal on CAN and
PVAN.
Support for the every-day decision on which agent (MMF or
AZA) a kidney transplant recipient should be started on could be
addressed by decision analyses in which the benefits and harms are
weighted against each other in various settings. Another approach
could be to stratify patients in RCTs at baseline according to
immunological risk. The benefits and harms of certain therapies
(e.g. MMF versus AZA) could then be investigated across all
as well as within subgroups of lower, moderate, and higher
risk patients (Wagner 2009). With these endeavours, research in
kidney transplantation can make one important step forward
to individualise medical therapy and towards choosing the best
immunosuppressive regimen for a particular patient.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by year of study]
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: July 1992 to September 1993• Duration of follow-up: 3 years
Participants • Country: USA• Setting: multicentre (14)• Patients ≥18 years of age receiving a cadaveric kidney allograft as their first transplant; no contraindi-
cation for CsA, prednisone, AZA or ALG; able to receive oral medication; negative T cell crossmatch;
women were to have a negative pregnancy test at time of entry; both men and women were instructed
to utilize an adequate method of contraception* Deceased donor: 100%* Previous transplantation: 0%* PRA > 20%: 4.7%* HLA mismatch (mean): 3.4* Cold ischaemia time (mean): 22 h* Delayed graB function: not reported• Number (randomised/analysed): treatment group 1 (167/165); treatment group 2 (166/166); control
group (166/164)• Mean age ± SD (years): treatment group 1 (45.1 ± 13.2); treatment group 2 (46.1 ± 12.6); control group
(45.9 ± 12.2)• Sex (M/F): treatment group 1 (59/41); treatment group 2 (57/43); control group (57/43)• Exclusion criteria: WCC < 2.5 x 103/µL, platelet count < 100 x 103/ µL, Hb < 6 g/dL; serologic evidence of
infection with HIV-I or HTLV-I or the presence of HBsAg; active peptic ulcer disease, severe diarrhoea,
or other GI disorder that might interfere with their ability to absorb oral medications; pregnancy or
lactation; malignancy or history of malignancy other than adequately treated non-melanoma skin
carcinoma
Interventions Treatment group 1
• MMF• 2 g/d, orally
Treatment group 2
• MMF• 3 g/d, orally
Control group
• AZA• 1 to 2 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: ATG/ALG, all patients• CsA (original formulation), target C0 (month 3): according to local practice• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function
MMF US Study 1995 
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• Malignancy (except non-melanoma skin cancer)• Acute rejection• Infections• Non-melanoma skin cancer• Kidney function measures (SCr, CrCl)• Adverse events (diarrhoea, abdominal pain, nausea, vomiting, GI bleeding, anaemia, leucopenia,
thrombocytopenia)
Notes • Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Low risk The study was double-blind
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk The study was double-blind. Investigators and patients were blinded until all
patients had been in the study for 1 year
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported; four patients never received study drug and were ex-
cluded from some of the analysis; all patients followed-up or accounted for
Selective reporting (re-
porting bias)
Low risk The published report included all expected outcomes regarding efficacy and
safety
Other bias High risk This study was sponsored by a grant from Syntex (U.S.A.), Inc., Palo Alto, CA.
Syntex (funder) was unblinded to provide the results of the efficacy analysis
for all patients as of 6 months after transplant and the results of the analyses
of safety data collected for patients as of the data cut-oL date of March 4, 1994
MMF US Study 1995  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: August 1992 to September 1994• Duration of follow-up: 3 years
Participants • Countries: Canada, Australia, Finland, United Kingdom, Germany, France, Switzerland, Ireland, Italy• Setting: international multicentre study (21 centres)
MMF TRI Study 1996 
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• Patients ≥ 18 years of age receiving their first or second cadaveric kidney transplantable to receive
oral medication* Deceased donor: 100%* Previous transplantation: 11.9%* PRA > 20%: 8%* HLA mismatch: not reported* Cold ischaemia time (mean): 20 h* Delayed graB function: 18%• Number (randomised/analysed): treatment group 1 (173/171); treatment group 2 (164/164); control
group (166/162)• Mean age ± SD (years): treatment group 1 (46 ± 13); treatment group 2 (46 ± 13); control group (47 ± 13)• Sex (M/F): treatment group 1 (93/79); treatment group 2 (98/66); control group (111/55)• Exclusion criteria: history of malignancy, except successfully treated nonmetastatic basal or squa-
mous cell carcinoma of the skin; serologic evidence of HIV of HBV; systemic infections requiring con-
tinued antibiotic therapy at the time of entry; severe diarrhoea, GI disorders or active peptic ulcer
disease; pregnant women, nursing mothers and patients who did not agree to use of adequate con-
traception
Interventions Treatment group 1
• MMF• 2 g/d, orally
Treatment group 2
• MMF• 3 g/d, orally
Control group
• AZA• 100 mg/d if body weight < 75 kg, 150 mg/d if ≥ 75 kg
Concomitant immunosuppression
• Induction antibody: none• CsA (original formulation), target C0 (month 3): according to local practice• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Malignancy (except non-melanoma skin cancer)• Acute rejection• Infections• Non-melanoma skin cancer• Kidney function measures (SCr, proteinuria)• Adverse events (diarrhoea, abdominal pain, nausea, vomiting, anaemia, leucopenia, thrombocytope-
nia)
Notes • Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
MMF TRI Study 1996  (Continued)
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
36
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Low risk The study was double-blind
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blinding of investigators and patients continued throughout the 3
years of this study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported, six patients never received study drug and were exclud-
ed from some of the analysis; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk The published report included all expected outcomes regarding efficacy and
safety
Other bias High risk This study was supported by Roche Pharmaceuticals
MMF TRI Study 1996  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported• Duration of follow-up: 4 to 6 weeks
Participants • Country: Australia• Setting: single centre• Kidney transplant recipients; patient characteristics not reported• Number: treatment group (13); control group (25)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• MMF• Dose and administration: not reported
Control group
• AZA• Dose and administration: not reported
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation: not reported), target C0 (month 3): not reported• Corticosteroids
Outcomes • No relevant outcomes reported
Isbel 1997 
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Notes • Publication: conference abstract only• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not reported, presumably open-label
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
High risk ITT analysis unclear; number randomised or number of patients at the end of
the study not reported, data only available from conference abstract
Selective reporting (re-
porting bias)
High risk No relevant data for this review - data only available from conference abstract
Other bias Unclear risk Funding source not reported
Isbel 1997  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplant: 1996 to 1997• Duration of follow-up: 1 year
Participants • Country: USA• Setting: multicentre (13)• Patients ≥ 12 years old weighing ≥ 40 kg and receiving a cadaveric kidney transplant (primary or re-
transplant)* Deceased donor: 100%* Previous transplantation: 8%* PRA > 10%: 11.4%* HLA mismatch (mean): 3.4* Cold ischaemia time: not reported* Delayed graB function: 14%• Number: treatment group 1 (59); treatment group 2 (58); control group (59)• Mean age ± SD (years): treatment group 1 (44.0 ± 11.9); treatment group 2 (44.4 ± 12.4); control group
(45.5 ± 11.2)• Sex (M/F): treatment group 1 (24/36); treatment group 2 (22/36); control group (25/34)• Exclusion criteria: recipient of a living donor kidney transplant; recipient of other solid organ trans-
plants and receiving immunosuppressive medication; listed for any other solid organ transplant; re-
Mendez 1998 
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cipient of an ABO-incompatible transplant; pregnant or nursing women; patients with known sensi-
tivity to Tac, AZA, MMF; carriers of HIV
Interventions Treatment group 1
• MMF• 1 g/d, orally
Treatment group 2
• MMF• 2 g/d, orally
Control group
• AZA• 1.5 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: ATG/OKT3, all patients• Tac, target C0 (month 3): 5 to 15 ng/mL• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Malignancy (except non-melanoma skin cancer)• Acute rejection• Infections• NODAT• Non-melanoma skin cancer• Adverse events (diarrhoea, nausea, vomiting, anaemia, leucopenia, hyperlipidaemia)
Notes • Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
Low risk ITT analysis reported; eleven patients never received study drug or kidney
graB and were excluded from the analyses; all patients followed up or ac-
Mendez 1998  (Continued)
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All outcomes counted for. 11 patients in the AZA group discontinued AZA and crossed over
to the MMF group
Selective reporting (re-
porting bias)
Low risk The published report included all expected outcomes regarding efficacy and
safety
Other bias High risk This study was supported by a grant from Fujisawa Healthcare, Inc, Deerfield,
IL.
Mendez 1998  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported:• Duration of follow-up: 6 months
Participants • Country: China• Setting: single centre• Kidney transplant recipients* Deceased donor: 100%* Previous transplantation: not reported* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group 1 (5); treatment group 2 (6); control group (5)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• MMF• 1.5 g/d, orally
Treatment group 2
• MMF• 2 g/d, orally
Control group
• AZA• 2 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation not reported), target C0 (month 3): 100 to 200 ng/mL• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Acute rejection• Kidney function measures (SCr)
Ling 1998 
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• Adverse events (diarrhoea, leucopenia)
Notes • Publication: full journal article• Language: Chinese
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No information on blinding available (no blinding assumed)
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis unclear; all patients followed-up
Selective reporting (re-
porting bias)
Low risk The published report included most expected outcomes regarding efficacy
and safety
Other bias Unclear risk Funding source not reported
Ling 1998  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1996 to 1998• Duration of follow-up: 1 year
Participants • Country: Denmark• Setting: single centre• patients receiving first or second cadaveric kidney transplant* Deceased donor: 100%* Previous transplantation: not reported* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: 38%• Number: treatment group (25); control group (25)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
Egfjord 1999 
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• MMF• 2 g/d, orally
Control group
• AZA• 100 mg/d, orally
Concomitant immunosuppression
• Induction antibody: ATG, all patients• CsA-ME, target C0 (month 3): not reported• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Acute rejection• Kidney function measures (SCr)
Notes • Publication: conference abstract only• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment.
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No information on blinding available
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk ITT analysis unclear; number randomised or number of patients at the end of
the study was not reported. (data only available from conference abstract)
Selective reporting (re-
porting bias)
High risk The published report included few outcomes regarding efficacy and safety.
(data only available from conference abstract)
Other bias Unclear risk Funding source not reported
Egfjord 1999  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1996 to 1997
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• Duration of follow-up: 3 years
Participants • Country: Canada, USA• Setting: international multicentre (15)• Patients ≥ 12 years old weighing ≥ 40 kg body weight and receiving their first cadaveric kidney trans-
plant; female patients of child-bearing potential were to have a negative pregnancy test and agreed
to practice effective birth control during the study and for 6 weeks after discontinuation of MMF* Deceased donor: 100%* Previous transplantation: 0%* PRA > 20 %: 9.5%; PRA > 10%: 12.2%* HLA mismatch (mean): 3.4* Cold ischaemia time (mean): 18 h* Delayed graB function: 32%• Number: treatment group (72); control group (76)• Mean age ± SD (years): treatment group (49.9 ± 12.6); control group (46.5 ± 12.4)• Sex (M/F): treatment group (29/43); control group (44/32)• Exclusion criteria: recipient of a paediatric en bloc kidneys; recipient of a kidney from a non-heart
beating donor; recipient of a previous organ transplant; currently receiving multiorgan transplant;
recipient of a living donor kidney transplant or ABO incompatible with their donor; known carrier of
HIV; lactating female; known to have hypersensitivity to Tac, CsA, MMF, or castor oil; receiving inves-
tigational prophylactic immunosuppressants
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 1.5 to 2 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: ATG/ OKT3, if delayed graB function within the first day post-transplantation• Tac, target C0 (month 3): 5 to 15 ng/mL• Corticosteroids
Outcomes • Death• GraB loss• Malignancy (except non-melanoma skin cancer)• Acute rejection• Infections• NODAT• Kidney function measures (SCr, CrCl)• Adverse events (hyperlipidaemia, serum cholesterol)
Notes • Additional intervention arm (CsA/MMF)• Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Johnson 2000  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on method used is available
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported; all patients followed up or accounted for; twelve pa-
tients discontinued study drug
Selective reporting (re-
porting bias)
Low risk The published report included all expected outcomes regarding efficacy and
safety. Relevant outcomes (efficacy and safety) for this review have been re-
ported
Other bias High risk This study was supported by a grant from Fujisawa Healthcare, Inc, Deerfield,
IL
Johnson 2000  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1997 to 1999• Duration of follow-up: 6 months
Participants • Country: Singapore• Setting: single centre• Patients undergoing cadaveric kidney transplant* Deceased donor: 100%* Previous transplantation: 0%* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group (20); control group (20)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: seropositivity to hepatitis B surface antigen or hepatitis C; hematologic abnormal-
ities; need for antilymphocyte preparations for prophylaxis; abnormal perfusion scan within the first
24 hours post-kidney transplant
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
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• AZA• 1 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: none• CsA-ME, target C0(month 3): not reported• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Acute rejection• Infections• Kidney function measures (SCr)• Adverse events (diarrhoea, leucopenia)
Notes • Publication: Transplantation Proceedings• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on method used is available
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk ITT analysis unclear; number randomised or number of patients at the end of
the study was not reported
Selective reporting (re-
porting bias)
Low risk The published report included most expected outcomes regarding efficacy
and safety
Other bias Unclear risk Funding source not reported
Suhail 2000  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1997 to 1999• Duration of follow-up: 1 year
Participants • Country: Latvia
Folkmane 2001 
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• Setting: single centre• Patients receiving their first cadaveric kidney transplant* deceased donor: 100%* Previous transplantation: 0%* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group (23); control group (25)• Median age ± SD: 42.6 ± 13.2 years• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 1 to 2 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation not reported), target C0 (month 3): 150 to 250 ng/mL• Corticosteroids
Outcomes • GraB loss• Primary non-function• Acute rejection• Infections
Notes • Additional intervention arm (basiliximab/CsA/AZA)• Funding: not reported• Publication: Transplantation Proceedings• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No information on blinding available
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Insufficient information to permit judgment
Folkmane 2001  (Continued)
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk ITT analysis unclear; number randomised or number of patients at the end of
the study was not reported
Selective reporting (re-
porting bias)
High risk The published report included few outcomes regarding efficacy and safety
Other bias Unclear risk Funding source not reported
Folkmane 2001  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported• Duration of follow-up: 6 months
Participants • Country: Canada• Setting: multicentre (6)• Adult recipients receiving their first cadaveric kidney transplant* Deceased donor: 100%* previous transplantation: 0%* PRA level: not reported* HLA mismatch (median): 3* Cold ischaemia time (mean): 15 h* Delayed graB function: 22%• Number: treatment group (23); control group (23)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 1.5 to 2 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: agent unclear, if delayed graB function• Tac target C0 (month 3): 5 to 15 ng/mL• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Acute rejection• NODAT• Kidney function measures (SCr)
Busque 2001 
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Notes • Additional intervention arm (CsA/MMF)• Publication: Transplantation Proceedings• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk ITT analysis unclear; number randomised or number of patients at the end of
the study was not reported
Selective reporting (re-
porting bias)
Low risk The published report included most expected outcomes regarding efficacy
and safety
Other bias High risk The study was supported by Fujisawa Canada Inc.
Busque 2001  (Continued)
 
 
Methods • Study type: quasi-RCT• Study time frame/year of transplantation: 1996 to 1998• Duration of follow-up: 6 months
Participants • Country: China• Setting: single centre• Primary deceased donor kidney transplantation; PRA negative; negative cross-match* Deceased donor: 100%* Previous transplantation: not reported* PRA level: max. 6%* HLA mismatch (mean): 3* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group (56); control group (50)• Mean age: 39• Sex (M/F): not reported• Exclusion criteria: HLA (A, B, DR) > 3 mismatches; contraindication against CsA, steroids, AZA, MMF;
contraindication against oral medication
Ji 2001 
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Interventions Treatment group
• MMF• 1 g/d, orally
Control group
• AZA• 50 mg/d, orally
Concomitant immunosuppression
• Induction antibody: ATG/ALG, all patients• CsA (formulation not reported), target C0 (month 3): 500 ng/mL• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Acute rejection• Infections• Adverse events (diarrhoea, leucopenia, elevated liver enzymes)
Notes • Publication: full journal article• Language: Chinese
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quasi-RCT, patients allocated in alternating sequence
Allocation concealment
(selection bias)
High risk Patients were consecutively enrolled and were allocated to the treatment
arms in alternating sequence
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis unclear; all patients followed-up
Selective reporting (re-
porting bias)
Low risk The published report included most expected outcomes regarding efficacy
and safety
Other bias Low risk The study was funded by a university grant
Ji 2001  (Continued)
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Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1998 to 2000• Duration of follow-up: 2 years
Participants • Country: Germany• Setting: single centre• Patients receiving a kidney allograft (deceased or living donor)* Deceased donor: 75%* Previous transplantation: 14.3%* PRA level: max 8%* HLA mismatch (mean): 2.6* Cold ischaemia time (mean): 13 h* Delayed graB function: 16 %• Number: treatment group (31); control group (25)• Mean age: 47 years• Sex: 39% male• Exclusion criteria: not reported
Interventions Treatment group
• MMF• Dose unclear
Control group
• AZA• Dose unclear
Concomitant immunosuppression
• Induction antibody: ATG if previous transplantation, or PRA > 5 %, or delayed graB function• CsA-ME, target C0 (month 3): not reported• Corticosteroids
Outcomes • Death• GraB loss• Primary non-function• Acute rejection• CAN• Infections• Kidney function measures (SCr, CrCl)
Notes • Additional intervention arm (Tac/AZA)• Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Weimer 2002 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported; all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk The published report included most expected outcomes regarding efficacy
and safety
Other bias High risk The study was supported in part by the Fujisawa, Roche, Novartis, Biotest and
Fresenius companies
Weimer 2002  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported• Duration of follow-up: 1 year
Participants • Country: China• Setting: single centre• Deceased donor transplantation; cause of ESRD chronic glomerulonephritis; ABO compatible; nega-
tive cross-match* Deceased donor: 100%* Previous transplantation: not reported* age (mean): 35 years, gender: 80 % male* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group (40); control group (46)• Mean age: 35 years• Sex: 80% male• Exclusion criteria: not reported
Interventions Treatment group
• MMF• 1.5 to 2 g/d, orally
Control group
• AZA• 50 to 75 mg/d, orally
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation not reported), target C0 (month 3): not reported
Sun 2002b 
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• Corticosteroids
Outcomes • GraB loss• Acute rejection• Infections• Kidney function measures (SCr)• Adverse events (diarrhoea, leucopenia, thrombocytopenia, elevated liver enzymes)
Notes • Publication: full journal article• Language: Chinese
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment.
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No information on blinding available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis unclear; all patients followed-up.
Selective reporting (re-
porting bias)
Low risk The published report included most expected outcomes regarding efficacy
and safety.
Other bias Unclear risk Funding source not reported
Sun 2002b  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1995 to 1999• Duration of follow-up: 5 years
Participants • Country: Turkey• Setting: single centre• Patients receiving their first-graB cadaveric or living donor kidney transplant* Deceased donor: 19.7%* Previous transplantation: 0%* PRA level: not reported* HLA mismatch (mean): 2.6* Cold ischaemia time: not reported* Delayed graB function: not reported
Tuncer 2002 
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• Number: treatment group (38); control group (38)• Mean age ± SE (years): treatment group (34.8 ± 2.3); control group (41.4 ± 3.0)• Sex (M/F): treatment group (27/11); control group (28/10)• Exclusion criteria: not reported
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 1.5 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: ATG, if deceased donor transplantation• CsA/CsA-ME, target C0 (month 3): not reported• Corticosteroids
Outcomes • Death• GraB loss• Acute rejection• CAN
Notes • Publication: Transplantation Proceedings• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk "non-blinded study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis unclear; all patients were followed up
Selective reporting (re-
porting bias)
Unclear risk The published report included few outcomes regarding efficacy and safety
Other bias Unclear risk Funding source not reported
Tuncer 2002  (Continued)
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Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported• Duration of follow-up: unclear
Participants • Country: India• Setting: single centre• Kidney transplant recipients; living graB donation* deceased donor: 0%* previous transplantation: 0%* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group (17); control group (16)• Mean age: 34 years• Sex: 82% male• Exclusion criteria: not reported
Interventions Treatment group
• MMF• Dose and administration unclear
Control group
• AZA• Dose and administration unclear
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation not reported), target C0 (month 3): not reported• Corticosteroids
Outcomes • Acute rejection• Infections• Kidney function measures (SCr)• Adverse events (anaemia, leucopenia)
Notes • Publication: conference abstract only• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment.
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Army Hospital 2002 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No information on blinding available
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
High risk ITT analysis unclear; number randomised and number of patients at the end of
the study not reported. (data only available from conference abstract)
Selective reporting (re-
porting bias)
High risk The published report included few outcomes regarding efficacy and safety.
(data only available from conference abstract)
Other bias Unclear risk Funding source not reported
Army Hospital 2002  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported• Duration of follow-up: 1 year
Participants • Country: Belgium, Brazil, Canada, Italy, Norway, Spain, Switzerland, UK• Setting: international multicentre (28)• Patients between 18 to 70 years old receiving a first cadaveric or living donor kidney transplant; female
patients of childbearing age required a negative pregnancy test* Deceased donor: 86.5%* Previous transplantation: 0 %* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group (162); control group 157()• Mean age ± SD (years): treatment group (43.9 ± 12.8); control group (43.9 ± 13.0)• Sex (M): treatment group (71.0%); control group (59.9%)• Exclusion criteria: graB originated from an asystolic donor; previous kidney transplant or other trans-
planted organ; induction therapy with any antilymphocytic antibody preparation, positive T-cell
crossmatch, and ABO incompatibility against the donor; positive HIV status; malignancy (other than
local basal or squamous cell carcinoma of the skin) within the last 5 years; pre-existing gout treated
with allopurinol; use of any other investigational drug within 30 days of study entry; female patients
of childbearing potential who were unwilling to use an effective for of contraception for 12 months
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 1 to 2 mg/kg body weight/d, orally
Concomitant immunosuppression
Sadek 2002 
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• Induction antibody: none• CsA-ME, target C0 (month 3): 150 to 250 ng/mL• Corticosteroids
Outcomes • Death• GraB loss• Malignancy (except non-melanoma skin cancer)• Acute rejection• Infections• Kidney function measures (SCr)• Adverse events (diarrhoea, abdominal pain, nausea, vomiting, anaemia, leucopenia, hypertension)
Notes • Additional intervention arm (MMF replaced by AZA, 3 months post-transplantation)• Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “...randomization was [...] performed with the Almedica Drug Labeling Sys-
tem (Almedica Service Corp., Allendale, New Jersey). The numbers assigned to
each center were sequential within each stratum.”
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported, all patients followed up or accounted for
Selective reporting (re-
porting bias)
Low risk The published report included all expected outcomes regarding efficacy and
safety
Other bias High risk This study was supported by a grant from Novartis Pharma AG, Basel, Switzer-
land
Sadek 2002  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1997 to 2000• Duration of follow-up: 6 months
Participants • Country: Iran• Setting: single centre
Miladipour 2002 
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• Kidney transplant recipients; primary or secondary transplantation; patient characteristics not re-
ported• Number: treatment group (40); control group (40)• Mean age, range: 39, 20 to 68 years• Sex (M/F): 21/22• Exclusion criteria: not reported
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 100 to 150 mg/d, orally
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation not reported), target C0 (month 3): not reported• Corticosteroids
Outcomes • GraB loss• Acute rejection• Infections• Kidney function measures (SCr)• Adverse events (diarrhoea, GI bleeding, leucopenia, thrombocytopenia, elevated liver enzymes)
Notes • Publication: Transplantation proceedings• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No information on blinding available
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis unclear; all patients followed up
Selective reporting (re-
porting bias)
Low risk The published report included most outcomes regarding efficacy and safety
Miladipour 2002  (Continued)
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Other bias Unclear risk Funding source not reported
Miladipour 2002  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1999 to 2001• Duration of follow-up: 6 months
Participants • Countries: Poland, Hungary, Czech Republic, Ireland• Setting: international multicentre• Patients ≥18 years old and candidates for primary kidney transplantation or re-transplantation; fe-
male patients were to maintain effective birth control during the study* Deceased donor: 96%* Previous transplantation: 5.3%* PRA level: not reported* HLA mismatch (mean): 2.7* Cold ischaemia time (mean): 21 h* Delayed graB function: not reported• Number: treatment group (243); control group (246)• Mean age (years): treatment group (43.8); control group (42.1)• Sex (M/F): treatment group (156/87); control group (157/89)• Exclusion criteria: PRA grade > 50%; loss of a previous graB within <1 year due to immunological rea-
sons; intolerance to any of the study drugs, HCO-60, or macrolide antibiotics; requiring systemic im-
munosuppressive medication for other reasons that transplantation; significant liver disease; severe
diarrhoea; history of malignancy, uncontrolled infections or HIV; unlikely to comply or had a history
of substance abuse
Interventions Treatment group
• MMF• 1 g/d, orally
Control group
• AZA• 1 to 2 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: none• Tac, target C0 (month 3): 5 to 10 ng/mL• Corticosteroids, withdrawal planned by study protocol at month 3
Outcomes • Death• GraB loss• Acute rejection• Infections• NODAT• Kidney function measures (SCr)• Adverse events (diarrhoea, leucopenia, hyperlipidaemia)
Notes • Publication: full journal article• Language: English
COSTAMP Study 2002 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk “The histological evaluation of the biopsy was performed by the local
histopathologist who was blinded towards the patient’s treatment.”
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported, all patients followed up or accounted for. The majority
of patients (452 patients; 92 %) completed the study
Selective reporting (re-
porting bias)
Low risk The published report included most expected outcomes regarding efficacy
and safety
Other bias High risk This study was supported by Fujisawa GmbH, Munich, Germany
COSTAMP Study 2002  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported• Duration of follow-up: 1 year
Participants • Country: Spain• Setting: single centre• Primary deceased donor kidney transplantation* Deceased donor: 100%* Previous transplantation: 0%* PRA level: not reported* HLA mismatch (mean): 2.2* Cold ischaemia time (mean): 17 h* Delayed graB function: 35%• Number: treatment group (14); control group (12)• Median age, range: 41, 32 to 47 years• Sex (M/F): 69%/31%• Exclusion criteria: not reported
Interventions Treatment group
• MMF• dose and administration unclear
Control group
Baltar 2002 
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• AZA• dose and administration unclear
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation not reported), target C0 (month 3): not reported• Corticosteroids
Outcomes • acute rejection
Notes • Publication: full journal article• Language: Spanish
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis unclear; all patients followed up
Selective reporting (re-
porting bias)
High risk The published report included very few outcomes regarding efficacy
Other bias High risk The study was supported by Roche
Baltar 2002  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 2000 to 2002• Duration of follow-up: 6 months
Participants • Country: Turkey• Setting: single centre
Keven 2003 
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• Patients 18 to 60 years old receiving cadaveric or living related kidney transplant* Deceased donor: 24.4%* Previous transplantation: not reported* PRA level: not reported* HLA mismatch: not reported* Cold ischaemia time: not reported* Delayed graB function: not reported• Number: treatment group (24); control group (17)• Mean age ± SD (years): treatment group (32.9 ± 9.9); control group (32.1 ± 11.2)• Sex (M/F): treatment group (15/7); control group (10/7)• Exclusion criteria: ascites; chronic diarrhoea (for longer than 3 weeks); significant proteinuria before
or after transplantation (> 1 g/d); stopping or interruption of their MMF or AZA for 15 days; as least one
low immunoglobulin level before transplantation
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 2 to 3 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: ATG, if delayed graB function in deceased donor transplantation• Tac or CsA (formulation not reported): "randomly selected", target C0 (month 3): not reported• Corticosteroids
Outcomes • Acute rejection• Infections
Notes • Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No information on blinding available
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
High risk No ITT analysis: eight patients not analysed due to reported reasons (e.g. diar-
rhoea, proteinuria, etc.); however, all patients followed up
Keven 2003  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
High risk The published report included very few outcomes regarding efficacy and safe-
ty
Other bias Unclear risk Funding source not reported
Keven 2003  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: not reported• Duration of follow-up: 1 year
Participants • Country: France• Setting: multicentre (3)• Men and women, 18 to 70 years of age; first ABO-compatible cadaver kidney transplant* Deceased donor: 100%* Previous transplantation: 0%* PRA > 20%: 8.5%* HLA mismatch (mean): 2.8* Cold ischaemia time (mean): 22 h* Delayed graB function: 42%• Number: treatment group (37); control group (34)• Mean age ± SD (years): treatment group (41 ± 16); control group (42 ± 14)• Sex (M/F): treatment group (26/11); control group (23/11)• Exclusion criteria: previous organ transplant; receiving a multiorgan transplant; high immunological
risk (PRA ≥ 80%); donor age ≥ 65 years; currently receiving immunosuppressants; patients were ex-
cluded after randomisation if the randomised drug therapy was discontinued for more than 14 days
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 1.5 to 2 mg/kg body weight/d, orally
Concomitant immunosuppression
• Induction antibody: ATG, all patients• CsA-ME, target C0 (month 3): 100 to 150 ng/mL• Corticosteroids
Outcomes • Death• GraB loss• Acute rejection• CAN• Infections• Kidney function measures (SCr, CrCl, proteinuria)• Adverse events (total cholesterol)
Notes • Publication: full journal article
Merville 2004 
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• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information about the sequence generation process to permit
judgment
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk “All biopsies (from donors and recipients) were blindly and centrally examined
by the same pathologist (CD).”
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported; all patients followed up or accounted for; 3 patients, 2 in
the MMF group and one in the AZA group, were excluded after randomisation
for discontinuation of the randomised drug and a total of 71 individuals was fi-
nally available for analysis
Selective reporting (re-
porting bias)
Low risk The published report included all expected outcomes regarding efficacy and
safety
Other bias Low risk The study was financially supported partly by the Association Promotion
Transplantation Renale and the Centre Hospitalier Universitaire de Bordeaux
(non-industry)
Merville 2004  (Continued)
 
 
Methods • Study type: parallel RCT• Study time frame/year of transplantation: 1997 to 2001• Duration of follow-up: 18 months, follow-up study up to 7 years
Participants • Countries: Italy, France, Belgium• Setting: international multicentre (11)• Patients 18 to 70 years old receiving their first kidney transplant from a cadaver donor* Deceased donor: 100%* Previous transplantation: 0%* age (mean): 45 years, gender: 66 % male* PRA level: not reported* HLA mismatch (mean): 1.9* Cold ischaemia time (mean): 16 h* Delayed graB function: 33%• Number (randomised/analysed): treatment group (168/167); control group (168/167)• Mean age ± SD (years): treatment group (43.3 ± 12.9); control group (45.9 ± 11.5)• Sex (M/F): treatment group (119/49); control group (101/67)• Exclusion criteria: history of malignant disorders (apart from successfully treated non-metastatic
basal or squamous cell carcinoma of the skin); serological evidence of infection with HIV or hepatitis B
MYSS Study 2004 
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virus; systemic infections requiring continued antibiotic therapy; haematological abnormalities (WCC
< 3 x109/L, platelet count < 1 x109/L, or Hb < 50 g/L); severe GI disorders, active peptic ulcer disease;
inability to take oral medication long term; pregnant women, nursing mothers, women who did not
agree to use adequate contraception; not fully understanding the purposes of the study or already
involved in other studies
Interventions Treatment group
• MMF• 2 g/d, orally
Control group
• AZA• 100 mg/d if body weight < 75 kg, 150 mg/d if body weight ≥ 75 kg, orally
Concomitant immunosuppression
• Induction antibody: none• CsA-ME, target C0 (month 3): 150 to 250 ng/mL• Corticosteroids, withdrawal planned by study protocol at month 6
Outcomes • Death• GraB loss• Primary non-function• Malignancy (except non-melanoma skin cancer)• Acute rejection• Infections• Non-melanoma skin cancer• Kidney function measures (SCr, CrCl, GFR, proteinuria)• Adverse events (diarrhoea, anaemia, leucopenia)
Notes • Publication: full journal article• Language: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “Randomisation was centralised at the Laboratory of Biostatistics of the Clini-
cal Research Centre for Rare Diseases Aldo e Cele Daccò of the Mario Negri In-
stitute for Pharmacological Research, under the responsibility of an indepen-
dent investigator who was not involved in design or performance of the study.”
Allocation concealment
(selection bias)
Unclear risk Randomisation stated, but no information on allocation method used is avail-
able
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
MYSS Study 2004  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk ITT analysis reported, two patients did not receive study drug or kidney graB
and were excluded from the analyses; all patients followed up or accounted
for
Selective reporting (re-
porting bias)
Low risk The published report included all expected outcomes regarding efficacy and
safety
Other bias Low risk No conflicts of interest declared. The study was supported by non-industry
funding
MYSS Study 2004  (Continued)
 
 
Methods • Study type: quasi-RCT• Study time frame/year of transplantation: 1998 to 2000• Duration of follow-up: 5 years
Participants • Country: Korea• Setting: single centre• Patients receiving cadaveric kidney transplant* Deceased donor: 100%* Previous transplantation: not reported* PRA > 20%: 2.9%* HLA mismatch: not reported* Cold ischaemia time (mean): 6.6 h* Delayed graB function: not reported• Number: treatment group (34); control group (34)• Mean age: 39 years• Sex: 53% male• Exclusion criteria: not reported
Interventions Treatment group
• MMF• 1.5 g/d, orally
Control group
• AZA• 100 to 130 mg/d, orally
Concomitant immunosuppression
• Induction antibody: none• CsA (formulation not reported), target C0 (month 3): not reported• Corticosteroids
Outcomes • Death• GraB loss• Acute rejection• Infections
Notes • Publication: full journal article• Language: English
Joh 2005 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quasi-RCT: "When two cases of kidney transplantation took place from the
same cadaveric donor in our hospital, transplantation was performed on a first
come first serve base. MMF was administered to the early-transplanted patient
and AZA to the following patient and vice versa in the next case"
Allocation concealment
(selection bias)
High risk Patients were consecutively enrolled and were allocated to the treatment
arms in alternating sequence
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient information to permit judgment
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis unclear; all patients were followed up
Selective reporting (re-
porting bias)
Unclear risk The published report included few outcomes regarding efficacy and safety
Other bias Unclear risk Funding source not reported
Joh 2005  (Continued)
ALG - antilymphocyte globulin; ATG - antithymocyte globulin; AZA - azathioprine; CAN - chronic allograB nephropathy; CrCl - creatinine
clearance; CsA - cyclosporin A, CsA-ME - cyclosporin A microemulsion; GI - gastrointestinal; Hb - haemoglobin; HBV - hepatitis B virus;
HIV - human immunodeficiency virus; HLA - human leucocyte antigen; HTLV - human T-lymphotropic virus; ITT - intention-to-treat; MMF
- mycophenolate mofetil; NODAT - new onset diabetes aBer transplantation; PRA - panel reactive antibody; RCT - randomised controlled
trial; SCr - serum creatinine; SD - standard deviation; SE - standard error; Tac - tacrolimus; WCC - white cell count
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Araujo 1999 Not primary regimen
Asci 2002 Not primary regimen
Baek 2004 Not RCT
Bataille 2010 Unequal concomitant regimen
Benfield 1999 Randomised to OKT3 and CsA (not AZA and MMF)
Boletis 1999b Not RCT
Brennan 2005 Not comparison of interest
Cransberg 2007 Not primary regimen, no comparison of interest
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Study Reason for exclusion
El-Agroudy 2009 Not primary regimen
Ettenger 1995 Not comparison of interest
Griffin 2003 Not primary regimen
Ha 2004 Not primary regimen
Hernandez 2007 No comparison of interest
Jain 2001 Not primary regimen
Jirasiritham 2000 Not primary regimen
Kasiske 1997 Not RCT
Khosroshahi 2006a not RCT
Kim 1999 not RCT
Langman 1996 Not primary regimen
Lezaic 2005 Not primary regimen
Lison 2004 Not comparison of interest
Makhdoomi 2005 Not RCT
Mandelbaum 1998 not RCT
Merion 2000 Multi-organ transplantation
Metcalfe 2002 Not primary regimen
MMF 1998 Not primary regimen
MO2ART Study 2003 Not comparison of interest
Nowacka-Cieciur 2000 Not primary regimen, no comparison of interest
Oliveira 1999 No RCT
Schurter 1997 Not primary regimen
Smak Gregoor 2000 Not primary regimen
Touchard 2005 Not primary regimen
Tsinalis 2000 Unequal concomitant regimen
Vacher-Coponat 2006 Unequal concomitant regimen
van der Mast 2000 Not primary regimen
Vanrenterghem 1998 Not comparison of interest
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Study Reason for exclusion
Woeste 2002 Multi-organ transplantation, unequal concomitant regimen
Wuthrich 2000 Not primary regimen
AZA - azathioprine; CsA - cyclosporin A; MMF - mycophenolate mofetil; RCT - randomised controlled trial
Legend: no RCT: study design not RCT or quasi-RCT; multi-organ transplantation: not solely kidney transplantation, exclusion of studies
enrolling patients undergoing multi-organ transplantation, e.g. simultaneous kidney-pancreas transplantation; not primary regimen: the
randomisation to MMF versus AZA was not performed at the time of transplantation, but subsequently during the maintenance phase
(e.g. due to previous acute rejection, chronic allograB nephropathy, calcineurin-inhibitor-toxicity or in stable graB function status); no
comparison of interest: randomised intervention not of interest for the review, i.e. not MMF versus AZA; unequal concomitant regimen,
i.e. patients randomised to intervention and control were treated with diLerent immunosuppressive regimens (e.g. MMF/cyclosporin A
versus AZA/tacrolimus)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropa-
thy prevention of mycophenolate mofetil versus azathioprine as the sole immunosuppressive ther-
apy for kidney transplant recipients (ATHENA)
Methods RCT, multicentre (6)
Year of transplantation: 2007 to 2012
Study duration: 4 years
Participants Estimated enrolment: 224
Country: Italy
Deceased donor: 100%
Previous transplantation: 0%
Inclusion criteria
• Patients 18 to 75 years, receiving their first single or double kidney transplant from deceased
donors
Exclusion criteria
• WCC < 2000/µl• "high immunological risk" (previous transplantation, PRA level > 10%)• History of malignancy• Evidence of active Hepatitis C, Hepatitis B or HIV• Pregnancy or lactation• Women of childbearing potential without following a scientifically accepted form of contracep-
tion• Legal incapacity and/or other circumstances rendering the patient unable to understand the na-
ture, scope and possible consequence of the trial• Evidence of an uncooperative attitude• Any evidence that the patient will not be able to complete the trial follow-up
Interventions Treatment group
• MMF• 1.5 g/d, orally
ATHENA Study 2012 
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Control group
• AZA• 75 mg/d if body weight < 75 kg, 125 mg/d if body weight ≥ 75 kg, orally
Concomitant regimen
• Induction therapy: IL-2 receptor antibody (20 mg basiliximab twice) and RATG (0.5 mg/kg for 7
days) and IV steroids (6 days)• CsA-ME, withdrawn after 1 year, if rejection-free and no evidence of tubulitis in graB biopsy
Outcomes Primary endpoint
• Biopsy proven CAN 3 years post-transplant in patients completing CsA withdrawal
Secondary endpoints
• overall incidence of acute rejections at 1 and 2 years• overall incidence of CAN at 3 years• graB and patient survival at 4 years
Starting date May 2007
Contact information Norberto Perico, MD; Mario Negri Institute for Pharmacological Research; Milano, Italy
Notes The study was registered at clinicaltrials.gov (#NCT00494741) on June 29, 2007
This study is ongoing, but not recruiting participants (last update February 24, 2014)
Estimated completion date: September 2016
ATHENA Study 2012  (Continued)
AZA - azathioprine; CAN - chronic allograB nephropathy; CsA-ME - cyclosporin A emulsion; HIV - human immunodeficiency virus; IL-2 -
interleukin 2; IV - intravenous; MMF - mycophenolate mofetil; PRA - panel reactive antibody; RATG - rabbit antithymocyte globulin; WCC
- white cell count
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Mycophenolate mofetil versus azathioprine
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death: all cause 16   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 Follow-up ≤ 1 year 16 2987 Risk Ratio (M-H, Random, 95%
CI)
1.13 [0.76, 1.68]
1.2 Follow-up 1 to 4 years 7 1595 Risk Ratio (M-H, Random, 95%
CI)
0.84 [0.59, 1.20]
1.3 Follow-up > 4 years 3 457 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.59, 1.07]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.4 Longest duration of follow-up 16 2987 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.70, 1.29]
2 GraB loss: including death 15   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 Follow-up ≤ 1 year 15 2653 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.62, 1.02]
2.2 Follow-up 1 to 4 years 6 1347 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.66, 1.04]
2.3 Follow-up > 4 years 2 209 Risk Ratio (M-H, Random, 95%
CI)
0.70 [0.29, 1.66]
2.4 Longest duration of follow-up 15 2653 Risk Ratio (M-H, Random, 95%
CI)
0.82 [0.67, 1.00]
3 GraB loss: censored for death 17   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
3.1 Follow-up ≤ 1 year 15 2384 Risk Ratio (M-H, Random, 95%
CI)
0.68 [0.49, 0.94]
3.2 Follow-up 1 to 4 years 6 1512 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.64, 1.13]
3.3 Follow-up > 4 years 4 525 Risk Ratio (M-H, Random, 95%
CI)
0.87 [0.60, 1.25]
3.4 Longest duration of follow-up 17 2540 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.62, 0.99]
4 Primary non-function 11 1864 Risk Ratio (M-H, Random, 95%
CI)
0.47 [0.19, 1.18]
5 Malignancy: longest duration of fol-
low-up
6   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
5.1 Any malignancy 5 1735 Risk Ratio (M-H, Random, 95%
CI)
0.81 [0.60, 1.09]
5.2 Lymphoma/PTLD 5 1564 Risk Ratio (M-H, Random, 95%
CI)
1.26 [0.43, 3.66]
5.3 Non-melanoma skin cancer 4 1416 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.46, 1.34]
6 Acute rejection: total 22   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
6.1 Follow-up ≤ 6 months 19 3128 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.55, 0.75]
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6.2 Follow-up 6 to 12 months 10 2086 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.58, 0.74]
6.3 Follow-up > 12 months 5 603 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.61, 0.99]
6.4 Longest duration of follow-up 22 3301 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.57, 0.73]
7 Acute rejection: confirmed by biopsy 12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
7.1 Follow-up ≤ 6 months 10 2306 Risk Ratio (M-H, Random, 95%
CI)
0.59 [0.50, 0.69]
7.2 Follow-up 6 to 12 months 4 714 Risk Ratio (M-H, Random, 95%
CI)
0.66 [0.49, 0.88]
7.3 Follow-up > 12 months 1 148 Risk Ratio (M-H, Random, 95%
CI)
0.79 [0.40, 1.56]
7.4 Longest duration of follow-up 12 2696 Risk Ratio (M-H, Random, 95%
CI)
0.59 [0.52, 0.68]
8 Acute rejection: steroid resistant/anti-
body treated
15   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
8.1 Follow-up ≤ 6 months 11 2350 Risk Ratio (M-H, Random, 95%
CI)
0.53 [0.35, 0.80]
8.2 Follow-up 6 to 12 months 5 740 Risk Ratio (M-H, Random, 95%
CI)
0.49 [0.29, 0.81]
8.3 Follow-up > 12 months 2 223 Risk Ratio (M-H, Random, 95%
CI)
0.52 [0.11, 2.44]
8.4 Longest duration of follow-up 15 2914 Risk Ratio (M-H, Random, 95%
CI)
0.48 [0.36, 0.65]
9 Chronic allograft nephropathy 3   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
9.1 Follow-up ≤ 1 year 1 71 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.43, 0.98]
9.2 Follow-up > 1 year 2 132 Risk Ratio (M-H, Random, 95%
CI)
0.86 [0.39, 1.87]
9.3 Longest duration of follow-up 3 203 Risk Ratio (M-H, Random, 95%
CI)
0.69 [0.48, 0.99]
10 Infection: other (longest duration of fol-
low-up)
10   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
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10.1 Aspergillus 4 1316 Risk Ratio (M-H, Random, 95%
CI)
2.61 [0.65, 10.58]
10.2 BK-virus 1 56 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
10.3 Candida 4 1316 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.77, 1.31]
10.4 Candida tissue invasive 4 1502 Risk Ratio (M-H, Random, 95%
CI)
0.89 [0.34, 2.31]
10.5 Herpes zoster 4 1629 Risk Ratio (M-H, Random, 95%
CI)
1.28 [0.80, 2.04]
10.6 Pneumocystis carinii/jiroveci 5 1650 Risk Ratio (M-H, Random, 95%
CI)
0.19 [0.05, 0.69]
10.7 Urinary tract/cystitis 6 1553 Risk Ratio (M-H, Random, 95%
CI)
1.15 [0.93, 1.42]
11 Infection: CMV viraemia/syndrome 13   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
11.1 Follow-up ≤ 1 year 13 2880 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.81, 1.20]
11.2 Follow-up > 1 year 3 1240 Risk Ratio (M-H, Random, 95%
CI)
1.08 [0.77, 1.50]
11.3 Longest duration of follow-up 13 2880 Risk Ratio (M-H, Random, 95%
CI)
1.06 [0.85, 1.32]
12 Infection: CMV tissue invasive 7   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
12.1 Follow-up ≤ 1 year 7 1510 Risk Ratio (M-H, Random, 95%
CI)
1.73 [1.12, 2.69]
12.2 Follow-up > 1 year 2 992 Risk Ratio (M-H, Random, 95%
CI)
1.51 [0.95, 2.40]
12.3 Longest duration of follow-up 7 1510 Risk Ratio (M-H, Random, 95%
CI)
1.70 [1.10, 2.61]
13 GraB function: serum creatinine 15   Mean Difference (IV, Random,
95% CI)
Subtotals only
13.1 Follow-up ≤ 1 year 15 2457 Mean Difference (IV, Random,
95% CI)
0.03 [-0.07, 0.14]
13.2 Follow-up 1 to 4 years 4 712 Mean Difference (IV, Random,
95% CI)
-0.05 [-0.14, 0.03]
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13.3 Longest duration of follow-up 15 2233 Mean Difference (IV, Random,
95% CI)
0.05 [-0.05, 0.15]
14 GraB function: CrCl/GFR 6   Mean Difference (IV, Random,
95% CI)
Subtotals only
14.1 Follow-up ≤ 1 year 5 970 Mean Difference (IV, Random,
95% CI)
1.74 [-1.77, 5.25]
14.2 Follow-up 1 to 4 years 3 376 Mean Difference (IV, Random,
95% CI)
1.44 [-3.05, 5.94]
14.3 Follow-up > 4 years 2 120 Mean Difference (IV, Random,
95% CI)
0.56 [-3.48, 4.60]
14.4 Longest duration of follow-up 6 976 Mean Difference (IV, Random,
95% CI)
1.56 [-1.15, 4.27]
15 GraB function: proteinuria 2   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
15.1 Follow-up 2 to 5 years 2 745 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.70, 1.43]
16 GraB function: proteinuria 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
16.1 Follow-up ≤ 1 year 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
17 Adverse events: gastrointestinal
(longest duration of follow-up)
11   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
17.1 Diarrhoea 11 2638 Risk Ratio (M-H, Random, 95%
CI)
1.55 [1.32, 1.83]
17.2 Abdominal pain 3 1311 Risk Ratio (M-H, Random, 95%
CI)
1.18 [0.97, 1.44]
17.3 Vomiting 4 1487 Risk Ratio (M-H, Random, 95%
CI)
1.27 [0.83, 1.94]
17.4 Gastrointestinal bleeding 2 575 Risk Ratio (M-H, Random, 95%
CI)
3.99 [1.07, 14.86]
17.5 Nausea 5 1573 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.85, 1.20]
18 Adverse events: other (longest duration
of follow-up)
8   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
18.1 New onset diabetes in patients with-
out diabetes at baseline, insulin-treated
4 445 Risk Ratio (M-H, Random, 95%
CI)
0.57 [0.34, 0.95]
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18.2 Hypertension 1 319 Risk Ratio (M-H, Random, 95%
CI)
0.97 [0.64, 1.47]
18.3 Hyperlipidaemia 3 813 Risk Ratio (M-H, Random, 95%
CI)
1.41 [0.59, 3.39]
18.4 Elevated liver enzymes 3 272 Risk Ratio (M-H, Random, 95%
CI)
0.50 [0.21, 1.23]
19 Adverse events: haematological (longest
duration of follow-up)
12   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
19.1 Anaemia 5 1821 Risk Ratio (M-H, Random, 95%
CI)
1.07 [0.87, 1.31]
19.2 Severe anaemia 2 528 Risk Ratio (M-H, Random, 95%
CI)
1.42 [0.61, 3.28]
19.3 Leucopenia 12 2671 Risk Ratio (M-H, Random, 95%
CI)
1.04 [0.78, 1.39]
19.4 Severe leucopenia 3 1025 Risk Ratio (M-H, Random, 95%
CI)
1.44 [0.33, 6.19]
19.5 Thrombocytopenia 5 1492 Risk Ratio (M-H, Random, 95%
CI)
0.73 [0.52, 1.03]
19.6 Severe thrombocytopenia 2 992 Risk Ratio (M-H, Random, 95%
CI)
0.60 [0.11, 3.21]
20 Total cholesterol 2   Mean Difference (IV, Random,
95% CI)
Subtotals only
20.1 Follow-up ≤ 1 year 2 219 Mean Difference (IV, Random,
95% CI)
-2.57 [-15.65, 10.51]
 
 
Analysis 1.1.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 1 Death: all cause.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Follow-up ≤ 1 year  
MMF US Study 1995 19/331 7/164 21.74% 1.34[0.58,3.13]
MMF TRI Study 1996 13/335 7/162 19.23% 0.9[0.37,2.21]
Mendez 1998 6/117 2/59 6.32% 1.51[0.31,7.27]
Ling 1998 0/11 0/5   Not estimable
Egfjord 1999 3/25 2/25 5.38% 1.5[0.27,8.22]
Johnson 2000 5/72 3/76 8% 1.76[0.44,7.1]
Suhail 2000 0/20 0/20   Not estimable
Busque 2001 0/23 2/23 1.75% 0.2[0.01,3.95]
Less with MMF 5000.002 100.1 1 Less with AZA
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ji 2001 0/56 0/50   Not estimable
Tuncer 2002 0/38 1/38 1.55% 0.33[0.01,7.93]
Weimer 2002 0/31 0/25   Not estimable
Sadek 2002 8/162 7/157 15.87% 1.11[0.41,2.98]
COSTAMP Study 2002 4/243 4/246 8.24% 1.01[0.26,4]
Merville 2004 1/37 1/34 2.08% 0.92[0.06,14.12]
MYSS Study 2004 4/167 4/167 8.3% 1[0.25,3.93]
Joh 2005 1/34 0/34 1.55% 3[0.13,71.15]
Subtotal (95% CI) 1702 1285 100% 1.13[0.76,1.68]
Total events: 64 (MMF), 40 (AZA)  
Heterogeneity: Tau2=0; Chi2=3.35, df=11(P=0.99); I2=0%  
Test for overall effect: Z=0.62(P=0.54)  
   
1.1.2 Follow-up 1 to 4 years  
MMF US Study 1995 37/331 20/164 49.07% 0.92[0.55,1.53]
MMF TRI Study 1996 23/335 14/162 31.51% 0.79[0.42,1.5]
Johnson 2000 4/72 3/76 5.99% 1.41[0.33,6.07]
COSTAMP Study 2002 1/41 3/34 2.6% 0.28[0.03,2.54]
Weimer 2002 0/31 0/25   Not estimable
Tuncer 2002 3/38 4/38 6.28% 0.75[0.18,3.13]
MYSS Study 2004 2/124 4/124 4.54% 0.5[0.09,2.68]
Subtotal (95% CI) 972 623 100% 0.84[0.59,1.2]
Total events: 70 (MMF), 48 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.98, df=5(P=0.85); I2=0%  
Test for overall effect: Z=0.97(P=0.33)  
   
1.1.3 Follow-up > 4 years  
MMF TRI Study 1996 43/88 28/45 89.77% 0.79[0.57,1.07]
Tuncer 2002 3/38 4/38 4.29% 0.75[0.18,3.13]
MYSS Study 2004 5/124 5/124 5.94% 1[0.3,3.37]
Subtotal (95% CI) 250 207 100% 0.8[0.59,1.07]
Total events: 51 (MMF), 37 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.92); I2=0%  
Test for overall effect: Z=1.52(P=0.13)  
   
1.1.4 Longest duration of follow-up  
MMF US Study 1995 37/331 20/164 36.74% 0.92[0.55,1.53]
MMF TRI Study 1996 23/335 14/162 23.59% 0.79[0.42,1.5]
Mendez 1998 6/117 2/59 3.89% 1.51[0.31,7.27]
Ling 1998 0/11 0/5   Not estimable
Egfjord 1999 3/25 2/25 3.31% 1.5[0.27,8.22]
Suhail 2000 0/20 0/20   Not estimable
Johnson 2000 4/72 3/76 4.49% 1.41[0.33,6.07]
Busque 2001 0/23 2/23 1.08% 0.2[0.01,3.95]
Ji 2001 0/56 0/50   Not estimable
Weimer 2002 0/31 0/25   Not estimable
COSTAMP Study 2002 4/243 4/246 5.07% 1.01[0.26,4]
Tuncer 2002 3/38 4/38 4.7% 0.75[0.18,3.13]
Sadek 2002 8/162 7/157 9.77% 1.11[0.41,2.98]
MYSS Study 2004 4/167 4/167 5.11% 1[0.25,3.93]
Merville 2004 1/37 1/34 1.28% 0.92[0.06,14.12]
Joh 2005 1/34 0/34 0.96% 3[0.13,71.15]
Less with MMF 5000.002 100.1 1 Less with AZA
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  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 1702 1285 100% 0.95[0.7,1.29]
Total events: 94 (MMF), 63 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.98, df=11(P=0.99); I2=0%  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Chi2=2.25, df=1 (P=0.52), I2=0%  
Less with MMF 5000.002 100.1 1 Less with AZA
 
 
Analysis 1.2.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 2 GraB loss: including death.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Follow-up ≤ 1 year  
MMF US Study 1995 31/331 20/164 21.54% 0.77[0.45,1.3]
MMF TRI Study 1996 38/335 22/162 25.16% 0.84[0.51,1.36]
Mendez 1998 7/117 5/59 4.96% 0.71[0.23,2.13]
Ling 1998 0/11 0/5   Not estimable
Egfjord 1999 4/25 7/25 5.04% 0.57[0.19,1.71]
Suhail 2000 0/20 0/20   Not estimable
Johnson 2000 8/72 9/76 7.54% 0.94[0.38,2.3]
Busque 2001 0/23 2/23 0.68% 0.2[0.01,3.95]
Ji 2001 0/56 2/50 0.67% 0.18[0.01,3.64]
COSTAMP Study 2002 12/243 16/246 11.44% 0.76[0.37,1.57]
Sadek 2002 22/162 20/157 19% 1.07[0.61,1.87]
Tuncer 2002 1/38 4/38 1.32% 0.25[0.03,2.13]
Weimer 2002 0/31 0/25   Not estimable
Merville 2004 1/37 6/34 1.42% 0.15[0.02,1.21]
Joh 2005 3/34 1/34 1.24% 3[0.33,27.42]
Subtotal (95% CI) 1535 1118 100% 0.8[0.62,1.02]
Total events: 127 (MMF), 114 (AZA)  
Heterogeneity: Tau2=0; Chi2=8.39, df=11(P=0.68); I2=0%  
Test for overall effect: Z=1.8(P=0.07)  
   
1.2.2 Follow-up 1 to 4 years  
MMF US Study 1995 69/331 41/164 45.2% 0.83[0.59,1.17]
MMF TRI Study 1996 56/335 32/162 33.68% 0.85[0.57,1.25]
Johnson 2000 14/72 15/76 12.11% 0.99[0.51,1.89]
Tuncer 2002 3/38 11/38 3.62% 0.27[0.08,0.9]
COSTAMP Study 2002 6/41 6/34 4.81% 0.83[0.29,2.34]
Weimer 2002 2/31 0/25 0.58% 4.06[0.2,80.94]
Subtotal (95% CI) 848 499 100% 0.83[0.66,1.04]
Total events: 150 (MMF), 105 (AZA)  
Heterogeneity: Tau2=0; Chi2=4.7, df=5(P=0.45); I2=0%  
Test for overall effect: Z=1.62(P=0.1)  
   
1.2.3 Follow-up > 4 years  
MMF TRI Study 1996 63/88 34/45 63.11% 0.95[0.77,1.17]
Tuncer 2002 5/38 12/38 36.89% 0.42[0.16,1.07]
Subtotal (95% CI) 126 83 100% 0.7[0.29,1.66]
Total events: 68 (MMF), 46 (AZA)  
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.3; Chi2=3.45, df=1(P=0.06); I2=70.99%  
Test for overall effect: Z=0.81(P=0.42)  
   
1.2.4 Longest duration of follow-up  
MMF US Study 1995 69/331 41/164 33.39% 0.83[0.59,1.17]
MMF TRI Study 1996 56/335 32/162 24.88% 0.85[0.57,1.25]
Ling 1998 0/11 0/5   Not estimable
Mendez 1998 7/117 5/59 3.13% 0.71[0.23,2.13]
Egfjord 1999 4/25 7/25 3.18% 0.57[0.19,1.71]
Suhail 2000 0/20 0/20   Not estimable
Johnson 2000 14/72 15/76 8.95% 0.99[0.51,1.89]
Ji 2001 0/56 2/50 0.42% 0.18[0.01,3.64]
Busque 2001 0/23 2/23 0.43% 0.2[0.01,3.95]
Tuncer 2002 5/38 12/38 4.31% 0.42[0.16,1.07]
COSTAMP Study 2002 12/243 16/246 7.22% 0.76[0.37,1.57]
Sadek 2002 22/162 20/157 11.99% 1.07[0.61,1.87]
Weimer 2002 2/31 0/25 0.43% 4.06[0.2,80.94]
Merville 2004 1/37 6/34 0.9% 0.15[0.02,1.21]
Joh 2005 3/34 1/34 0.78% 3[0.33,27.42]
Subtotal (95% CI) 1535 1118 100% 0.82[0.67,1]
Total events: 195 (MMF), 159 (AZA)  
Heterogeneity: Tau2=0; Chi2=10.51, df=12(P=0.57); I2=0%  
Test for overall effect: Z=1.99(P=0.05)  
Test for subgroup differences: Chi2=0.17, df=1 (P=0.98), I2=0%  
Less with MMF 2000.005 100.1 1 Less with AZA
 
 
Analysis 1.3.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 3 GraB loss: censored for death.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Follow-up ≤ 1 year  
MMF US Study 1995 14/331 14/164 21.38% 0.5[0.24,1.01]
MMF TRI Study 1996 28/335 18/162 34.83% 0.75[0.43,1.32]
Mendez 1998 1/117 3/59 2.19% 0.17[0.02,1.58]
Ling 1998 0/11 0/5   Not estimable
Egfjord 1999 1/25 5/25 2.55% 0.2[0.03,1.59]
Suhail 2000 0/20 0/20   Not estimable
Ji 2001 0/56 2/50 1.21% 0.18[0.01,3.64]
Folkmane 2001 2/23 3/25 3.81% 0.72[0.13,3.96]
Busque 2001 0/23 0/23   Not estimable
Weimer 2002 0/31 0/25   Not estimable
Miladipour 2002 0/40 1/40 1.09% 0.33[0.01,7.95]
Sadek 2002 16/162 16/157 25.43% 0.97[0.5,1.87]
MYSS Study 2004 1/124 2/124 1.93% 0.5[0.05,5.44]
Merville 2004 0/37 5/34 1.34% 0.08[0,1.46]
Joh 2005 3/34 1/34 2.24% 3[0.33,27.42]
Joh 2005 2/34 1/34 1.98% 2[0.19,21.03]
Subtotal (95% CI) 1403 981 100% 0.68[0.49,0.94]
Total events: 68 (MMF), 71 (AZA)  
Less with MMF 5000.002 100.1 1 Less with AZA
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=10.54, df=11(P=0.48); I2=0%  
Test for overall effect: Z=2.31(P=0.02)  
   
1.3.2 Follow-up 1 to 4 years  
MMF US Study 1995 50/331 28/164 44.4% 0.88[0.58,1.35]
MMF TRI Study 1996 39/335 25/162 36.63% 0.75[0.47,1.2]
Johnson 2000 9/72 9/76 10.6% 1.06[0.44,2.51]
Weimer 2002 2/31 0/25 0.89% 4.06[0.2,80.94]
MYSS Study 2004 3/124 7/124 4.5% 0.43[0.11,1.62]
Joh 2005 4/34 2/34 2.99% 2[0.39,10.2]
Subtotal (95% CI) 927 585 100% 0.85[0.64,1.13]
Total events: 107 (MMF), 71 (AZA)  
Heterogeneity: Tau2=0; Chi2=3.66, df=5(P=0.6); I2=0%  
Test for overall effect: Z=1.09(P=0.28)  
   
1.3.3 Follow-up > 4 years  
MMF TRI Study 1996 34/88 17/45 63.1% 1.02[0.65,1.62]
Tuncer 2002 5/38 11/38 14.47% 0.45[0.17,1.18]
MYSS Study 2004 7/124 7/124 12.79% 1[0.36,2.77]
Joh 2005 4/34 6/34 9.64% 0.67[0.21,2.15]
Subtotal (95% CI) 284 241 100% 0.87[0.6,1.25]
Total events: 50 (MMF), 41 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.56, df=3(P=0.47); I2=0%  
Test for overall effect: Z=0.75(P=0.45)  
   
1.3.4 Longest duration of follow-up  
MMF US Study 1995 50/331 28/164 31.29% 0.88[0.58,1.35]
MMF TRI Study 1996 39/335 25/162 25.82% 0.75[0.47,1.2]
Ling 1998 0/11 0/5   Not estimable
Mendez 1998 1/117 3/59 1.11% 0.17[0.02,1.58]
Egfjord 1999 1/25 5/25 1.3% 0.2[0.03,1.59]
Suhail 2000 0/20 0/20   Not estimable
Johnson 2000 9/72 9/76 7.47% 1.06[0.44,2.51]
Ji 2001 0/56 2/50 0.62% 0.18[0.01,3.64]
Busque 2001 0/23 0/23   Not estimable
Folkmane 2001 2/23 3/25 1.94% 0.72[0.13,3.96]
Weimer 2002 2/31 0/25 0.63% 4.06[0.2,80.94]
Sadek 2002 16/162 16/157 12.97% 0.97[0.5,1.87]
Miladipour 2002 0/40 1/40 0.56% 0.33[0.01,7.95]
Tuncer 2002 5/38 11/38 6.12% 0.45[0.17,1.18]
Merville 2004 0/37 5/34 0.69% 0.08[0,1.46]
MYSS Study 2004 7/124 7/124 5.41% 1[0.36,2.77]
Joh 2005 4/34 6/34 4.07% 0.67[0.21,2.15]
Subtotal (95% CI) 1479 1061 100% 0.78[0.62,0.99]
Total events: 136 (MMF), 121 (AZA)  
Heterogeneity: Tau2=0; Chi2=11.04, df=13(P=0.61); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=1.42, df=1 (P=0.7), I2=0%  
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Analysis 1.4.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 4 Primary non-function.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
MMF US Study 1995 1/331 0/164 8.33% 1.49[0.06,36.4]
MMF TRI Study 1996 5/335 7/162 66.35% 0.35[0.11,1.07]
Mendez 1998 0/117 0/59   Not estimable
Ling 1998 0/11 0/5   Not estimable
Egfjord 1999 0/25 0/25   Not estimable
Suhail 2000 0/20 0/20   Not estimable
Busque 2001 0/23 0/23   Not estimable
Folkmane 2001 1/23 0/25 8.56% 3.25[0.14,76.01]
Ji 2001 0/56 0/50   Not estimable
Weimer 2002 0/31 0/25   Not estimable
MYSS Study 2004 1/167 3/167 16.76% 0.33[0.04,3.17]
   
Total (95% CI) 1139 725 100% 0.47[0.19,1.18]
Total events: 8 (MMF), 10 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.34, df=3(P=0.5); I2=0%  
Test for overall effect: Z=1.61(P=0.11)  
Favours MMF 1000.01 100.1 1 Favours AZA
 
 
Analysis 1.5.   Comparison 1 Mycophenolate mofetil versus
azathioprine, Outcome 5 Malignancy: longest duration of follow-up.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 Any malignancy  
MMF US Study 1995 36/331 20/164 33.49% 0.89[0.53,1.49]
MMF TRI Study 1996 44/335 29/162 47.85% 0.73[0.48,1.13]
Mendez 1998 2/117 1/59 1.56% 1.01[0.09,10.9]
Sadek 2002 6/162 3/157 4.72% 1.94[0.49,7.62]
MYSS Study 2004 8/124 13/124 12.38% 0.62[0.26,1.43]
Subtotal (95% CI) 1069 666 100% 0.81[0.6,1.09]
Total events: 96 (MMF), 66 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.34, df=4(P=0.67); I2=0%  
Test for overall effect: Z=1.42(P=0.16)  
   
1.5.2 Lymphoma/PTLD  
MMF US Study 1995 4/331 1/164 23.79% 1.98[0.22,17.59]
MMF TRI Study 1996 5/335 1/162 24.79% 2.42[0.28,20.53]
Mendez 1998 0/117 0/59   Not estimable
Johnson 2000 1/72 0/76 11.18% 3.16[0.13,76.44]
MYSS Study 2004 2/124 4/124 40.23% 0.5[0.09,2.68]
Subtotal (95% CI) 979 585 100% 1.26[0.43,3.66]
Total events: 12 (MMF), 6 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.01, df=3(P=0.57); I2=0%  
Test for overall effect: Z=0.43(P=0.67)  
   
1.5.3 Non-melanoma skin cancer  
MMF US Study 1995 23/331 8/164 33.6% 1.42[0.65,3.11]
MMF TRI Study 1996 26/335 22/162 54.26% 0.57[0.33,0.98]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Mendez 1998 1/117 1/59 3.66% 0.5[0.03,7.92]
MYSS Study 2004 2/124 3/124 8.48% 0.67[0.11,3.92]
Subtotal (95% CI) 907 509 100% 0.78[0.46,1.34]
Total events: 52 (MMF), 34 (AZA)  
Heterogeneity: Tau2=0.06; Chi2=3.7, df=3(P=0.3); I2=18.85%  
Test for overall effect: Z=0.89(P=0.37)  
Less with MMF 1000.01 100.1 1 Less with AZA
 
 
Analysis 1.6.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 6 Acute rejection: total.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 Follow-up ≤ 6 months  
MMF US Study 1995 79/331 73/164 15.27% 0.54[0.41,0.69]
MMF TRI Study 1996 99/335 80/162 16.93% 0.6[0.48,0.75]
Ling 1998 2/11 3/5 1.05% 0.3[0.07,1.28]
Mendez 1998 21/117 17/59 5.77% 0.62[0.36,1.09]
Egfjord 1999 8/25 10/25 3.55% 0.8[0.38,1.69]
Suhail 2000 2/20 7/20 1.05% 0.29[0.07,1.21]
Johnson 2000 9/72 13/76 3.24% 0.73[0.33,1.6]
Busque 2001 2/23 8/23 1.06% 0.25[0.06,1.05]
Ji 2001 11/56 22/50 4.93% 0.45[0.24,0.83]
Folkmane 2001 5/23 8/25 2.25% 0.68[0.26,1.78]
COSTAMP Study 2002 59/243 83/246 13.97% 0.72[0.54,0.95]
Sadek 2002 33/162 44/157 9.54% 0.73[0.49,1.08]
Weimer 2002 2/31 8/25 1.03% 0.2[0.05,0.87]
Miladipour 2002 4/40 10/40 1.84% 0.4[0.14,1.17]
Sun 2002b 2/40 6/46 0.92% 0.38[0.08,1.79]
Army Hospital 2002 1/17 3/16 0.48% 0.31[0.04,2.71]
Keven 2003 3/24 3/17 1.01% 0.71[0.16,3.1]
MYSS Study 2004 56/167 58/167 13.25% 0.97[0.72,1.3]
Joh 2005 10/34 7/34 2.88% 1.43[0.62,3.31]
Subtotal (95% CI) 1771 1357 100% 0.65[0.55,0.75]
Total events: 408 (MMF), 463 (AZA)  
Heterogeneity: Tau2=0.02; Chi2=23.65, df=18(P=0.17); I2=23.87%  
Test for overall effect: Z=5.7(P<0.0001)  
   
1.6.2 Follow-up 6 to 12 months  
MMF US Study 1995 87/331 77/164 25.41% 0.56[0.44,0.71]
MMF TRI Study 1996 105/335 81/162 30.71% 0.63[0.5,0.78]
Mendez 1998 24/117 19/59 5.67% 0.64[0.38,1.07]
Egfjord 1999 8/25 11/25 2.87% 0.73[0.35,1.5]
Johnson 2000 11/72 13/76 2.77% 0.89[0.43,1.86]
Weimer 2002 5/31 9/25 1.63% 0.45[0.17,1.17]
Sadek 2002 34/162 51/157 10.7% 0.65[0.44,0.94]
Baltar 2002 1/14 5/12 0.37% 0.17[0.02,1.27]
Merville 2004 5/37 7/34 1.36% 0.66[0.23,1.87]
MYSS Study 2004 50/124 58/124 18.49% 0.86[0.65,1.15]
Subtotal (95% CI) 1248 838 100% 0.65[0.58,0.74]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 330 (MMF), 331 (AZA)  
Heterogeneity: Tau2=0; Chi2=8.43, df=9(P=0.49); I2=0%  
Test for overall effect: Z=6.86(P<0.0001)  
   
1.6.3 Follow-up > 12 months  
Johnson 2000 12/72 16/76 11.96% 0.79[0.4,1.56]
COSTAMP Study 2002 11/41 11/34 11.15% 0.83[0.41,1.67]
Weimer 2002 5/31 11/25 6.68% 0.37[0.15,0.92]
Tuncer 2002 7/38 13/38 8.65% 0.54[0.24,1.2]
MYSS Study 2004 57/124 65/124 61.56% 0.88[0.68,1.13]
Subtotal (95% CI) 306 297 100% 0.78[0.61,0.99]
Total events: 92 (MMF), 116 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=4.34, df=4(P=0.36); I2=7.74%  
Test for overall effect: Z=2.03(P=0.04)  
   
1.6.4 Longest duration of follow-up  
MMF US Study 1995 87/331 77/164 16.96% 0.56[0.44,0.71]
MMF TRI Study 1996 105/335 81/162 19.18% 0.63[0.5,0.78]
Mendez 1998 24/117 19/59 5.08% 0.64[0.38,1.07]
Ling 1998 2/11 3/5 0.7% 0.3[0.07,1.28]
Egfjord 1999 8/25 11/25 2.7% 0.73[0.35,1.5]
Suhail 2000 2/20 7/20 0.7% 0.29[0.07,1.21]
Johnson 2000 12/72 16/76 3.07% 0.79[0.4,1.56]
Busque 2001 2/23 8/23 0.71% 0.25[0.06,1.05]
Folkmane 2001 5/23 8/25 1.56% 0.68[0.26,1.78]
Ji 2001 11/56 22/50 3.66% 0.45[0.24,0.83]
Sadek 2002 34/162 51/157 8.81% 0.65[0.44,0.94]
COSTAMP Study 2002 59/243 83/246 13.69% 0.72[0.54,0.95]
Tuncer 2002 7/38 13/38 2.22% 0.54[0.24,1.2]
Weimer 2002 5/31 11/25 1.71% 0.37[0.15,0.92]
Army Hospital 2002 1/17 3/16 0.32% 0.31[0.04,2.71]
Sun 2002b 2/40 6/46 0.62% 0.38[0.08,1.79]
Baltar 2002 1/14 5/12 0.37% 0.17[0.02,1.27]
Miladipour 2002 4/40 10/40 1.26% 0.4[0.14,1.17]
Keven 2003 3/24 3/17 0.68% 0.71[0.16,3.1]
Merville 2004 5/37 7/34 1.32% 0.66[0.23,1.87]
MYSS Study 2004 56/167 58/167 12.66% 0.97[0.72,1.3]
Joh 2005 10/34 7/34 2.02% 1.43[0.62,3.31]
Subtotal (95% CI) 1860 1441 100% 0.65[0.57,0.73]
Total events: 445 (MMF), 509 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=23.2, df=21(P=0.33); I2=9.48%  
Test for overall effect: Z=7.01(P<0.0001)  
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Analysis 1.7.   Comparison 1 Mycophenolate mofetil versus
azathioprine, Outcome 7 Acute rejection: confirmed by biopsy.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.7.1 Follow-up ≤ 6 months  
MMF US Study 1995 62/331 63/164 23.37% 0.49[0.36,0.66]
MMF TRI Study 1996 60/335 59/162 22.11% 0.49[0.36,0.67]
Mendez 1998 21/117 17/59 7.53% 0.62[0.36,1.09]
Suhail 2000 2/20 7/20 1.18% 0.29[0.07,1.21]
Johnson 2000 9/72 13/76 3.89% 0.73[0.33,1.6]
Folkmane 2001 5/23 8/25 2.62% 0.68[0.26,1.78]
Busque 2001 2/23 8/23 1.19% 0.25[0.06,1.05]
Army Hospital 2002 1/17 3/16 0.53% 0.31[0.04,2.71]
COSTAMP Study 2002 59/243 83/246 25.26% 0.72[0.54,0.95]
MYSS Study 2004 30/167 38/167 12.31% 0.79[0.51,1.21]
Subtotal (95% CI) 1348 958 100% 0.59[0.5,0.69]
Total events: 251 (MMF), 299 (AZA)  
Heterogeneity: Tau2=0; Chi2=9.68, df=9(P=0.38); I2=7.07%  
Test for overall effect: Z=6.63(P<0.0001)  
   
1.7.2 Follow-up 6 to 12 months  
Mendez 1998 24/117 19/59 31.55% 0.64[0.38,1.07]
Johnson 2000 11/72 13/76 15.42% 0.89[0.43,1.86]
Sadek 2002 27/162 43/157 45.46% 0.61[0.4,0.93]
Merville 2004 5/37 7/34 7.58% 0.66[0.23,1.87]
Subtotal (95% CI) 388 326 100% 0.66[0.49,0.88]
Total events: 67 (MMF), 82 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.81, df=3(P=0.85); I2=0%  
Test for overall effect: Z=2.83(P=0)  
   
1.7.3 Follow-up > 12 months  
Johnson 2000 12/72 16/76 100% 0.79[0.4,1.56]
Subtotal (95% CI) 72 76 100% 0.79[0.4,1.56]
Total events: 12 (MMF), 16 (AZA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
   
1.7.4 Longest duration of follow-up  
MMF US Study 1995 62/331 63/164 20.84% 0.49[0.36,0.66]
MMF TRI Study 1996 60/335 59/162 19.5% 0.49[0.36,0.67]
Mendez 1998 24/117 19/59 6.93% 0.64[0.38,1.07]
Johnson 2000 12/72 16/76 4.02% 0.79[0.4,1.56]
Suhail 2000 2/20 7/20 0.88% 0.29[0.07,1.21]
Busque 2001 2/23 8/23 0.89% 0.25[0.06,1.05]
Folkmane 2001 5/23 8/25 1.97% 0.68[0.26,1.78]
COSTAMP Study 2002 59/243 83/246 22.91% 0.72[0.54,0.95]
Army Hospital 2002 1/17 3/16 0.39% 0.31[0.04,2.71]
Sadek 2002 27/162 43/157 9.99% 0.61[0.4,0.93]
MYSS Study 2004 30/167 38/167 10.01% 0.79[0.51,1.21]
Merville 2004 5/37 7/34 1.67% 0.66[0.23,1.87]
Subtotal (95% CI) 1547 1149 100% 0.59[0.52,0.68]
Total events: 289 (MMF), 354 (AZA)  
Heterogeneity: Tau2=0; Chi2=10.23, df=11(P=0.51); I2=0%  
Less with MMF 1000.01 100.1 1 Less with AZA
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
82
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=7.53(P<0.0001)  
Test for subgroup differences: Chi2=1.13, df=1 (P=0.77), I2=0%  
Less with MMF 1000.01 100.1 1 Less with AZA
 
 
Analysis 1.8.   Comparison 1 Mycophenolate mofetil versus azathioprine,
Outcome 8 Acute rejection: steroid resistant/antibody treated.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.8.1 Follow-up ≤ 6 months  
MMF US Study 1995 26/331 33/164 25.1% 0.39[0.24,0.63]
MMF TRI Study 1996 23/335 25/162 23.23% 0.44[0.26,0.76]
Mendez 1998 7/117 4/59 9.35% 0.88[0.27,2.89]
Suhail 2000 0/20 2/20 1.89% 0.2[0.01,3.92]
Busque 2001 0/23 0/23   Not estimable
Folkmane 2001 0/23 3/25 1.97% 0.15[0.01,2.84]
Ji 2001 10/56 2/50 6.69% 4.46[1.03,19.41]
Sun 2002b 0/40 2/46 1.85% 0.23[0.01,4.64]
Army Hospital 2002 1/17 0/16 1.71% 2.83[0.12,64.89]
COSTAMP Study 2002 5/243 13/246 11.7% 0.39[0.14,1.08]
MYSS Study 2004 9/167 18/167 16.51% 0.5[0.23,1.08]
Subtotal (95% CI) 1372 978 100% 0.53[0.35,0.8]
Total events: 81 (MMF), 102 (AZA)  
Heterogeneity: Tau2=0.12; Chi2=13.34, df=9(P=0.15); I2=32.52%  
Test for overall effect: Z=2.98(P=0)  
   
1.8.2 Follow-up 6 to 12 months  
Mendez 1998 9/117 5/59 23.4% 0.91[0.32,2.59]
Johnson 2000 3/72 9/76 16.01% 0.35[0.1,1.25]
Sadek 2002 11/162 23/157 54.85% 0.46[0.23,0.92]
Baltar 2002 0/14 1/12 2.65% 0.29[0.01,6.5]
Merville 2004 0/37 4/34 3.08% 0.1[0.01,1.83]
Subtotal (95% CI) 402 338 100% 0.49[0.29,0.81]
Total events: 23 (MMF), 42 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.9, df=4(P=0.57); I2=0%  
Test for overall effect: Z=2.77(P=0.01)  
   
1.8.3 Follow-up > 12 months  
Johnson 2000 4/72 12/76 79.91% 0.35[0.12,1.04]
COSTAMP Study 2002 1/41 0/34 20.09% 2.5[0.11,59.46]
Subtotal (95% CI) 113 110 100% 0.52[0.11,2.44]
Total events: 5 (MMF), 12 (AZA)  
Heterogeneity: Tau2=0.47; Chi2=1.32, df=1(P=0.25); I2=24.3%  
Test for overall effect: Z=0.83(P=0.41)  
   
1.8.4 Longest duration of follow-up  
MMF US Study 1995 26/331 33/164 22.79% 0.39[0.24,0.63]
MMF TRI Study 1996 23/335 25/162 19.95% 0.44[0.26,0.76]
Mendez 1998 9/117 5/59 7.14% 0.91[0.32,2.59]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Johnson 2000 4/72 12/76 6.72% 0.35[0.12,1.04]
Suhail 2000 0/20 2/20 1% 0.2[0.01,3.92]
Busque 2001 0/23 0/23   Not estimable
Ji 2001 10/56 2/50 3.88% 4.46[1.03,19.41]
Folkmane 2001 0/23 3/25 1.05% 0.15[0.01,2.84]
COSTAMP Study 2002 5/243 13/246 7.53% 0.39[0.14,1.08]
Baltar 2002 0/14 1/12 0.92% 0.29[0.01,6.5]
Sadek 2002 11/162 23/157 14.22% 0.46[0.23,0.92]
Army Hospital 2002 1/17 0/16 0.91% 2.83[0.12,64.89]
Sun 2002b 0/40 2/46 0.98% 0.23[0.01,4.64]
MYSS Study 2004 9/167 18/167 11.86% 0.5[0.23,1.08]
Merville 2004 0/37 4/34 1.06% 0.1[0.01,1.83]
Subtotal (95% CI) 1657 1257 100% 0.48[0.36,0.65]
Total events: 98 (MMF), 143 (AZA)  
Heterogeneity: Tau2=0.04; Chi2=15.15, df=13(P=0.3); I2=14.21%  
Test for overall effect: Z=4.79(P<0.0001)  
Test for subgroup differences: Chi2=0.14, df=1 (P=0.99), I2=0%  
Less with MMF 2000.005 100.1 1 Less with AZA
 
 
Analysis 1.9.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 9 Chronic allograB nephropathy.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.9.1 Follow-up ≤ 1 year  
Merville 2004 17/37 24/34 100% 0.65[0.43,0.98]
Subtotal (95% CI) 37 34 100% 0.65[0.43,0.98]
Total events: 17 (MMF), 24 (AZA)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.05(P=0.04)  
   
1.9.2 Follow-up > 1 year  
Weimer 2002 3/31 3/25 26.58% 0.81[0.18,3.65]
Tuncer 2002 7/38 8/38 73.42% 0.88[0.35,2.17]
Subtotal (95% CI) 69 63 100% 0.86[0.39,1.87]
Total events: 10 (MMF), 11 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.93); I2=0%  
Test for overall effect: Z=0.39(P=0.7)  
   
1.9.3 Longest duration of follow-up  
Weimer 2002 3/31 3/25 5.8% 0.81[0.18,3.65]
Tuncer 2002 7/38 8/38 16.01% 0.88[0.35,2.17]
Merville 2004 17/37 24/34 78.2% 0.65[0.43,0.98]
Subtotal (95% CI) 106 97 100% 0.69[0.48,0.99]
Total events: 27 (MMF), 35 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.41, df=2(P=0.81); I2=0%  
Test for overall effect: Z=1.99(P=0.05)  
Test for subgroup differences: Chi2=0.37, df=1 (P=0.83), I2=0%  
Less with MMF 100.1 50.2 20.5 1 Less with AZA
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Analysis 1.10.   Comparison 1 Mycophenolate mofetil versus azathioprine,
Outcome 10 Infection: other (longest duration of follow-up).
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.10.1 Aspergillus  
MMF US Study 1995 5/331 0/164 23.42% 5.47[0.3,98.27]
MMF TRI Study 1996 2/335 1/162 34.14% 0.97[0.09,10.59]
Mendez 1998 4/117 0/59 23.16% 4.58[0.25,83.6]
Johnson 2000 1/72 0/76 19.28% 3.16[0.13,76.44]
Subtotal (95% CI) 855 461 100% 2.61[0.65,10.58]
Total events: 12 (MMF), 1 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.11, df=3(P=0.77); I2=0%  
Test for overall effect: Z=1.35(P=0.18)  
   
1.10.2 BK-virus  
Weimer 2002 0/31 0/25   Not estimable
Subtotal (95% CI) 31 25 Not estimable
Total events: 0 (MMF), 0 (AZA)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.10.3 Candida  
MMF US Study 1995 69/331 37/164 57.12% 0.92[0.65,1.31]
MMF TRI Study 1996 41/335 19/162 27.27% 1.04[0.63,1.74]
Mendez 1998 17/117 8/59 11.69% 1.07[0.49,2.34]
Johnson 2000 6/72 3/76 3.91% 2.11[0.55,8.13]
Subtotal (95% CI) 855 461 100% 1[0.77,1.31]
Total events: 133 (MMF), 67 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.44, df=3(P=0.7); I2=0%  
Test for overall effect: Z=0.03(P=0.98)  
   
1.10.4 Candida tissue invasive  
MMF US Study 1995 3/331 0/164 10.52% 3.48[0.18,66.96]
MMF TRI Study 1996 1/335 1/162 12.02% 0.48[0.03,7.68]
Mendez 1998 3/117 1/59 18.3% 1.51[0.16,14.23]
MYSS Study 2004 4/167 6/167 59.16% 0.67[0.19,2.32]
Subtotal (95% CI) 950 552 100% 0.89[0.34,2.31]
Total events: 11 (MMF), 8 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.45, df=3(P=0.69); I2=0%  
Test for overall effect: Z=0.25(P=0.81)  
   
1.10.5 Herpes zoster  
MMF US Study 1995 37/331 14/164 44.01% 1.31[0.73,2.35]
MMF TRI Study 1996 35/335 16/162 46.73% 1.06[0.6,1.85]
Johnson 2000 3/72 2/76 6.66% 1.58[0.27,9.2]
COSTAMP Study 2002 7/243 0/246 2.6% 15.18[0.87,264.41]
Subtotal (95% CI) 981 648 100% 1.28[0.8,2.04]
Total events: 82 (MMF), 32 (AZA)  
Heterogeneity: Tau2=0.04; Chi2=3.54, df=3(P=0.32); I2=15.33%  
Test for overall effect: Z=1.04(P=0.3)  
   
1.10.6 Pneumocystis carinii/jiroveci  
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
MMF US Study 1995 0/331 2/164 18.13% 0.1[0,2.06]
MMF TRI Study 1996 1/335 3/162 32.73% 0.16[0.02,1.54]
Mendez 1998 0/117 1/59 16.41% 0.17[0.01,4.1]
Johnson 2000 0/72 1/76 16.42% 0.35[0.01,8.49]
MYSS Study 2004 0/167 1/167 16.32% 0.33[0.01,8.12]
Subtotal (95% CI) 1022 628 100% 0.19[0.05,0.69]
Total events: 1 (MMF), 8 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.46, df=4(P=0.98); I2=0%  
Test for overall effect: Z=2.52(P=0.01)  
   
1.10.7 Urinary tract/cystitis  
MMF TRI Study 1996 139/335 57/162 68.5% 1.18[0.92,1.51]
Ji 2001 4/56 4/50 2.56% 0.89[0.24,3.38]
COSTAMP Study 2002 28/243 34/246 20.22% 0.83[0.52,1.33]
Sun 2002b 2/40 0/46 0.5% 5.73[0.28,115.97]
Keven 2003 9/24 3/17 3.43% 2.13[0.67,6.71]
MYSS Study 2004 11/167 6/167 4.8% 1.83[0.69,4.84]
Subtotal (95% CI) 865 688 100% 1.15[0.93,1.42]
Total events: 193 (MMF), 104 (AZA)  
Heterogeneity: Tau2=0; Chi2=5.07, df=5(P=0.41); I2=1.46%  
Test for overall effect: Z=1.26(P=0.21)  
Favours MMF 5000.002 100.1 1 Favours AZA
 
 
Analysis 1.11.   Comparison 1 Mycophenolate mofetil versus
azathioprine, Outcome 11 Infection: CMV viraemia/syndrome.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.11.1 Follow-up ≤ 1 year  
MMF US Study 1995 46/331 25/164 14.94% 0.91[0.58,1.43]
MMF TRI Study 1996 39/335 19/162 12.01% 0.99[0.59,1.66]
Mendez 1998 6/117 3/59 2.07% 1.01[0.26,3.89]
Johnson 2000 7/72 3/76 2.18% 2.46[0.66,9.16]
Ji 2001 12/56 16/50 8.22% 0.67[0.35,1.28]
COSTAMP Study 2002 12/243 14/246 6.26% 0.87[0.41,1.84]
Miladipour 2002 3/40 0/40 0.45% 7[0.37,131.28]
Weimer 2002 13/31 11/25 9.14% 0.95[0.52,1.75]
Sadek 2002 32/162 17/157 10.92% 1.82[1.06,3.15]
Keven 2003 5/24 3/17 2.26% 1.18[0.33,4.29]
MYSS Study 2004 43/167 42/167 20.17% 1.02[0.71,1.48]
Merville 2004 11/37 17/34 9.33% 0.59[0.33,1.08]
Joh 2005 3/34 5/34 2.07% 0.6[0.16,2.31]
Subtotal (95% CI) 1649 1231 100% 0.98[0.81,1.2]
Total events: 232 (MMF), 175 (AZA)  
Heterogeneity: Tau2=0.02; Chi2=13.59, df=12(P=0.33); I2=11.68%  
Test for overall effect: Z=0.17(P=0.86)  
   
1.11.2 Follow-up > 1 year  
MMF US Study 1995 50/331 16/164 26.83% 1.55[0.91,2.63]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
MMF TRI Study 1996 44/335 20/162 29.51% 1.06[0.65,1.74]
MYSS Study 2004 39/124 45/124 43.66% 0.87[0.61,1.23]
Subtotal (95% CI) 790 450 100% 1.08[0.77,1.5]
Total events: 133 (MMF), 81 (AZA)  
Heterogeneity: Tau2=0.03; Chi2=3.3, df=2(P=0.19); I2=39.34%  
Test for overall effect: Z=0.43(P=0.67)  
   
1.11.3 Longest duration of follow-up  
MMF US Study 1995 50/331 16/164 11.66% 1.55[0.91,2.63]
MMF TRI Study 1996 44/335 20/162 12.79% 1.06[0.65,1.74]
Mendez 1998 6/117 3/59 2.52% 1.01[0.26,3.89]
Johnson 2000 7/72 3/76 2.66% 2.46[0.66,9.16]
Ji 2001 12/56 16/50 8.88% 0.67[0.35,1.28]
Miladipour 2002 3/40 0/40 0.57% 7[0.37,131.28]
Sadek 2002 32/162 17/157 11.24% 1.82[1.06,3.15]
Weimer 2002 13/31 11/25 9.71% 0.95[0.52,1.75]
COSTAMP Study 2002 12/243 14/246 7.02% 0.87[0.41,1.84]
Keven 2003 5/24 3/17 2.75% 1.18[0.33,4.29]
Merville 2004 11/37 17/34 9.88% 0.59[0.33,1.08]
MYSS Study 2004 43/167 42/167 17.81% 1.02[0.71,1.48]
Joh 2005 3/34 5/34 2.52% 0.6[0.16,2.31]
Subtotal (95% CI) 1649 1231 100% 1.06[0.85,1.32]
Total events: 241 (MMF), 167 (AZA)  
Heterogeneity: Tau2=0.04; Chi2=15.82, df=12(P=0.2); I2=24.15%  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=0.33, df=1 (P=0.85), I2=0%  
Favours MMF 2000.005 100.1 1 Favours AZA
 
 
Analysis 1.12.   Comparison 1 Mycophenolate mofetil versus
azathioprine, Outcome 12 Infection: CMV tissue invasive.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.12.1 Follow-up ≤ 1 year  
MMF US Study 1995 36/331 11/164 45.61% 1.62[0.85,3.1]
MMF TRI Study 1996 30/335 10/162 40.24% 1.45[0.73,2.89]
Mendez 1998 2/117 0/59 2.1% 2.54[0.12,52.12]
Johnson 2000 3/72 0/76 2.21% 7.38[0.39,140.48]
Suhail 2000 1/20 0/20 1.94% 3[0.13,69.52]
Folkmane 2001 5/23 1/25 4.48% 5.43[0.69,43.11]
Ji 2001 2/56 1/50 3.42% 1.79[0.17,19.1]
Subtotal (95% CI) 954 556 100% 1.73[1.12,2.69]
Total events: 79 (MMF), 23 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.6, df=6(P=0.86); I2=0%  
Test for overall effect: Z=2.46(P=0.01)  
   
1.12.2 Follow-up > 1 year  
MMF US Study 1995 38/331 11/164 51.56% 1.71[0.9,3.26]
MMF TRI Study 1996 30/335 11/162 48.44% 1.32[0.68,2.56]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 666 326 100% 1.51[0.95,2.4]
Total events: 68 (MMF), 22 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.3, df=1(P=0.58); I2=0%  
Test for overall effect: Z=1.74(P=0.08)  
   
1.12.3 Longest duration of follow-up  
MMF US Study 1995 38/331 11/164 44.53% 1.71[0.9,3.26]
MMF TRI Study 1996 30/335 11/162 41.83% 1.32[0.68,2.56]
Mendez 1998 2/117 0/59 2.03% 2.54[0.12,52.12]
Suhail 2000 1/20 0/20 1.87% 3[0.13,69.52]
Johnson 2000 3/72 0/76 2.13% 7.38[0.39,140.48]
Folkmane 2001 5/23 1/25 4.31% 5.43[0.69,43.11]
Ji 2001 2/56 1/50 3.29% 1.79[0.17,19.1]
Subtotal (95% CI) 954 556 100% 1.7[1.1,2.61]
Total events: 81 (MMF), 24 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.95, df=6(P=0.81); I2=0%  
Test for overall effect: Z=2.41(P=0.02)  
Test for subgroup differences: Chi2=0.21, df=1 (P=0.9), I2=0%  
Favours MMF 2000.005 100.1 1 Favours AZA
 
 
Analysis 1.13.   Comparison 1 Mycophenolate mofetil versus
azathioprine, Outcome 13 GraB function: serum creatinine.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.13.1 Follow-up ≤ 1 year  
Army Hospital 2002 17 1.3 (1.6) 16 1.5 (1.6) 0.89% -0.16[-1.25,0.93]
Busque 2001 23 1.3 (0.8) 23 1.6 (0.7) 4.28% -0.3[-0.73,0.13]
COSTAMP Study 2002 232 1.6 (0.8) 233 1.6 (0.6) 12.39% 0.03[-0.1,0.16]
Egfjord 1999 25 1.4 (0.8) 25 1.5 (0.7) 4.54% -0.08[-0.5,0.34]
Johnson 2000 63 1.3 (0.8) 65 1.3 (0.6) 8.36% 0[-0.25,0.25]
Ling 1998 11 1.6 (0.8) 5 1.4 (0.7) 1.67% 0.2[-0.57,0.97]
Merville 2004 37 1.6 (0.6) 34 1.4 (0.4) 8.67% 0.19[-0.05,0.43]
Miladipour 2002 40 1.3 (1.5) 40 1.3 (1.4) 2.35% 0[-0.64,0.64]
MMF TRI Study 1996 243 1.5 (0.8) 111 1.6 (0.7) 11.1% -0.07[-0.23,0.09]
MMF US Study 1995 253 1.6 (0.6) 126 1.8 (0.4) 13.3% -0.11[-0.21,-0.01]
MYSS Study 2004 167 1.5 (0.2) 167 1.3 (0.2) 14.78% 0.2[0.16,0.24]
Sadek 2002 162 1.7 (1.1) 157 1.5 (0.4) 10.53% 0.2[0.02,0.38]
Suhail 2000 20 1.6 (1.8) 20 1.4 (1.3) 1.1% 0.2[-0.77,1.17]
Sun 2002b 40 1.4 (1.9) 46 1.5 (1.4) 1.92% -0.1[-0.81,0.61]
Weimer 2002 31 2.2 (0.6) 25 2.2 (1) 4.13% 0[-0.45,0.45]
Subtotal *** 1364   1093   100% 0.03[-0.07,0.14]
Heterogeneity: Tau2=0.02; Chi2=47.44, df=14(P<0.0001); I2=70.49%  
Test for overall effect: Z=0.63(P=0.53)  
   
1.13.2 Follow-up 1 to 4 years  
COSTAMP Study 2002 41 1.5 (0.7) 34 1.5 (0.6) 8.55% -0.03[-0.32,0.26]
Johnson 2000 47 1.4 (0.7) 53 1.4 (0.6) 11.19% 0[-0.26,0.26]
MMF TRI Study 1996 168 1.7 (0.9) 83 1.7 (0.9) 13.21% -0.03[-0.27,0.21]
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Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
MMF US Study 1995 200 1.7 (0.5) 86 1.8 (0.4) 67.05% -0.07[-0.18,0.04]
Subtotal *** 456   256   100% -0.05[-0.14,0.03]
Heterogeneity: Tau2=0; Chi2=0.32, df=3(P=0.96); I2=0%  
Test for overall effect: Z=1.22(P=0.22)  
   
1.13.3 Longest duration of follow-up  
Army Hospital 2002 17 1.3 (1.6) 16 1.5 (1.6) 0.76% -0.16[-1.25,0.93]
Busque 2001 23 1.3 (0.8) 23 1.6 (0.7) 3.9% -0.3[-0.73,0.13]
COSTAMP Study 2002 232 1.6 (0.8) 233 1.6 (0.7) 13.15% 0.03[-0.11,0.17]
Egfjord 1999 25 1.4 (0.8) 25 1.5 (0.7) 4.16% -0.08[-0.5,0.34]
Johnson 2000 47 1.4 (0.7) 53 1.4 (0.6) 7.91% 0[-0.26,0.26]
Ling 1998 11 1.6 (0.8) 5 1.4 (0.7) 1.44% 0.2[-0.57,0.97]
Merville 2004 37 1.6 (0.6) 34 1.4 (0.4) 8.69% 0.19[-0.05,0.43]
Miladipour 2002 40 1.3 (1.5) 40 1.3 (1.4) 2.06% 0[-0.64,0.64]
MMF TRI Study 1996 168 1.7 (0.9) 83 1.7 (0.9) 8.64% -0.03[-0.27,0.21]
MMF US Study 1995 200 1.7 (0.5) 86 1.8 (0.4) 14.73% -0.07[-0.18,0.04]
MYSS Study 2004 167 1.5 (0.2) 167 1.3 (0.2) 17.2% 0.2[0.16,0.24]
Sadek 2002 162 1.7 (1.1) 157 1.5 (0.4) 11.01% 0.2[0.02,0.38]
Suhail 2000 20 1.6 (1.8) 20 1.4 (1.3) 0.94% 0.2[-0.77,1.17]
Sun 2002b 40 1.4 (1.9) 46 1.5 (1.4) 1.67% -0.1[-0.81,0.61]
Weimer 2002 31 2.2 (0.6) 25 2.2 (1) 3.75% 0[-0.45,0.45]
Subtotal *** 1220   1013   100% 0.05[-0.05,0.15]
Heterogeneity: Tau2=0.01; Chi2=35.41, df=14(P=0); I2=60.46%  
Test for overall effect: Z=1.03(P=0.3)  
Test for subgroup differences: Chi2=2.92, df=1 (P=0.23), I2=31.51%  
Favours MMF 21-2 -1 0 Favours AZA
 
 
Analysis 1.14.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 14 GraB function: CrCl/GFR.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.14.1 Follow-up ≤ 1 year  
MMF US Study 1995 253 66.4 (32.3) 126 62.8 (28.3) 30.61% 3.6[-2.74,9.94]
Johnson 2000 65 61 (32.3) 65 63 (28.3) 11.3% -2[-12.44,8.44]
Weimer 2002 31 46 (16.7) 25 39 (15) 17.82% 7[-1.31,15.31]
Merville 2004 37 61.3 (15.8) 34 63.1 (16.8) 21.31% -1.8[-9.4,5.8]
MYSS Study 2004 167 65.5 (40.1) 167 65.5 (34.9) 18.95% 0[-8.06,8.06]
Subtotal *** 553   417   100% 1.74[-1.77,5.25]
Heterogeneity: Tau2=0; Chi2=3.37, df=4(P=0.5); I2=0%  
Test for overall effect: Z=0.97(P=0.33)  
   
1.14.2 Follow-up 1 to 4 years  
Johnson 2000 47 59.3 (32.3) 53 62.3 (28.3) 14.11% -3[-14.97,8.97]
Weimer 2002 29 48 (21.5) 25 42 (25) 12.86% 6[-6.54,18.54]
MYSS Study 2004 113 53.6 (20.2) 109 52.1 (19.8) 73.03% 1.5[-3.76,6.76]
Subtotal *** 189   187   100% 1.44[-3.05,5.94]
Heterogeneity: Tau2=0; Chi2=1.04, df=2(P=0.6); I2=0%  
Test for overall effect: Z=0.63(P=0.53)  
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Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.14.3 Follow-up > 4 years  
MMF TRI Study 1996 26 48.2 (5.8) 12 46.1 (5.7) 64.14% 2.1[-1.82,6.02]
MYSS Study 2004 41 47.3 (14.1) 41 49.5 (13.4) 35.86% -2.2[-8.15,3.75]
Subtotal *** 67   53   100% 0.56[-3.48,4.6]
Heterogeneity: Tau2=2.63; Chi2=1.4, df=1(P=0.24); I2=28.45%  
Test for overall effect: Z=0.27(P=0.79)  
   
1.14.4 Longest duration of follow-up  
MMF US Study 1995 253 66.4 (32.3) 126 62.8 (28.3) 18.28% 3.6[-2.74,9.94]
MMF TRI Study 1996 26 48.2 (5.8) 12 46.1 (5.7) 47.87% 2.1[-1.82,6.02]
Johnson 2000 47 59.3 (32.3) 53 62.3 (28.3) 5.13% -3[-14.97,8.97]
Weimer 2002 29 48 (21.5) 25 42 (25) 4.68% 6[-6.54,18.54]
MYSS Study 2004 167 65.5 (40.1) 167 65.5 (34.9) 11.32% 0[-8.06,8.06]
Merville 2004 37 61.3 (15.8) 34 63.1 (16.8) 12.73% -1.8[-9.4,5.8]
Subtotal *** 559   417   100% 1.56[-1.15,4.27]
Heterogeneity: Tau2=0; Chi2=2.4, df=5(P=0.79); I2=0%  
Test for overall effect: Z=1.13(P=0.26)  
Test for subgroup differences: Chi2=0.22, df=1 (P=0.97), I2=0%  
Favours MMF 2010-20 -10 0 Favours AZA
 
 
Analysis 1.15.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 15 GraB function: proteinuria.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.15.1 Follow-up 2 to 5 years  
MMF TRI Study 1996 19/335 12/162 26.42% 0.77[0.38,1.54]
MYSS Study 2004 34/124 31/124 73.58% 1.1[0.72,1.67]
Subtotal (95% CI) 459 286 100% 1[0.7,1.43]
Total events: 53 (MMF), 43 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.76, df=1(P=0.38); I2=0%  
Test for overall effect: Z=0.01(P=0.99)  
Favours MMF 50.2 20.5 1 Favours AZA
 
 
Analysis 1.16.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 16 GraB function: proteinuria.
Study or subgroup MMF AZA Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.16.1 Follow-up ≤ 1 year  
Merville 2004 37 0.2 (0.6) 34 0.2 (0.3) 0[-0.22,0.22]
Favours MMF 10.5-1 -0.5 0 Favours AZA
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Analysis 1.17.   Comparison 1 Mycophenolate mofetil versus azathioprine,
Outcome 17 Adverse events: gastrointestinal (longest duration of follow-up).
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.17.1 Diarrhoea  
MMF US Study 1995 147/331 54/164 42.6% 1.35[1.05,1.73]
MMF TRI Study 1996 123/335 32/162 22.84% 1.86[1.32,2.61]
Ling 1998 1/11 0/5 0.29% 1.5[0.07,31.57]
Mendez 1998 63/117 24/59 21.54% 1.32[0.93,1.88]
Suhail 2000 2/20 0/20 0.3% 5[0.26,98]
Ji 2001 6/56 0/50 0.33% 11.63[0.67,201.39]
Sadek 2002 28/162 13/157 6.9% 2.09[1.12,3.88]
Miladipour 2002 6/40 2/40 1.12% 3[0.64,13.98]
Sun 2002b 4/40 0/46 0.32% 10.32[0.57,185.93]
COSTAMP Study 2002 13/243 7/246 3.26% 1.88[0.76,4.63]
MYSS Study 2004 3/167 1/167 0.52% 3[0.32,28.55]
Subtotal (95% CI) 1522 1116 100% 1.55[1.32,1.83]
Total events: 396 (MMF), 133 (AZA)  
Heterogeneity: Tau2=0; Chi2=9.81, df=10(P=0.46); I2=0%  
Test for overall effect: Z=5.3(P<0.0001)  
   
1.17.2 Abdominal pain  
MMF US Study 1995 105/331 48/164 47.24% 1.08[0.81,1.44]
MMF TRI Study 1996 107/335 42/162 41.81% 1.23[0.91,1.67]
Sadek 2002 24/162 16/157 10.95% 1.45[0.8,2.63]
Subtotal (95% CI) 828 483 100% 1.18[0.97,1.44]
Total events: 236 (MMF), 106 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.9, df=2(P=0.64); I2=0%  
Test for overall effect: Z=1.66(P=0.1)  
   
1.17.3 Vomiting  
MMF US Study 1995 63/331 30/164 28.4% 1.04[0.7,1.54]
MMF TRI Study 1996 60/335 12/162 21.65% 2.42[1.34,4.37]
Mendez 1998 35/117 21/59 26.66% 0.84[0.54,1.31]
Sadek 2002 28/162 19/157 23.29% 1.43[0.83,2.45]
Subtotal (95% CI) 945 542 100% 1.27[0.83,1.94]
Total events: 186 (MMF), 82 (AZA)  
Heterogeneity: Tau2=0.12; Chi2=9.13, df=3(P=0.03); I2=67.13%  
Test for overall effect: Z=1.11(P=0.27)  
   
1.17.4 Gastrointestinal bleeding  
MMF US Study 1995 14/331 2/164 79.91% 3.47[0.8,15.08]
Miladipour 2002 3/40 0/40 20.09% 7[0.37,131.28]
Subtotal (95% CI) 371 204 100% 3.99[1.07,14.86]
Total events: 17 (MMF), 2 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=2.07(P=0.04)  
   
1.17.5 Nausea  
MMF US Study 1995 115/331 55/164 43.65% 1.04[0.8,1.35]
MMF TRI Study 1996 73/335 35/162 23.41% 1.01[0.71,1.44]
Mendez 1998 49/117 25/59 22.2% 0.99[0.69,1.43]
Sun 2002b 0/40 2/46 0.33% 0.23[0.01,4.64]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sadek 2002 23/162 23/157 10.42% 0.97[0.57,1.65]
Subtotal (95% CI) 985 588 100% 1.01[0.85,1.2]
Total events: 260 (MMF), 140 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.01, df=4(P=0.91); I2=0%  
Test for overall effect: Z=0.08(P=0.94)  
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Analysis 1.18.   Comparison 1 Mycophenolate mofetil versus azathioprine,
Outcome 18 Adverse events: other (longest duration of follow-up).
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.18.1 New onset diabetes in patients without diabetes at baseline, in-
sulin-treated
 
Mendez 1998 7/117 8/59 28.53% 0.44[0.17,1.16]
Johnson 2000 6/72 11/76 30% 0.58[0.22,1.48]
Busque 2001 2/23 1/23 4.89% 2[0.19,20.55]
COSTAMP Study 2002 7/41 10/34 36.58% 0.58[0.25,1.36]
Subtotal (95% CI) 253 192 100% 0.57[0.34,0.95]
Total events: 22 (MMF), 30 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.39, df=3(P=0.71); I2=0%  
Test for overall effect: Z=2.14(P=0.03)  
   
1.18.2 Hypertension  
Sadek 2002 35/162 35/157 100% 0.97[0.64,1.47]
Subtotal (95% CI) 162 157 100% 0.97[0.64,1.47]
Total events: 35 (MMF), 35 (AZA)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.15(P=0.88)  
   
1.18.3 Hyperlipidaemia  
Mendez 1998 9/117 5/59 38.83% 0.91[0.32,2.59]
Johnson 2000 13/72 10/76 52.77% 1.37[0.64,2.93]
COSTAMP Study 2002 6/243 0/246 8.4% 13.16[0.75,232.33]
Subtotal (95% CI) 432 381 100% 1.41[0.59,3.39]
Total events: 28 (MMF), 15 (AZA)  
Heterogeneity: Tau2=0.23; Chi2=3.2, df=2(P=0.2); I2=37.59%  
Test for overall effect: Z=0.77(P=0.44)  
   
1.18.4 Elevated liver enzymes  
Ji 2001 6/56 10/50 39.01% 0.54[0.21,1.37]
Miladipour 2002 9/40 11/40 45.57% 0.82[0.38,1.76]
Sun 2002b 1/40 11/46 15.42% 0.1[0.01,0.77]
Subtotal (95% CI) 136 136 100% 0.5[0.21,1.23]
Total events: 16 (MMF), 32 (AZA)  
Heterogeneity: Tau2=0.3; Chi2=4.01, df=2(P=0.13); I2=50.09%  
Test for overall effect: Z=1.5(P=0.13)  
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Analysis 1.19.   Comparison 1 Mycophenolate mofetil versus azathioprine,
Outcome 19 Adverse events: haematological (longest duration of follow-up).
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.19.1 Anaemia  
MMF US Study 1995 150/331 70/164 42.09% 1.06[0.86,1.31]
MMF TRI Study 1996 56/335 15/162 12.24% 1.81[1.05,3.09]
Mendez 1998 51/117 29/59 25.61% 0.89[0.64,1.24]
Sadek 2002 28/162 25/157 14.16% 1.09[0.66,1.78]
MYSS Study 2004 10/167 12/167 5.91% 0.83[0.37,1.88]
Subtotal (95% CI) 1112 709 100% 1.07[0.87,1.31]
Total events: 295 (MMF), 151 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=5.38, df=4(P=0.25); I2=25.67%  
Test for overall effect: Z=0.65(P=0.52)  
   
1.19.2 Severe anaemia  
MMF US Study 1995 20/331 7/164 100% 1.42[0.61,3.28]
Army Hospital 2002 0/17 0/16   Not estimable
Subtotal (95% CI) 348 180 100% 1.42[0.61,3.28]
Total events: 20 (MMF), 7 (AZA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
   
1.19.3 Leucopenia  
MMF US Study 1995 108/331 39/164 18.11% 1.37[1,1.88]
MMF TRI Study 1996 96/335 50/162 18.83% 0.93[0.7,1.24]
Mendez 1998 40/117 13/59 12.65% 1.55[0.9,2.67]
Ling 1998 0/11 1/5 0.85% 0.17[0.01,3.51]
Suhail 2000 6/20 2/20 3.23% 3[0.69,13.12]
Ji 2001 0/56 4/50 0.93% 0.1[0.01,1.8]
Sun 2002b 2/40 4/46 2.68% 0.57[0.11,2.98]
Sadek 2002 30/162 29/157 14.48% 1[0.63,1.59]
Miladipour 2002 7/40 8/40 6.87% 0.88[0.35,2.18]
Army Hospital 2002 0/17 0/16   Not estimable
COSTAMP Study 2002 7/243 21/246 7.76% 0.34[0.15,0.78]
MYSS Study 2004 32/167 22/167 13.6% 1.45[0.88,2.39]
Subtotal (95% CI) 1539 1132 100% 1.04[0.78,1.39]
Total events: 328 (MMF), 193 (AZA)  
Heterogeneity: Tau2=0.09; Chi2=20.62, df=10(P=0.02); I2=51.51%  
Test for overall effect: Z=0.28(P=0.78)  
   
1.19.4 Severe leucopenia  
MMF US Study 1995 4/331 2/164 74.92% 0.99[0.18,5.35]
MMF TRI Study 1996 4/335 0/162 25.08% 4.37[0.24,80.61]
Army Hospital 2002 0/17 0/16   Not estimable
Subtotal (95% CI) 683 342 100% 1.44[0.33,6.19]
Total events: 8 (MMF), 2 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.78, df=1(P=0.38); I2=0%  
Test for overall effect: Z=0.49(P=0.63)  
   
1.19.5 Thrombocytopenia  
MMF US Study 1995 42/331 24/164 53.09% 0.87[0.54,1.38]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
MMF TRI Study 1996 25/335 20/162 37.01% 0.6[0.35,1.06]
Sun 2002b 2/40 0/46 1.27% 5.73[0.28,115.97]
Miladipour 2002 2/40 4/40 4.27% 0.5[0.1,2.58]
MYSS Study 2004 2/167 5/167 4.35% 0.4[0.08,2.03]
Subtotal (95% CI) 913 579 100% 0.73[0.52,1.03]
Total events: 73 (MMF), 53 (AZA)  
Heterogeneity: Tau2=0; Chi2=3.5, df=4(P=0.48); I2=0%  
Test for overall effect: Z=1.79(P=0.07)  
   
1.19.6 Severe thrombocytopenia  
MMF US Study 1995 2/331 0/164 26.12% 2.48[0.12,51.46]
MMF TRI Study 1996 3/335 4/162 73.88% 0.36[0.08,1.6]
Subtotal (95% CI) 666 326 100% 0.6[0.11,3.21]
Total events: 5 (MMF), 4 (AZA)  
Heterogeneity: Tau2=0.42; Chi2=1.28, df=1(P=0.26); I2=22.05%  
Test for overall effect: Z=0.6(P=0.55)  
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Analysis 1.20.   Comparison 1 Mycophenolate mofetil versus azathioprine, Outcome 20 Total cholesterol.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.20.1 Follow-up ≤ 1 year  
Johnson 2000 72 199.9 (46) 76 201.9 (50) 71.48% -2[-17.47,13.47]
Merville 2004 37 228 (46) 34 232 (58) 28.52% -4[-28.49,20.49]
Subtotal *** 109   110   100% -2.57[-15.65,10.51]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=0.39(P=0.7)  
Favours MMF 5025-50 -25 0 Favours AZA
 
 
Comparison 2.   Subgroup analyses: RCT versus quasi-RCT
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 GraB loss: censored for
death
17 2540 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.62, 0.99]
1.1 RCT 15 2366 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.62, 1.01]
1.2 quasi-RCT 2 174 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.19, 1.67]
2 Acute rejection (total) 22 3301 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.57, 0.73]
2.1 RCT 20 3127 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.58, 0.72]
2.2 quasi-RCT 2 174 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.25, 2.40]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Infection: CMV vi-
raemia/syndrome
13 2880 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.85, 1.32]
3.1 RCT 11 2706 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.89, 1.42]
3.2 quasi-RCT 2 174 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.37, 1.17]
4 GraB function, serum crea-
tinine
15 2233 Mean Difference (IV, Random, 95% CI) 0.05 [-0.05, 0.15]
4.1 RCT 15 2233 Mean Difference (IV, Random, 95% CI) 0.05 [-0.05, 0.15]
4.2 quasi-RCT 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Subgroup analyses: RCT versus quasi-RCT, Outcome 1 GraB loss: censored for death.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 RCT  
MMF US Study 1995 50/331 28/164 31.29% 0.88[0.58,1.35]
MMF TRI Study 1996 39/335 25/162 25.82% 0.75[0.47,1.2]
Ling 1998 0/11 0/5   Not estimable
Mendez 1998 1/117 3/59 1.11% 0.17[0.02,1.58]
Egfjord 1999 1/25 5/25 1.3% 0.2[0.03,1.59]
Suhail 2000 0/20 0/20   Not estimable
Johnson 2000 9/72 9/76 7.47% 1.06[0.44,2.51]
Folkmane 2001 2/23 3/25 1.94% 0.72[0.13,3.96]
Busque 2001 0/23 0/23   Not estimable
Tuncer 2002 5/38 11/38 6.12% 0.45[0.17,1.18]
Miladipour 2002 0/40 1/40 0.56% 0.33[0.01,7.95]
Weimer 2002 2/31 0/25 0.63% 4.06[0.2,80.94]
Sadek 2002 16/162 16/157 12.97% 0.97[0.5,1.87]
MYSS Study 2004 7/124 7/124 5.41% 1[0.36,2.77]
Merville 2004 0/37 5/34 0.69% 0.08[0,1.46]
Subtotal (95% CI) 1389 977 95.31% 0.79[0.62,1.01]
Total events: 132 (MMF), 113 (AZA)  
Heterogeneity: Tau2=0; Chi2=10.01, df=11(P=0.53); I2=0%  
Test for overall effect: Z=1.87(P=0.06)  
   
2.1.2 quasi-RCT  
Ji 2001 0/56 2/50 0.62% 0.18[0.01,3.64]
Joh 2005 4/34 6/34 4.07% 0.67[0.21,2.15]
Subtotal (95% CI) 90 84 4.69% 0.56[0.19,1.67]
Total events: 4 (MMF), 8 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.66, df=1(P=0.42); I2=0%  
Test for overall effect: Z=1.04(P=0.3)  
   
Total (95% CI) 1479 1061 100% 0.78[0.62,0.99]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 136 (MMF), 121 (AZA)  
Heterogeneity: Tau2=0; Chi2=11.04, df=13(P=0.61); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=0.37, df=1 (P=0.54), I2=0%  
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Analysis 2.2.   Comparison 2 Subgroup analyses: RCT versus quasi-RCT, Outcome 2 Acute rejection (total).
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 RCT  
MMF US Study 1995 87/331 77/164 16.96% 0.56[0.44,0.71]
MMF TRI Study 1996 105/335 81/162 19.18% 0.63[0.5,0.78]
Mendez 1998 24/117 19/59 5.08% 0.64[0.38,1.07]
Ling 1998 2/11 3/5 0.7% 0.3[0.07,1.28]
Egfjord 1999 8/25 11/25 2.7% 0.73[0.35,1.5]
Suhail 2000 2/20 7/20 0.7% 0.29[0.07,1.21]
Johnson 2000 12/72 16/76 3.07% 0.79[0.4,1.56]
Busque 2001 2/23 8/23 0.71% 0.25[0.06,1.05]
Folkmane 2001 5/23 8/25 1.56% 0.68[0.26,1.78]
Sun 2002b 2/40 6/46 0.62% 0.38[0.08,1.79]
Army Hospital 2002 1/17 3/16 0.32% 0.31[0.04,2.71]
Sadek 2002 34/162 51/157 8.81% 0.65[0.44,0.94]
Miladipour 2002 4/40 10/40 1.26% 0.4[0.14,1.17]
COSTAMP Study 2002 59/243 83/246 13.69% 0.72[0.54,0.95]
Weimer 2002 5/31 11/25 1.71% 0.37[0.15,0.92]
Baltar 2002 1/14 5/12 0.37% 0.17[0.02,1.27]
Tuncer 2002 7/38 13/38 2.22% 0.54[0.24,1.2]
Keven 2003 3/24 3/17 0.68% 0.71[0.16,3.1]
MYSS Study 2004 56/167 58/167 12.66% 0.97[0.72,1.3]
Merville 2004 5/37 7/34 1.32% 0.66[0.23,1.87]
Subtotal (95% CI) 1770 1357 94.32% 0.65[0.58,0.72]
Total events: 424 (MMF), 480 (AZA)  
Heterogeneity: Tau2=0; Chi2=18.4, df=19(P=0.5); I2=0%  
Test for overall effect: Z=7.82(P<0.0001)  
   
2.2.2 quasi-RCT  
Ji 2001 11/56 22/50 3.66% 0.45[0.24,0.83]
Joh 2005 10/34 7/34 2.02% 1.43[0.62,3.31]
Subtotal (95% CI) 90 84 5.68% 0.77[0.25,2.4]
Total events: 21 (MMF), 29 (AZA)  
Heterogeneity: Tau2=0.54; Chi2=4.79, df=1(P=0.03); I2=79.12%  
Test for overall effect: Z=0.45(P=0.65)  
   
Total (95% CI) 1860 1441 100% 0.65[0.57,0.73]
Total events: 445 (MMF), 509 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=23.2, df=21(P=0.33); I2=9.48%  
Test for overall effect: Z=7.01(P<0.0001)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.77), I2=0%  
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Analysis 2.3.   Comparison 2 Subgroup analyses: RCT versus
quasi-RCT, Outcome 3 Infection: CMV viraemia/syndrome.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 RCT  
MMF US Study 1995 50/331 16/164 11.66% 1.55[0.91,2.63]
MMF TRI Study 1996 44/335 20/162 12.79% 1.06[0.65,1.74]
Mendez 1998 6/117 3/59 2.52% 1.01[0.26,3.89]
Johnson 2000 7/72 3/76 2.66% 2.46[0.66,9.16]
COSTAMP Study 2002 12/243 14/246 7.02% 0.87[0.41,1.84]
Miladipour 2002 3/40 0/40 0.57% 7[0.37,131.28]
Sadek 2002 32/162 17/157 11.24% 1.82[1.06,3.15]
Weimer 2002 13/31 11/25 9.71% 0.95[0.52,1.75]
Keven 2003 5/24 3/17 2.75% 1.18[0.33,4.29]
MYSS Study 2004 43/167 42/167 17.81% 1.02[0.71,1.48]
Merville 2004 11/37 17/34 9.88% 0.59[0.33,1.08]
Subtotal (95% CI) 1559 1147 88.59% 1.12[0.89,1.42]
Total events: 226 (MMF), 146 (AZA)  
Heterogeneity: Tau2=0.03; Chi2=12.91, df=10(P=0.23); I2=22.52%  
Test for overall effect: Z=0.99(P=0.32)  
   
2.3.2 quasi-RCT  
Ji 2001 12/56 16/50 8.88% 0.67[0.35,1.28]
Joh 2005 3/34 5/34 2.52% 0.6[0.16,2.31]
Subtotal (95% CI) 90 84 11.41% 0.66[0.37,1.17]
Total events: 15 (MMF), 21 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=1.42(P=0.16)  
   
Total (95% CI) 1649 1231 100% 1.06[0.85,1.32]
Total events: 241 (MMF), 167 (AZA)  
Heterogeneity: Tau2=0.04; Chi2=15.82, df=12(P=0.2); I2=24.15%  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=2.84, df=1 (P=0.09), I2=64.84%  
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Analysis 2.4.   Comparison 2 Subgroup analyses: RCT versus quasi-RCT, Outcome 4 GraB function, serum creatinine.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 RCT  
MMF US Study 1995 200 1.7 (0.5) 86 1.8 (0.4) 14.73% -0.07[-0.18,0.04]
MMF TRI Study 1996 168 1.7 (0.9) 83 1.7 (0.9) 8.64% -0.03[-0.27,0.21]
Ling 1998 11 1.6 (0.8) 5 1.4 (0.7) 1.44% 0.2[-0.57,0.97]
Egfjord 1999 25 1.4 (0.8) 25 1.5 (0.7) 4.16% -0.08[-0.5,0.34]
Johnson 2000 47 1.4 (0.7) 53 1.4 (0.6) 7.91% 0[-0.26,0.26]
Suhail 2000 20 1.6 (1.8) 20 1.4 (1.3) 0.94% 0.2[-0.77,1.17]
Busque 2001 23 1.3 (0.8) 23 1.6 (0.7) 3.9% -0.3[-0.73,0.13]
Sadek 2002 162 1.7 (1.1) 157 1.5 (0.4) 11.01% 0.2[0.02,0.38]
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Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Weimer 2002 31 2.2 (0.6) 25 2.2 (1) 3.75% 0[-0.45,0.45]
Miladipour 2002 40 1.3 (1.5) 40 1.3 (1.4) 2.06% 0[-0.64,0.64]
COSTAMP Study 2002 232 1.6 (0.8) 233 1.6 (0.7) 13.15% 0.03[-0.11,0.17]
Sun 2002b 40 1.4 (1.9) 46 1.5 (1.4) 1.67% -0.1[-0.81,0.61]
Army Hospital 2002 17 1.3 (1.6) 16 1.5 (1.6) 0.76% -0.16[-1.25,0.93]
MYSS Study 2004 167 1.5 (0.2) 167 1.3 (0.2) 17.2% 0.2[0.16,0.24]
Merville 2004 37 1.6 (0.6) 34 1.4 (0.4) 8.69% 0.19[-0.05,0.43]
Subtotal *** 1220   1013   100% 0.05[-0.05,0.15]
Heterogeneity: Tau2=0.01; Chi2=35.41, df=14(P=0); I2=60.46%  
Test for overall effect: Z=1.03(P=0.3)  
   
2.4.2 quasi-RCT  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 1220   1013   100% 0.05[-0.05,0.15]
Heterogeneity: Tau2=0.01; Chi2=35.41, df=14(P=0); I2=60.46%  
Test for overall effect: Z=1.03(P=0.3)  
Test for subgroup differences: Not applicable  
Favours MMF 21-2 -1 0 Favours AZA
 
 
Comparison 3.   Subgroup analyses: ITT analysis
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 GraB loss: censored for death 17 2540 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.62, 0.99]
1.1 ITT analysis performed 10 2132 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.65, 1.08]
1.2 ITT analysis unclear 7 408 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.26, 0.93]
1.3 ITT analysis not performed 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Acute rejection: total 22 3301 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.57, 0.73]
2.1 ITT analysis performed 12 2757 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.58, 0.75]
2.2 ITT analysis unclear 8 470 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.34, 0.84]
2.3 ITT analysis not performed 2 74 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.16, 1.85]
3 Infection: CMV viraemia/syndrome 13 2880 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.85, 1.32]
3.1 ITT analysis performed 10 2691 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.83, 1.34]
3.2 ITT analysis unclear 2 148 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.13, 16.10]
3.3 ITT analysis not performed 1 41 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.33, 4.29]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 GraB function: serum creatinine 15 2233 Mean Difference (IV, Random,
95% CI)
0.05 [-0.05, 0.15]
4.1 ITT performed 10 1948 Mean Difference (IV, Random,
95% CI)
0.07 [-0.03, 0.17]
4.2 ITT unclear 4 252 Mean Difference (IV, Random,
95% CI)
-0.15 [-0.45, 0.16]
4.3 ITT not performed 1 33 Mean Difference (IV, Random,
95% CI)
-0.16 [-1.25, 0.93]
 
 
Analysis 3.1.   Comparison 3 Subgroup analyses: ITT analysis, Outcome 1 GraB loss: censored for death.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 ITT analysis performed  
MMF US Study 1995 50/331 28/164 31.29% 0.88[0.58,1.35]
MMF TRI Study 1996 39/335 25/162 25.82% 0.75[0.47,1.2]
Mendez 1998 1/117 3/59 1.11% 0.17[0.02,1.58]
Ling 1998 0/11 0/5   Not estimable
Johnson 2000 9/72 9/76 7.47% 1.06[0.44,2.51]
Ji 2001 0/56 2/50 0.62% 0.18[0.01,3.64]
Weimer 2002 2/31 0/25 0.63% 4.06[0.2,80.94]
Sadek 2002 16/162 16/157 12.97% 0.97[0.5,1.87]
MYSS Study 2004 7/124 7/124 5.41% 1[0.36,2.77]
Merville 2004 0/37 5/34 0.69% 0.08[0,1.46]
Subtotal (95% CI) 1276 856 86% 0.84[0.65,1.08]
Total events: 124 (MMF), 95 (AZA)  
Heterogeneity: Tau2=0; Chi2=7.44, df=8(P=0.49); I2=0%  
Test for overall effect: Z=1.34(P=0.18)  
   
3.1.2 ITT analysis unclear  
Egfjord 1999 1/25 5/25 1.3% 0.2[0.03,1.59]
Suhail 2000 0/20 0/20   Not estimable
Folkmane 2001 2/23 3/25 1.94% 0.72[0.13,3.96]
Busque 2001 0/23 0/23   Not estimable
Tuncer 2002 5/38 11/38 6.12% 0.45[0.17,1.18]
Miladipour 2002 0/40 1/40 0.56% 0.33[0.01,7.95]
Joh 2005 4/34 6/34 4.07% 0.67[0.21,2.15]
Subtotal (95% CI) 203 205 14% 0.5[0.26,0.93]
Total events: 12 (MMF), 26 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.28, df=4(P=0.86); I2=0%  
Test for overall effect: Z=2.17(P=0.03)  
   
3.1.3 ITT analysis not performed  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (MMF), 0 (AZA)  
Favours MMF 5000.002 100.1 1 Favours AZA
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 1479 1061 100% 0.78[0.62,0.99]
Total events: 136 (MMF), 121 (AZA)  
Heterogeneity: Tau2=0; Chi2=11.04, df=13(P=0.61); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=2.29, df=1 (P=0.13), I2=56.33%  
Favours MMF 5000.002 100.1 1 Favours AZA
 
 
Analysis 3.2.   Comparison 3 Subgroup analyses: ITT analysis, Outcome 2 Acute rejection: total.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 ITT analysis performed  
MMF US Study 1995 87/331 77/164 16.96% 0.56[0.44,0.71]
MMF TRI Study 1996 105/335 81/162 19.18% 0.63[0.5,0.78]
Ling 1998 2/11 3/5 0.7% 0.3[0.07,1.28]
Mendez 1998 24/117 19/59 5.08% 0.64[0.38,1.07]
Egfjord 1999 8/25 11/25 2.7% 0.73[0.35,1.5]
Johnson 2000 12/72 16/76 3.07% 0.79[0.4,1.56]
Ji 2001 11/56 22/50 3.66% 0.45[0.24,0.83]
Sadek 2002 34/162 51/157 8.81% 0.65[0.44,0.94]
Weimer 2002 5/31 11/25 1.71% 0.37[0.15,0.92]
COSTAMP Study 2002 59/243 83/246 13.69% 0.72[0.54,0.95]
MYSS Study 2004 56/167 58/167 12.66% 0.97[0.72,1.3]
Merville 2004 5/37 7/34 1.32% 0.66[0.23,1.87]
Subtotal (95% CI) 1587 1170 89.55% 0.66[0.58,0.75]
Total events: 408 (MMF), 439 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=13.22, df=11(P=0.28); I2=16.8%  
Test for overall effect: Z=6.27(P<0.0001)  
   
3.2.2 ITT analysis unclear  
Suhail 2000 2/20 7/20 0.7% 0.29[0.07,1.21]
Folkmane 2001 5/23 8/25 1.56% 0.68[0.26,1.78]
Busque 2001 2/23 8/23 0.71% 0.25[0.06,1.05]
Tuncer 2002 7/38 13/38 2.22% 0.54[0.24,1.2]
Sun 2002b 2/40 6/46 0.62% 0.38[0.08,1.79]
Miladipour 2002 4/40 10/40 1.26% 0.4[0.14,1.17]
Baltar 2002 1/14 5/12 0.37% 0.17[0.02,1.27]
Joh 2005 10/34 7/34 2.02% 1.43[0.62,3.31]
Subtotal (95% CI) 232 238 9.46% 0.53[0.34,0.84]
Total events: 33 (MMF), 64 (AZA)  
Heterogeneity: Tau2=0.1; Chi2=9.05, df=7(P=0.25); I2=22.63%  
Test for overall effect: Z=2.7(P=0.01)  
   
3.2.3 ITT analysis not performed  
Army Hospital 2002 1/17 3/16 0.32% 0.31[0.04,2.71]
Keven 2003 3/24 3/17 0.68% 0.71[0.16,3.1]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 41 33 0.99% 0.55[0.16,1.85]
Total events: 4 (MMF), 6 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%  
Test for overall effect: Z=0.97(P=0.33)  
   
Total (95% CI) 1860 1441 100% 0.65[0.57,0.73]
Total events: 445 (MMF), 509 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=23.2, df=21(P=0.33); I2=9.48%  
Test for overall effect: Z=7.01(P<0.0001)  
Test for subgroup differences: Chi2=0.85, df=1 (P=0.65), I2=0%  
Favours MMF 1000.01 100.1 1 Favours AZA
 
 
Analysis 3.3.   Comparison 3 Subgroup analyses: ITT analysis, Outcome 3 Infection: CMV viraemia/syndrome.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 ITT analysis performed  
MMF US Study 1995 50/331 16/164 11.66% 1.55[0.91,2.63]
MMF TRI Study 1996 44/335 20/162 12.79% 1.06[0.65,1.74]
Mendez 1998 6/117 3/59 2.52% 1.01[0.26,3.89]
Johnson 2000 7/72 3/76 2.66% 2.46[0.66,9.16]
Ji 2001 12/56 16/50 8.88% 0.67[0.35,1.28]
COSTAMP Study 2002 12/243 14/246 7.02% 0.87[0.41,1.84]
Sadek 2002 32/162 17/157 11.24% 1.82[1.06,3.15]
Weimer 2002 13/31 11/25 9.71% 0.95[0.52,1.75]
Merville 2004 11/37 17/34 9.88% 0.59[0.33,1.08]
MYSS Study 2004 43/167 42/167 17.81% 1.02[0.71,1.48]
Subtotal (95% CI) 1551 1140 94.16% 1.06[0.83,1.34]
Total events: 230 (MMF), 159 (AZA)  
Heterogeneity: Tau2=0.05; Chi2=13.47, df=9(P=0.14); I2=33.18%  
Test for overall effect: Z=0.46(P=0.64)  
   
3.3.2 ITT analysis unclear  
Miladipour 2002 3/40 0/40 0.57% 7[0.37,131.28]
Joh 2005 3/34 5/34 2.52% 0.6[0.16,2.31]
Subtotal (95% CI) 74 74 3.09% 1.47[0.13,16.1]
Total events: 6 (MMF), 5 (AZA)  
Heterogeneity: Tau2=1.87; Chi2=2.38, df=1(P=0.12); I2=58.04%  
Test for overall effect: Z=0.31(P=0.75)  
   
3.3.3 ITT analysis not performed  
Keven 2003 5/24 3/17 2.75% 1.18[0.33,4.29]
Subtotal (95% CI) 24 17 2.75% 1.18[0.33,4.29]
Total events: 5 (MMF), 3 (AZA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.8)  
   
Total (95% CI) 1649 1231 100% 1.06[0.85,1.32]
Total events: 241 (MMF), 167 (AZA)  
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.04; Chi2=15.82, df=12(P=0.2); I2=24.15%  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=0.1, df=1 (P=0.95), I2=0%  
Favours MMF 2000.005 100.1 1 Favours AZA
 
 
Analysis 3.4.   Comparison 3 Subgroup analyses: ITT analysis, Outcome 4 GraB function: serum creatinine.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.4.1 ITT performed  
MMF US Study 1995 200 1.7 (0.5) 86 1.8 (0.4) 14.73% -0.07[-0.18,0.04]
MMF TRI Study 1996 168 1.7 (0.9) 83 1.7 (0.9) 8.64% -0.03[-0.27,0.21]
Ling 1998 11 1.6 (0.8) 5 1.4 (0.7) 1.44% 0.2[-0.57,0.97]
Egfjord 1999 25 1.4 (0.8) 25 1.5 (0.7) 4.16% -0.08[-0.5,0.34]
Johnson 2000 47 1.4 (0.7) 53 1.4 (0.6) 7.91% 0[-0.26,0.26]
Weimer 2002 31 2.2 (0.6) 25 2.2 (1) 3.75% 0[-0.45,0.45]
Sadek 2002 162 1.7 (1.1) 157 1.5 (0.4) 11.01% 0.2[0.02,0.38]
COSTAMP Study 2002 232 1.6 (0.8) 233 1.6 (0.7) 13.15% 0.03[-0.11,0.17]
MYSS Study 2004 167 1.5 (0.2) 167 1.3 (0.2) 17.2% 0.2[0.16,0.24]
Merville 2004 37 1.6 (0.6) 34 1.4 (0.4) 8.69% 0.19[-0.05,0.43]
Subtotal *** 1080   868   90.68% 0.07[-0.03,0.17]
Heterogeneity: Tau2=0.01; Chi2=30.49, df=9(P=0); I2=70.48%  
Test for overall effect: Z=1.32(P=0.19)  
   
3.4.2 ITT unclear  
Suhail 2000 20 1.6 (1.8) 20 1.4 (1.3) 0.94% 0.2[-0.77,1.17]
Busque 2001 23 1.3 (0.8) 23 1.6 (0.7) 3.9% -0.3[-0.73,0.13]
Miladipour 2002 40 1.3 (1.5) 40 1.3 (1.4) 2.06% 0[-0.64,0.64]
Sun 2002b 40 1.4 (1.9) 46 1.5 (1.4) 1.67% -0.1[-0.81,0.61]
Subtotal *** 123   129   8.57% -0.15[-0.45,0.16]
Heterogeneity: Tau2=0; Chi2=1.19, df=3(P=0.76); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
   
3.4.3 ITT not performed  
Army Hospital 2002 17 1.3 (1.6) 16 1.5 (1.6) 0.76% -0.16[-1.25,0.93]
Subtotal *** 17   16   0.76% -0.16[-1.25,0.93]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.29(P=0.77)  
   
Total *** 1220   1013   100% 0.05[-0.05,0.15]
Heterogeneity: Tau2=0.01; Chi2=35.41, df=14(P=0); I2=60.46%  
Test for overall effect: Z=1.03(P=0.3)  
Test for subgroup differences: Chi2=1.87, df=1 (P=0.39), I2=0%  
Favours MMF 21-2 -1 0 Favours AZA
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Comparison 4.   Subgroup analyses: adults only versus children included
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 GraB loss: censored for death 17 2540 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.62, 0.99]
1.1 Adults only 6 1676 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.64, 1.10]
1.2 Children included 2 324 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.10, 3.15]
1.3 No details reported 9 540 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.28, 0.95]
2 Acute rejection: total 22 3301 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.57, 0.73]
2.1 Adults only 8 2292 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.57, 0.79]
2.2 Children included 2 324 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.46, 1.04]
2.3 No details reported 12 685 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.40, 0.71]
3 Infection: CMV viraemia/syndrome 13 2880 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.85, 1.32]
3.1 Adults only 7 2246 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.84, 1.45]
3.2 Children included 2 324 Risk Ratio (M-H, Random, 95% CI) 1.60 [0.62, 4.09]
3.3 No details reported 4 310 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.54, 1.24]
4 GraB function: serum creatinine 15 2233 Mean Difference (IV, Random, 95%
CI)
0.05 [-0.05, 0.15]
4.1 Adults only 7 1772 Mean Difference (IV, Random, 95%
CI)
0.06 [-0.06, 0.19]
4.2 Children included 1 100 Mean Difference (IV, Random, 95%
CI)
0.0 [-0.26, 0.26]
4.3 No details reported 7 361 Mean Difference (IV, Random, 95%
CI)
-0.01 [-0.24, 0.22]
 
 
Analysis 4.1.   Comparison 4 Subgroup analyses: adults only versus
children included, Outcome 1 GraB loss: censored for death.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Adults only  
MMF US Study 1995 50/331 28/164 31.29% 0.88[0.58,1.35]
MMF TRI Study 1996 39/335 25/162 25.82% 0.75[0.47,1.2]
Busque 2001 0/23 0/23   Not estimable
Sadek 2002 16/162 16/157 12.97% 0.97[0.5,1.87]
MYSS Study 2004 7/124 7/124 5.41% 1[0.36,2.77]
Merville 2004 0/37 5/34 0.69% 0.08[0,1.46]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 1012 664 76.17% 0.84[0.64,1.1]
Total events: 112 (MMF), 81 (AZA)  
Heterogeneity: Tau2=0; Chi2=3.1, df=4(P=0.54); I2=0%  
Test for overall effect: Z=1.25(P=0.21)  
   
4.1.2 Children included  
Mendez 1998 1/117 3/59 1.11% 0.17[0.02,1.58]
Johnson 2000 9/72 9/76 7.47% 1.06[0.44,2.51]
Subtotal (95% CI) 189 135 8.59% 0.57[0.1,3.15]
Total events: 10 (MMF), 12 (AZA)  
Heterogeneity: Tau2=0.96; Chi2=2.27, df=1(P=0.13); I2=55.99%  
Test for overall effect: Z=0.65(P=0.52)  
   
4.1.3 No details reported  
Ling 1998 0/11 0/5   Not estimable
Egfjord 1999 1/25 5/25 1.3% 0.2[0.03,1.59]
Suhail 2000 0/20 0/20   Not estimable
Ji 2001 0/56 2/50 0.62% 0.18[0.01,3.64]
Folkmane 2001 2/23 3/25 1.94% 0.72[0.13,3.96]
Miladipour 2002 0/40 1/40 0.56% 0.33[0.01,7.95]
Weimer 2002 2/31 0/25 0.63% 4.06[0.2,80.94]
Tuncer 2002 5/38 11/38 6.12% 0.45[0.17,1.18]
Joh 2005 4/34 6/34 4.07% 0.67[0.21,2.15]
Subtotal (95% CI) 278 262 15.24% 0.52[0.28,0.95]
Total events: 14 (MMF), 28 (AZA)  
Heterogeneity: Tau2=0; Chi2=3.58, df=6(P=0.73); I2=0%  
Test for overall effect: Z=2.12(P=0.03)  
   
Total (95% CI) 1479 1061 100% 0.78[0.62,0.99]
Total events: 136 (MMF), 121 (AZA)  
Heterogeneity: Tau2=0; Chi2=11.04, df=13(P=0.61); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=2.15, df=1 (P=0.34), I2=7.01%  
Favours MMF 5000.002 100.1 1 Favours AZA
 
 
Analysis 4.2.   Comparison 4 Subgroup analyses: adults only
versus children included, Outcome 2 Acute rejection: total.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.2.1 Adults only  
MMF US Study 1995 87/331 77/164 16.96% 0.56[0.44,0.71]
MMF TRI Study 1996 105/335 81/162 19.18% 0.63[0.5,0.78]
Busque 2001 2/23 8/23 0.71% 0.25[0.06,1.05]
Sadek 2002 34/162 51/157 8.81% 0.65[0.44,0.94]
COSTAMP Study 2002 59/243 83/246 13.69% 0.72[0.54,0.95]
Keven 2003 3/24 3/17 0.68% 0.71[0.16,3.1]
Merville 2004 5/37 7/34 1.32% 0.66[0.23,1.87]
MYSS Study 2004 56/167 58/167 12.66% 0.97[0.72,1.3]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 1322 970 74.01% 0.67[0.57,0.79]
Total events: 351 (MMF), 368 (AZA)  
Heterogeneity: Tau2=0.02; Chi2=10.32, df=7(P=0.17); I2=32.18%  
Test for overall effect: Z=4.79(P<0.0001)  
   
4.2.2 Children included  
Mendez 1998 24/117 19/59 5.08% 0.64[0.38,1.07]
Johnson 2000 12/72 16/76 3.07% 0.79[0.4,1.56]
Subtotal (95% CI) 189 135 8.15% 0.69[0.46,1.04]
Total events: 36 (MMF), 35 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.61); I2=0%  
Test for overall effect: Z=1.78(P=0.08)  
   
4.2.3 No details reported  
Ling 1998 2/11 3/5 0.7% 0.3[0.07,1.28]
Egfjord 1999 8/25 11/25 2.7% 0.73[0.35,1.5]
Suhail 2000 2/20 7/20 0.7% 0.29[0.07,1.21]
Folkmane 2001 5/23 8/25 1.56% 0.68[0.26,1.78]
Ji 2001 11/56 22/50 3.66% 0.45[0.24,0.83]
Miladipour 2002 4/40 10/40 1.26% 0.4[0.14,1.17]
Sun 2002b 2/40 6/46 0.62% 0.38[0.08,1.79]
Army Hospital 2002 1/17 3/16 0.32% 0.31[0.04,2.71]
Tuncer 2002 7/38 13/38 2.22% 0.54[0.24,1.2]
Weimer 2002 5/31 11/25 1.71% 0.37[0.15,0.92]
Baltar 2002 1/14 5/12 0.37% 0.17[0.02,1.27]
Joh 2005 10/34 7/34 2.02% 1.43[0.62,3.31]
Subtotal (95% CI) 349 336 17.84% 0.53[0.4,0.71]
Total events: 58 (MMF), 106 (AZA)  
Heterogeneity: Tau2=0; Chi2=10.47, df=11(P=0.49); I2=0%  
Test for overall effect: Z=4.36(P<0.0001)  
   
Total (95% CI) 1860 1441 100% 0.65[0.57,0.73]
Total events: 445 (MMF), 509 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=23.2, df=21(P=0.33); I2=9.48%  
Test for overall effect: Z=7.01(P<0.0001)  
Test for subgroup differences: Chi2=2.12, df=1 (P=0.35), I2=5.78%  
Favours MMF 1000.01 100.1 1 Favours AZA
 
 
Analysis 4.3.   Comparison 4 Subgroup analyses: adults only versus
children included, Outcome 3 Infection: CMV viraemia/syndrome.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.3.1 Adults only  
MMF US Study 1995 50/331 16/164 11.66% 1.55[0.91,2.63]
MMF TRI Study 1996 44/335 20/162 12.79% 1.06[0.65,1.74]
COSTAMP Study 2002 12/243 14/246 7.02% 0.87[0.41,1.84]
Sadek 2002 32/162 17/157 11.24% 1.82[1.06,3.15]
Keven 2003 5/24 3/17 2.75% 1.18[0.33,4.29]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Merville 2004 11/37 17/34 9.88% 0.59[0.33,1.08]
MYSS Study 2004 43/167 42/167 17.81% 1.02[0.71,1.48]
Subtotal (95% CI) 1299 947 73.13% 1.11[0.84,1.45]
Total events: 197 (MMF), 129 (AZA)  
Heterogeneity: Tau2=0.05; Chi2=9.6, df=6(P=0.14); I2=37.47%  
Test for overall effect: Z=0.72(P=0.47)  
   
4.3.2 Children included  
Mendez 1998 6/117 3/59 2.52% 1.01[0.26,3.89]
Johnson 2000 7/72 3/76 2.66% 2.46[0.66,9.16]
Subtotal (95% CI) 189 135 5.18% 1.6[0.62,4.09]
Total events: 13 (MMF), 6 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.86, df=1(P=0.35); I2=0%  
Test for overall effect: Z=0.97(P=0.33)  
   
4.3.3 No details reported  
Ji 2001 12/56 16/50 8.88% 0.67[0.35,1.28]
Miladipour 2002 3/40 0/40 0.57% 7[0.37,131.28]
Weimer 2002 13/31 11/25 9.71% 0.95[0.52,1.75]
Joh 2005 3/34 5/34 2.52% 0.6[0.16,2.31]
Subtotal (95% CI) 161 149 21.69% 0.82[0.54,1.24]
Total events: 31 (MMF), 32 (AZA)  
Heterogeneity: Tau2=0; Chi2=2.91, df=3(P=0.41); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
   
Total (95% CI) 1649 1231 100% 1.06[0.85,1.32]
Total events: 241 (MMF), 167 (AZA)  
Heterogeneity: Tau2=0.04; Chi2=15.82, df=12(P=0.2); I2=24.15%  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=2.24, df=1 (P=0.33), I2=10.78%  
Favours MMF 2000.005 100.1 1 Favours AZA
 
 
Analysis 4.4.   Comparison 4 Subgroup analyses: adults only versus
children included, Outcome 4 GraB function: serum creatinine.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.4.1 Adults only  
MMF US Study 1995 200 1.7 (0.5) 86 1.8 (0.4) 14.73% -0.07[-0.18,0.04]
MMF TRI Study 1996 168 1.7 (0.9) 83 1.7 (0.9) 8.64% -0.03[-0.27,0.21]
Busque 2001 23 1.3 (0.8) 23 1.6 (0.7) 3.9% -0.3[-0.73,0.13]
Sadek 2002 162 1.7 (1.1) 157 1.5 (0.4) 11.01% 0.2[0.02,0.38]
COSTAMP Study 2002 232 1.6 (0.8) 233 1.6 (0.7) 13.15% 0.03[-0.11,0.17]
Merville 2004 37 1.6 (0.6) 34 1.4 (0.4) 8.69% 0.19[-0.05,0.43]
MYSS Study 2004 167 1.5 (0.2) 167 1.3 (0.2) 17.2% 0.2[0.16,0.24]
Subtotal *** 989   783   77.32% 0.06[-0.06,0.19]
Heterogeneity: Tau2=0.02; Chi2=31.74, df=6(P<0.0001); I2=81.1%  
Test for overall effect: Z=1.01(P=0.31)  
   
Favours MMF 21-2 -1 0 Favours AZA
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
106
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.4.2 Children included  
Johnson 2000 47 1.4 (0.7) 53 1.4 (0.6) 7.91% 0[-0.26,0.26]
Subtotal *** 47   53   7.91% 0[-0.26,0.26]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.4.3 No details reported  
Ling 1998 11 1.6 (0.8) 5 1.4 (0.7) 1.44% 0.2[-0.57,0.97]
Egfjord 1999 25 1.4 (0.8) 25 1.5 (0.7) 4.16% -0.08[-0.5,0.34]
Suhail 2000 20 1.6 (1.8) 20 1.4 (1.3) 0.94% 0.2[-0.77,1.17]
Miladipour 2002 40 1.3 (1.5) 40 1.3 (1.4) 2.06% 0[-0.64,0.64]
Army Hospital 2002 17 1.3 (1.6) 16 1.5 (1.6) 0.76% -0.16[-1.25,0.93]
Sun 2002b 40 1.4 (1.9) 46 1.5 (1.4) 1.67% -0.1[-0.81,0.61]
Weimer 2002 31 2.2 (0.6) 25 2.2 (1) 3.75% 0[-0.45,0.45]
Subtotal *** 184   177   14.77% -0.01[-0.24,0.22]
Heterogeneity: Tau2=0; Chi2=0.71, df=6(P=0.99); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
   
Total *** 1220   1013   100% 0.05[-0.05,0.15]
Heterogeneity: Tau2=0.01; Chi2=35.41, df=14(P=0); I2=60.46%  
Test for overall effect: Z=1.03(P=0.3)  
Test for subgroup differences: Chi2=0.44, df=1 (P=0.8), I2=0%  
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Comparison 5.   Subgroup analyses: industry versus non-industry funding
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 GraB loss: censored for death 17 2540 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.62, 0.99]
1.1 Industry funding 7 1737 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.66, 1.12]
1.2 Non-industry funding 2 319 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.03, 4.74]
1.3 No details reported 8 484 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.26, 0.88]
2 Acute rejection: total 22 3301 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.57, 0.73]
2.1 Industry funding 9 2252 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.55, 0.70]
2.2 Non-industry funding 2 405 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.25]
2.3 No details reported 11 644 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.43, 0.77]
3 Infection: CMV viraemia/syndrome 13 2880 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.85, 1.32]
3.1 Industry funding 7 2180 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.99, 1.62]
3.2 Non-industry funding 2 405 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.49, 1.39]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3.3 No details reported 4 295 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.46, 1.32]
4 GraB function: serum creatinine 15 2233 Mean Difference (IV, Random, 95%
CI)
0.05 [-0.05, 0.15]
4.1 Industry funding 7 1523 Mean Difference (IV, Random, 95%
CI)
0.00 [-0.09, 0.09]
4.2 Non-industry funding 2 405 Mean Difference (IV, Random, 95%
CI)
0.20 [0.16, 0.24]
4.3 No details reported 6 305 Mean Difference (IV, Random, 95%
CI)
-0.02 [-0.29, 0.25]
 
 
Analysis 5.1.   Comparison 5 Subgroup analyses: industry versus
non-industry funding, Outcome 1 GraB loss: censored for death.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.1.1 Industry funding  
MMF US Study 1995 50/331 28/164 31.29% 0.88[0.58,1.35]
MMF TRI Study 1996 39/335 25/162 25.82% 0.75[0.47,1.2]
Mendez 1998 1/117 3/59 1.11% 0.17[0.02,1.58]
Johnson 2000 9/72 9/76 7.47% 1.06[0.44,2.51]
Busque 2001 0/23 0/23   Not estimable
Weimer 2002 2/31 0/25 0.63% 4.06[0.2,80.94]
Sadek 2002 16/162 16/157 12.97% 0.97[0.5,1.87]
Subtotal (95% CI) 1071 666 79.29% 0.86[0.66,1.12]
Total events: 117 (MMF), 81 (AZA)  
Heterogeneity: Tau2=0; Chi2=3.73, df=5(P=0.59); I2=0%  
Test for overall effect: Z=1.14(P=0.26)  
   
5.1.2 Non-industry funding  
Merville 2004 0/37 5/34 0.69% 0.08[0,1.46]
MYSS Study 2004 7/124 7/124 5.41% 1[0.36,2.77]
Subtotal (95% CI) 161 158 6.09% 0.41[0.03,4.74]
Total events: 7 (MMF), 12 (AZA)  
Heterogeneity: Tau2=2.2; Chi2=2.83, df=1(P=0.09); I2=64.7%  
Test for overall effect: Z=0.72(P=0.47)  
   
5.1.3 No details reported  
Ling 1998 0/11 0/5   Not estimable
Egfjord 1999 1/25 5/25 1.3% 0.2[0.03,1.59]
Suhail 2000 0/20 0/20   Not estimable
Ji 2001 0/56 2/50 0.62% 0.18[0.01,3.64]
Folkmane 2001 2/23 3/25 1.94% 0.72[0.13,3.96]
Miladipour 2002 0/40 1/40 0.56% 0.33[0.01,7.95]
Tuncer 2002 5/38 11/38 6.12% 0.45[0.17,1.18]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Joh 2005 4/34 6/34 4.07% 0.67[0.21,2.15]
Subtotal (95% CI) 247 237 14.62% 0.48[0.26,0.88]
Total events: 12 (MMF), 28 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.72, df=5(P=0.89); I2=0%  
Test for overall effect: Z=2.36(P=0.02)  
   
Total (95% CI) 1479 1061 100% 0.78[0.62,0.99]
Total events: 136 (MMF), 121 (AZA)  
Heterogeneity: Tau2=0; Chi2=11.04, df=13(P=0.61); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=3.21, df=1 (P=0.2), I2=37.78%  
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Analysis 5.2.   Comparison 5 Subgroup analyses: industry
versus non-industry funding, Outcome 2 Acute rejection: total.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.2.1 Industry funding  
MMF US Study 1995 87/331 77/164 16.96% 0.56[0.44,0.71]
MMF TRI Study 1996 105/335 81/162 19.18% 0.63[0.5,0.78]
Mendez 1998 24/117 19/59 5.08% 0.64[0.38,1.07]
Johnson 2000 12/72 16/76 3.07% 0.79[0.4,1.56]
Busque 2001 2/23 8/23 0.71% 0.25[0.06,1.05]
Sadek 2002 34/162 51/157 8.81% 0.65[0.44,0.94]
COSTAMP Study 2002 59/243 83/246 13.69% 0.72[0.54,0.95]
Weimer 2002 5/31 11/25 1.71% 0.37[0.15,0.92]
Baltar 2002 1/14 5/12 0.37% 0.17[0.02,1.27]
Subtotal (95% CI) 1328 924 69.59% 0.62[0.55,0.7]
Total events: 329 (MMF), 351 (AZA)  
Heterogeneity: Tau2=0; Chi2=6.69, df=8(P=0.57); I2=0%  
Test for overall effect: Z=7.57(P<0.0001)  
   
5.2.2 Non-industry funding  
Merville 2004 5/37 7/34 1.32% 0.66[0.23,1.87]
MYSS Study 2004 56/167 58/167 12.66% 0.97[0.72,1.3]
Subtotal (95% CI) 204 201 13.98% 0.94[0.7,1.25]
Total events: 61 (MMF), 65 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.48, df=1(P=0.49); I2=0%  
Test for overall effect: Z=0.44(P=0.66)  
   
5.2.3 No details reported  
Ling 1998 2/11 3/5 0.7% 0.3[0.07,1.28]
Egfjord 1999 8/25 11/25 2.7% 0.73[0.35,1.5]
Suhail 2000 2/20 7/20 0.7% 0.29[0.07,1.21]
Ji 2001 11/56 22/50 3.66% 0.45[0.24,0.83]
Folkmane 2001 5/23 8/25 1.56% 0.68[0.26,1.78]
Miladipour 2002 4/40 10/40 1.26% 0.4[0.14,1.17]
Tuncer 2002 7/38 13/38 2.22% 0.54[0.24,1.2]
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Army Hospital 2002 1/17 3/16 0.32% 0.31[0.04,2.71]
Sun 2002b 2/40 6/46 0.62% 0.38[0.08,1.79]
Keven 2003 3/24 3/17 0.68% 0.71[0.16,3.1]
Joh 2005 10/34 7/34 2.02% 1.43[0.62,3.31]
Subtotal (95% CI) 328 316 16.44% 0.57[0.43,0.77]
Total events: 55 (MMF), 93 (AZA)  
Heterogeneity: Tau2=0; Chi2=8.46, df=10(P=0.58); I2=0%  
Test for overall effect: Z=3.69(P=0)  
   
Total (95% CI) 1860 1441 100% 0.65[0.57,0.73]
Total events: 445 (MMF), 509 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=23.2, df=21(P=0.33); I2=9.48%  
Test for overall effect: Z=7.01(P<0.0001)  
Test for subgroup differences: Chi2=7.56, df=1 (P=0.02), I2=73.56%  
Favours MMF 1000.01 100.1 1 Favours AZA
 
 
Analysis 5.3.   Comparison 5 Subgroup analyses: industry versus non-
industry funding, Outcome 3 Infection: CMV viraemia/syndrome.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.3.1 Industry funding  
MMF US Study 1995 50/331 16/164 11.66% 1.55[0.91,2.63]
MMF TRI Study 1996 44/335 20/162 12.79% 1.06[0.65,1.74]
Mendez 1998 6/117 3/59 2.52% 1.01[0.26,3.89]
Johnson 2000 7/72 3/76 2.66% 2.46[0.66,9.16]
COSTAMP Study 2002 12/243 14/246 7.02% 0.87[0.41,1.84]
Sadek 2002 32/162 17/157 11.24% 1.82[1.06,3.15]
Weimer 2002 13/31 11/25 9.71% 0.95[0.52,1.75]
Subtotal (95% CI) 1291 889 57.59% 1.27[0.99,1.62]
Total events: 164 (MMF), 84 (AZA)  
Heterogeneity: Tau2=0; Chi2=5.7, df=6(P=0.46); I2=0%  
Test for overall effect: Z=1.91(P=0.06)  
   
5.3.2 Non-industry funding  
MYSS Study 2004 43/167 42/167 17.81% 1.02[0.71,1.48]
Merville 2004 11/37 17/34 9.88% 0.59[0.33,1.08]
Subtotal (95% CI) 204 201 27.69% 0.82[0.49,1.39]
Total events: 54 (MMF), 59 (AZA)  
Heterogeneity: Tau2=0.08; Chi2=2.31, df=1(P=0.13); I2=56.7%  
Test for overall effect: Z=0.73(P=0.47)  
   
5.3.3 No details reported  
Ji 2001 12/56 16/50 8.88% 0.67[0.35,1.28]
Miladipour 2002 3/40 0/40 0.57% 7[0.37,131.28]
Keven 2003 5/24 3/17 2.75% 1.18[0.33,4.29]
Joh 2005 3/34 5/34 2.52% 0.6[0.16,2.31]
Subtotal (95% CI) 154 141 14.72% 0.78[0.46,1.32]
Total events: 23 (MMF), 24 (AZA)  
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=3.01, df=3(P=0.39); I2=0.4%  
Test for overall effect: Z=0.93(P=0.35)  
   
Total (95% CI) 1649 1231 100% 1.06[0.85,1.32]
Total events: 241 (MMF), 167 (AZA)  
Heterogeneity: Tau2=0.04; Chi2=15.82, df=12(P=0.2); I2=24.15%  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=4.15, df=1 (P=0.13), I2=51.79%  
Favours MMF 2000.005 100.1 1 Favours AZA
 
 
Analysis 5.4.   Comparison 5 Subgroup analyses: industry versus
non-industry funding, Outcome 4 GraB function: serum creatinine.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.4.1 Industry funding  
MMF US Study 1995 200 1.7 (0.5) 86 1.8 (0.4) 14.73% -0.07[-0.18,0.04]
MMF TRI Study 1996 168 1.7 (0.9) 83 1.7 (0.9) 8.64% -0.03[-0.27,0.21]
Johnson 2000 47 1.4 (0.7) 53 1.4 (0.6) 7.91% 0[-0.26,0.26]
Busque 2001 23 1.3 (0.8) 23 1.6 (0.7) 3.9% -0.3[-0.73,0.13]
COSTAMP Study 2002 232 1.6 (0.8) 233 1.6 (0.7) 13.15% 0.03[-0.11,0.17]
Sadek 2002 162 1.7 (1.1) 157 1.5 (0.4) 11.01% 0.2[0.02,0.38]
Weimer 2002 31 2.2 (0.6) 25 2.2 (1) 3.75% 0[-0.45,0.45]
Subtotal *** 863   660   63.09% 0[-0.09,0.09]
Heterogeneity: Tau2=0; Chi2=8.49, df=6(P=0.2); I2=29.31%  
Test for overall effect: Z=0.09(P=0.93)  
   
5.4.2 Non-industry funding  
MYSS Study 2004 167 1.5 (0.2) 167 1.3 (0.2) 17.2% 0.2[0.16,0.24]
Merville 2004 37 1.6 (0.6) 34 1.4 (0.4) 8.69% 0.19[-0.05,0.43]
Subtotal *** 204   201   25.89% 0.2[0.16,0.24]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.93); I2=0%  
Test for overall effect: Z=9.27(P<0.0001)  
   
5.4.3 No details reported  
Ling 1998 11 1.6 (0.8) 5 1.4 (0.7) 1.44% 0.2[-0.57,0.97]
Egfjord 1999 25 1.4 (0.8) 25 1.5 (0.7) 4.16% -0.08[-0.5,0.34]
Suhail 2000 20 1.6 (1.8) 20 1.4 (1.3) 0.94% 0.2[-0.77,1.17]
Sun 2002b 40 1.4 (1.9) 46 1.5 (1.4) 1.67% -0.1[-0.81,0.61]
Army Hospital 2002 17 1.3 (1.6) 16 1.5 (1.6) 0.76% -0.16[-1.25,0.93]
Miladipour 2002 40 1.3 (1.5) 40 1.3 (1.4) 2.06% 0[-0.64,0.64]
Subtotal *** 153   152   11.03% -0.02[-0.29,0.25]
Heterogeneity: Tau2=0; Chi2=0.7, df=5(P=0.98); I2=0%  
Test for overall effect: Z=0.13(P=0.9)  
   
Total *** 1220   1013   100% 0.05[-0.05,0.15]
Heterogeneity: Tau2=0.01; Chi2=35.41, df=14(P=0); I2=60.46%  
Test for overall effect: Z=1.03(P=0.3)  
Test for subgroup differences: Chi2=16.59, df=1 (P=0), I2=87.95%  
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Comparison 6.   Subgroup analyses: publication type
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 GraB loss: censored for death 17 2540 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.62, 0.99]
1.1 Conference abstract only 1 50 Risk Ratio (M-H, Random, 95%
CI)
0.2 [0.03, 1.59]
1.2 Transplantation Proceedings 5 290 Risk Ratio (M-H, Random, 95%
CI)
0.49 [0.22, 1.11]
1.3 Full peer reviewed journal article 11 2200 Risk Ratio (M-H, Random, 95%
CI)
0.83 [0.65, 1.07]
2 Acute rejection: total 22 3301 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.57, 0.73]
2.1 Conference abstract only 2 83 Risk Ratio (M-H, Random, 95%
CI)
0.67 [0.34, 1.33]
2.2 Transplantation Proceedings 5 290 Risk Ratio (M-H, Random, 95%
CI)
0.46 [0.29, 0.74]
2.3 Full peer reviewed journal article 15 2928 Risk Ratio (M-H, Random, 95%
CI)
0.66 [0.57, 0.76]
3 Infection: CMV viraemia/syndrome 13 2880 Risk Ratio (M-H, Random, 95%
CI)
1.06 [0.85, 1.32]
3.1 Conference abstract only 0 0 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
3.2 Transplantation Proceedings 1 80 Risk Ratio (M-H, Random, 95%
CI)
7.0 [0.37, 131.28]
3.3 Full peer reviewed journal article 12 2800 Risk Ratio (M-H, Random, 95%
CI)
1.05 [0.84, 1.30]
4 GraB function: serum creatinine 15 2233 Mean Difference (IV, Random,
95% CI)
0.05 [-0.05, 0.15]
4.1 Conference abstract only 2 83 Mean Difference (IV, Random,
95% CI)
-0.09 [-0.48, 0.30]
4.2 Transplantation Proceedings 3 166 Mean Difference (IV, Random,
95% CI)
-0.16 [-0.49, 0.18]
4.3 Full peer reviewed journal article 10 1984 Mean Difference (IV, Random,
95% CI)
0.07 [-0.03, 0.18]
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Analysis 6.1.   Comparison 6 Subgroup analyses: publication type, Outcome 1 GraB loss: censored for death.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.1.1 Conference abstract only  
Egfjord 1999 1/25 5/25 1.3% 0.2[0.03,1.59]
Subtotal (95% CI) 25 25 1.3% 0.2[0.03,1.59]
Total events: 1 (MMF), 5 (AZA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.52(P=0.13)  
   
6.1.2 Transplantation Proceedings  
Suhail 2000 0/20 0/20   Not estimable
Folkmane 2001 2/23 3/25 1.94% 0.72[0.13,3.96]
Busque 2001 0/23 0/23   Not estimable
Miladipour 2002 0/40 1/40 0.56% 0.33[0.01,7.95]
Tuncer 2002 5/38 11/38 6.12% 0.45[0.17,1.18]
Subtotal (95% CI) 144 146 8.62% 0.49[0.22,1.11]
Total events: 7 (MMF), 15 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.28, df=2(P=0.87); I2=0%  
Test for overall effect: Z=1.71(P=0.09)  
   
6.1.3 Full peer reviewed journal article  
MMF US Study 1995 50/331 28/164 31.29% 0.88[0.58,1.35]
MMF TRI Study 1996 39/335 25/162 25.82% 0.75[0.47,1.2]
Ling 1998 0/11 0/5   Not estimable
Mendez 1998 1/117 3/59 1.11% 0.17[0.02,1.58]
Johnson 2000 9/72 9/76 7.47% 1.06[0.44,2.51]
Ji 2001 0/56 2/50 0.62% 0.18[0.01,3.64]
Weimer 2002 2/31 0/25 0.63% 4.06[0.2,80.94]
Sadek 2002 16/162 16/157 12.97% 0.97[0.5,1.87]
MYSS Study 2004 7/124 7/124 5.41% 1[0.36,2.77]
Merville 2004 0/37 5/34 0.69% 0.08[0,1.46]
Joh 2005 4/34 6/34 4.07% 0.67[0.21,2.15]
Subtotal (95% CI) 1310 890 90.08% 0.83[0.65,1.07]
Total events: 128 (MMF), 101 (AZA)  
Heterogeneity: Tau2=0; Chi2=7.58, df=9(P=0.58); I2=0%  
Test for overall effect: Z=1.45(P=0.15)  
   
Total (95% CI) 1479 1061 100% 0.78[0.62,0.99]
Total events: 136 (MMF), 121 (AZA)  
Heterogeneity: Tau2=0; Chi2=11.04, df=13(P=0.61); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Test for subgroup differences: Chi2=3.13, df=1 (P=0.21), I2=36.06%  
Favours MMF 5000.002 100.1 1 Favours AZA
 
 
Analysis 6.2.   Comparison 6 Subgroup analyses: publication type, Outcome 2 Acute rejection: total.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.2.1 Conference abstract only  
Egfjord 1999 8/25 11/25 2.7% 0.73[0.35,1.5]
Favours MMF 1000.01 100.1 1 Favours AZA
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Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Army Hospital 2002 1/17 3/16 0.32% 0.31[0.04,2.71]
Subtotal (95% CI) 42 41 3.02% 0.67[0.34,1.33]
Total events: 9 (MMF), 14 (AZA)  
Heterogeneity: Tau2=0; Chi2=0.54, df=1(P=0.46); I2=0%  
Test for overall effect: Z=1.15(P=0.25)  
   
6.2.2 Transplantation Proceedings  
Suhail 2000 2/20 7/20 0.7% 0.29[0.07,1.21]
Busque 2001 2/23 8/23 0.71% 0.25[0.06,1.05]
Folkmane 2001 5/23 8/25 1.56% 0.68[0.26,1.78]
Miladipour 2002 4/40 10/40 1.26% 0.4[0.14,1.17]
Tuncer 2002 7/38 13/38 2.22% 0.54[0.24,1.2]
Subtotal (95% CI) 144 146 6.45% 0.46[0.29,0.74]
Total events: 20 (MMF), 46 (AZA)  
Heterogeneity: Tau2=0; Chi2=1.98, df=4(P=0.74); I2=0%  
Test for overall effect: Z=3.2(P=0)  
   
6.2.3 Full peer reviewed journal article  
MMF US Study 1995 87/331 77/164 16.96% 0.56[0.44,0.71]
MMF TRI Study 1996 105/335 81/162 19.18% 0.63[0.5,0.78]
Mendez 1998 24/117 19/59 5.08% 0.64[0.38,1.07]
Ling 1998 2/11 3/5 0.7% 0.3[0.07,1.28]
Johnson 2000 12/72 16/76 3.07% 0.79[0.4,1.56]
Ji 2001 11/56 22/50 3.66% 0.45[0.24,0.83]
COSTAMP Study 2002 59/243 83/246 13.69% 0.72[0.54,0.95]
Sadek 2002 34/162 51/157 8.81% 0.65[0.44,0.94]
Sun 2002b 2/40 6/46 0.62% 0.38[0.08,1.79]
Weimer 2002 5/31 11/25 1.71% 0.37[0.15,0.92]
Baltar 2002 1/14 5/12 0.37% 0.17[0.02,1.27]
Keven 2003 3/24 3/17 0.68% 0.71[0.16,3.1]
MYSS Study 2004 56/167 58/167 12.66% 0.97[0.72,1.3]
Merville 2004 5/37 7/34 1.32% 0.66[0.23,1.87]
Joh 2005 10/34 7/34 2.02% 1.43[0.62,3.31]
Subtotal (95% CI) 1674 1254 90.53% 0.66[0.57,0.76]
Total events: 416 (MMF), 449 (AZA)  
Heterogeneity: Tau2=0.02; Chi2=18.61, df=14(P=0.18); I2=24.79%  
Test for overall effect: Z=5.56(P<0.0001)  
   
Total (95% CI) 1860 1441 100% 0.65[0.57,0.73]
Total events: 445 (MMF), 509 (AZA)  
Heterogeneity: Tau2=0.01; Chi2=23.2, df=21(P=0.33); I2=9.48%  
Test for overall effect: Z=7.01(P<0.0001)  
Test for subgroup differences: Chi2=2, df=1 (P=0.37), I2=0.16%  
Favours MMF 1000.01 100.1 1 Favours AZA
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Analysis 6.3.   Comparison 6 Subgroup analyses: publication type, Outcome 3 Infection: CMV viraemia/syndrome.
Study or subgroup MMF AZA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.3.1 Conference abstract only  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (MMF), 0 (AZA)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.3.2 Transplantation Proceedings  
Miladipour 2002 3/40 0/40 0.57% 7[0.37,131.28]
Subtotal (95% CI) 40 40 0.57% 7[0.37,131.28]
Total events: 3 (MMF), 0 (AZA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.3(P=0.19)  
   
6.3.3 Full peer reviewed journal article  
MMF US Study 1995 50/331 16/164 11.66% 1.55[0.91,2.63]
MMF TRI Study 1996 44/335 20/162 12.79% 1.06[0.65,1.74]
Mendez 1998 6/117 3/59 2.52% 1.01[0.26,3.89]
Johnson 2000 7/72 3/76 2.66% 2.46[0.66,9.16]
Ji 2001 12/56 16/50 8.88% 0.67[0.35,1.28]
Weimer 2002 13/31 11/25 9.71% 0.95[0.52,1.75]
Sadek 2002 32/162 17/157 11.24% 1.82[1.06,3.15]
COSTAMP Study 2002 12/243 14/246 7.02% 0.87[0.41,1.84]
Keven 2003 5/24 3/17 2.75% 1.18[0.33,4.29]
Merville 2004 11/37 17/34 9.88% 0.59[0.33,1.08]
MYSS Study 2004 43/167 42/167 17.81% 1.02[0.71,1.48]
Joh 2005 3/34 5/34 2.52% 0.6[0.16,2.31]
Subtotal (95% CI) 1609 1191 99.43% 1.05[0.84,1.3]
Total events: 238 (MMF), 167 (AZA)  
Heterogeneity: Tau2=0.03; Chi2=14.15, df=11(P=0.22); I2=22.28%  
Test for overall effect: Z=0.41(P=0.68)  
   
Total (95% CI) 1649 1231 100% 1.06[0.85,1.32]
Total events: 241 (MMF), 167 (AZA)  
Heterogeneity: Tau2=0.04; Chi2=15.82, df=12(P=0.2); I2=24.15%  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=1.61, df=1 (P=0.21), I2=37.7%  
Favours MMF 2000.005 100.1 1 Favours AZA
 
 
Analysis 6.4.   Comparison 6 Subgroup analyses: publication type, Outcome 4 GraB function: serum creatinine.
Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.4.1 Conference abstract only  
Egfjord 1999 25 1.4 (0.8) 25 1.5 (0.7) 4.16% -0.08[-0.5,0.34]
Army Hospital 2002 17 1.3 (1.6) 16 1.5 (1.6) 0.76% -0.16[-1.25,0.93]
Subtotal *** 42   41   4.91% -0.09[-0.48,0.3]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=0.45(P=0.65)  
Favours MMF 21-2 -1 0 Favours AZA
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Study or subgroup MMF AZA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
6.4.2 Transplantation Proceedings  
Suhail 2000 20 1.6 (1.8) 20 1.4 (1.3) 0.94% 0.2[-0.77,1.17]
Busque 2001 23 1.3 (0.8) 23 1.6 (0.7) 3.9% -0.3[-0.73,0.13]
Miladipour 2002 40 1.3 (1.5) 40 1.3 (1.4) 2.06% 0[-0.64,0.64]
Subtotal *** 83   83   6.9% -0.16[-0.49,0.18]
Heterogeneity: Tau2=0; Chi2=1.17, df=2(P=0.56); I2=0%  
Test for overall effect: Z=0.91(P=0.36)  
   
6.4.3 Full peer reviewed journal article  
MMF US Study 1995 200 1.7 (0.5) 86 1.8 (0.4) 14.73% -0.07[-0.18,0.04]
MMF TRI Study 1996 168 1.7 (0.9) 83 1.7 (0.9) 8.64% -0.03[-0.27,0.21]
Ling 1998 11 1.6 (0.8) 5 1.4 (0.7) 1.44% 0.2[-0.57,0.97]
Johnson 2000 47 1.4 (0.7) 53 1.4 (0.6) 7.91% 0[-0.26,0.26]
Weimer 2002 31 2.2 (0.6) 25 2.2 (1) 3.75% 0[-0.45,0.45]
Sun 2002b 40 1.4 (1.9) 46 1.5 (1.4) 1.67% -0.1[-0.81,0.61]
Sadek 2002 162 1.7 (1.1) 157 1.5 (0.4) 11.01% 0.2[0.02,0.38]
COSTAMP Study 2002 232 1.6 (0.8) 233 1.6 (0.7) 13.15% 0.03[-0.11,0.17]
Merville 2004 37 1.6 (0.6) 34 1.4 (0.4) 8.69% 0.19[-0.05,0.43]
MYSS Study 2004 167 1.5 (0.2) 167 1.3 (0.2) 17.2% 0.2[0.16,0.24]
Subtotal *** 1095   889   88.19% 0.07[-0.03,0.18]
Heterogeneity: Tau2=0.01; Chi2=29.82, df=9(P=0); I2=69.82%  
Test for overall effect: Z=1.38(P=0.17)  
   
Total *** 1220   1013   100% 0.05[-0.05,0.15]
Heterogeneity: Tau2=0.01; Chi2=35.41, df=14(P=0); I2=60.46%  
Test for overall effect: Z=1.03(P=0.3)  
Test for subgroup differences: Chi2=2.13, df=1 (P=0.35), I2=5.93%  
Favours MMF 21-2 -1 0 Favours AZA
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  Death (all
cause)
GraB loss
(censored for
death)
Malignancy
(any)
Acute rejec-
tion (any)
CMV vi-
raemia/syn-
drome
CMV tissue
invasive
Serum creati-
nine [mg/dl]
Diarrhoea Leukopenia
Number of studies 16 17 5 22 13 7 15 11 12
Study level factors
Year of transplanta-
tiona
per year
1.01
(0.86 to
1.18)
0.99
(0.91 to 1.08)
1.06
(0.92 to 1.22)
1.03
(0.99 to 1.06)
0.95
(0.83 to
1.10)
1.08
(0.14 to
8.30)
0.04
(-0.03 to 0.10)
1.16
(0.91 to 1.49)
0.84
(0.64 to
1.11)
Donor typeb
Both versus deceased
only
Living only versus de-
ceased only
1.02
(0.42 to
2.47)
(no living
donor only
studies)
1.04
(0.57 to 1.90)
(no living
donor only
studies)
2.04
(0.43 to 9.71)
(no living
donor
only studies)
1.01
(0.77 to
1.33)
0.46
(0.05 to
4.07)
1.33
(0.87 to 2.02)
(no living
donor only
studies)
--
(all studies
deceased
donor only)
-0.08
(-0.20 to 0.03)
-0.37
(-1.46 to 0.73)
1.35
(0.73 to 2.50)
(no living
donor only
studies)
0.59
(0.34 to
1.02)
0.72
(0.01 to 35.2)
Previous transplanta-
tion
Yes versus 1st trans-
plantation only
0.97
(0.51 to
1.85)
0.80
(0.48 to 1.34)
0.76
(0.41 to 1.41)
0.95
(0.74 to
1.22)
0.81
(0.53 to
1.24)
0.73
(0.27 to
1.97)
-0.13
(-0.25 to
-0.02)
1.10
(0.77 to 1.57)
0.71
(0.51 to
0.99)
MMF dosec
per g/d
1.20
(0.62 to
2.33)
0.26
(0.06 to 1.24)
0.92
(0.47 to 1.79)
0.90
(0.74 to
1.08)
1.31
(0.84 to
2.03)
1.40
(0.63 to
3.10)
0.08
(-0.04 to 0.19)
1.23
(0.88 to 1.72)
1.60
(1.13 to
2.27)
AZA dosed
per mg/d
0.99
(0.96 to
1.03)
1.01
(0.98 to 1.03)
0.98
(0.93 to 1.03)
1.01
(1.00 to
1.01)
1.00
(0.99 to
1.01)
1.01
(0.97 to
1.05)
0.004
(-0.001 to
0.009)
1.00
(0.98 to 1.02)
1.00
(0.99 to
1.02)
Inductione
Some versus no
All versus no
1.06
(0.35 to
3.20)
1.16
0.87
(0.42 to 1.79)
0.91
(0.54 to 1.54)
(no studies
with induc-
tion in some)
1.10
(0.58 to 2.08)
0.80
(0.41 to
1.58)
0.82
1.05
(0.60 to
1.85)
0.76
2.48
(0.10 to
64.07)
1.21
-0.22
(-0.42 to
-0.01)
-0.05
(no studies
with induc-
tion in some)
0.68
(0.49 to 0.96)
(no stud-
ies with in-
duction in
some)
1.46
Table 1.   Meta-regression analyses 
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(0.59 to
2.28)
(0.64 to 1.04) (0.50 to 1.15) (0.45 to
3.22)
(-0.23 to 0.12) (1.03 to
2.08)
CNI
Tac versus CsA
1.07
(0.40 to
2.82)
1.03
(0.46 to 2.32)
0.89
(0.08 to 10.63)
1.08
(0.81 to
1.44)
1.16
(0.60 to
2.24)
1.42
(0.12 to
16.53)
-0.19
(-0.31 to
-0.06)
0.54
(0.30 to 0.99)
0.85
(0.44 to
1.65)
CsA formulation
CsA-ME versus original
or unclear
1.03
(0.26 to
4.10)
1.12
(0.62 to 2.04)
1.54
(0.60 to 3.97)
1.27
(0.98 to
1.65)
1.24
(0.73 to
2.11)
0.89
(0.03 to
29.84)
0.18
(-0.16 to 0.53)
0.64
(0.21 to 1.95)
1.69
(0.79 to 3.63)
Study quality/risk of bias factors
Blinding
Yes versus no or un-
clear
0.89
(0.39 to
2.06)
1.12
(0.69 to 1.83)
0.72
(0.30 to 1.68)
0.87
(0.70 to 1.07)
0.88
(0.11 to
7.13)
0.42
(0.12 to 1.50)
-0.23
(-0.98 to 0.53)
7.16
(0.32 to 159.8)
0.38
(0.02 to
6.15)
Industry funding
Yes versus no/unclear
0.96
(0.42 to
2.19)
1.60
(0.88 to 2.90)
0.43
(0.05 to 3.66)
0.84
(0.66 to 1.07)
1.53
(0.96 to
2.41)
1.58
(0.10 to
23.76)
-0.14
(-0.25 to
-0.02)
0.39
(0.14 to 1.07)
0.78
(0.40 to
1.49)
Publication
Full manuscript versus
abstract or Transplan-
tation Proceedings
1.09
(0.38 to
3.12)
1.82
(0.84 to 3.95)
(all published
as
full manu-
script)
1.25
(0.80 to
1.93)
0.14
(0.01 to 2.61)
0.68
(0.06 to
7.44)
0.31
(0.06 to 0.57)
0.49
(0.12 to 2.00)
0.75
(0.30 to
1.89)
Table 1.   Meta-regression analyses  (Continued)
Meta-regression was performed on the displayed outcomes, while data classified as “longest duration of follow-up” were used (see Methods). Displayed are Relative Risk Ratios
(RRR), i.e. back-transformed values of the coeLicient of the meta-regression, or the untransformed coeLicient of the meta-regression for the mean diLerence (MD) for continuous
outcome serum creatinine, along with 95% CI. All regression analyses were adjusted for duration of follow-up. Statistical significance values of P < 0.20 are highlighted as Italic,
values of P < 0.10 are bolded-Italic , respectively.
Abbreviations: MMF: mycophenolate mofetil, AZA: azathioprine; CNI: calcineurin-inhibitor; Tac: tacrolimus; CsA: cyclosporin A; CsA-ME: cyclosporin A microemulsion; CMV:
cytomegalovirus
Interpretation
Summary eLect for the outcome RR < 1 (e.g. acute rejection): RRR < 1 indicate a pronounced risk reduction for higher covariate values, while RRR > 1 indicate attenuated risk
reduction.
Summary eLect for the outcome RR > 1 (e.g. tissue invasive CMV disease): RRR < 1 indicate attenuated risk for higher covariate values, while RRR > 1 indicate increased risk.
Summary eLect mean diLerence SCr: positive coeLicients indicate greater diLerence in SCr, i.e. lower SCr values in AZA treated patients for higher covariate values, while negative
coeLicients indicate reduced diLerence or even negative diLerence in SCr, i.e. lower SCr values in MMF treated patients. Examples of various associations displayed in bubble-
plots can be found in Figure 4; Figure 6; Figure 7.
a If missing, year of first publication minus duration of follow-up minus two years
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b Both: living or deceased donor
c Studies in which more than one MMF dose was tested were split into two studies and each compared to half of the group of AZA-patients/ outcomes
d If reported to be body-weight-adjusted (mg/kg/d), transformation into mg/d using the mean body weight as reported in the study, and by using 70 kg (60 kg in exclusively Asian
populations) if information on body weight was missing
e Some: antibody induction therapy used in selected patients, e.g. sensitised patients or those experiencing delayed graB function
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A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. MeSH descriptor Kidney Transplantation, this term only
2. ((kidney or renal) NEXT transplant*):ti,ab,kw in Clinical Trials
3. (#1 OR #2)
4. MeSH descriptor Mycophenolic Acid, this term only
5. Mycophenolic Acid:ti,ab,kw in Clinical Trials
6. mmf:ti,ab,kw in Clinical Trials
7. mycophenolate mofetil:ti,ab,kw in Clinical Trials
8. Morpholinoethyl Ester:ti,ab,kw in Clinical Trials
9. cellcept:ti,ab,kw in Clinical Trials
10.myfortic:ti,ab,kw in Clinical Trials
11.MeSH descriptor Azathioprine, this term only
12.azathioprine:ti,ab,kw in Clinical Trials
13.aza:ti,ab,kw in Clinical Trials
14.azahexal:ti,ab,kw in Clinical Trials
15.azamun:ti,ab,kw in Clinical Trials
16.azapin:ti,ab,kw in Clinical Trials
17.imuran:ti,ab,kw in Clinical Trials
18.immuran:ti,ab,kw in Clinical Trials
19.imurel:ti,ab,kw in Clinical Trials
20.azasan:ti,ab,kw in Clinical Trials
21.(#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
OR #18 OR #19 OR #20)
22.(#3 AND #21)
MEDLINE 1. Kidney Transplantation/
2. Mycophenolic Acid/
3. mmf.tw.
4. Mycophenolate mofetil.tw.
5. Morpholinoethyl Ester.tw.
6. cellcept.tw.
7. myfortic.tw.
8. Azathioprine/
9. aza.tw.
10.azahexal.tw.
11.azamun.tw.
12.azapin.tw.
13.imuran.tw.
14.immuran.tw.
15.imurek.tw.
16.imurel.tw.
17.or/2-16
EMBASE 1. exp Kidney Transplantation/
2. Mycophenolic Acid 2 Morpholinoethyl Ester/
3. Mycophenolic Acid/
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4. mycophenolate mofetil.tw.
5. mmf.tw.
6. Cellcept.tw.
7. myfortic.tw.
8. Azathioprine/
9. aza.tw.
10.azahexal/
11.azahexal.tw.
12.azamun.tw.
13.azapin.tw.
14.imuran.tw.
15.immuran.tw.
16.imurel.tw.
17.azasan.tw.
18.or/2-17
19.and/1,18
  (Continued)
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
Unclear: Insufficient information about the sequence generation process to permit judgement.
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
Unclear: Randomisation stated but no information on method used is available.
Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
 
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
121
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Selective reporting
Reporting bias due to selective
outcome reporting
Unclear: Insufficient information to permit judgement
Low risk of bias: The study appears to be free of other sources of bias.
High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Other bias
Bias due to problems not cov-
ered elsewhere in the table
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
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